Guide to German Biotech Companies

2027

In cooperation with:

BIO Deutschland

BPI German Pharmaceutical Industry Association

DECHEMA Society for Chemical Engineering and Biotechnology

VDGH German Diagnostics Industry Association

ISBN 978-3-928383-99-8

Knowbio

28th Guide to German Biotech Companies

2027

Knowbio

MESSE
MÜNCHEN
Immerse
and discover:
the world of
the laboratory
analytica
From laboratory technology and analysis to biotechnology and the analytica conference: The lab world is evolving rapidly – and at analytica, you are at the center of progress. The World's Leading Trade Fair for Laboratory Technology, Analysis, and Biotechnology offers a complete market overview across 55,000 m². Meet industry leaders and experts, discover world premieres, and find the perfect solution for your needs.
April 25–28, 2028
analytica.de/en

Editorial

Don’t be intimidated

Georg Kääb
Editor-in-Chief |transkript

Anyone talking about Germany’s biotechnology sector today encounters a new reality alongside the familiar calls for more support, more money and more public funding. As the conditions for biotechnology and biomanufacturing are changing rapidly in both the West and the Far East, the balance of power is shifting as well.

The Trump administration continues to grapple with how best to deal with China. At the same time, tariffs, threats and calls for more domestic production have triggered a new wave of investment in biomanufacturing. China, meanwhile, has set ambitious goals for its pharmaceutical industry in its new five-year plan. Among other things, it aims to significantly increase the share of Chinese-origin active pharmaceutical ingredients in FDA approvals to 35% by 2040. Today, roughly 50% to 60% of annual FDA approvals come from companies headquartered in the United States, around 30% from Europe, and about 5% from China. The question, therefore, is not only how these shares will shift, but also whether, a few years from now, it will still be possible to clearly distinguish where a drug development program originally came from.

After all, drug research is already a global process. At the latest by the preclinical stage, and particularly during clinical development, substantial parts of the value chain are outsourced to specialized CROs, CDMOs and providers of enabling technologies and platforms — ranging from analytics and automation to high-throughput methods and advanced model systems, as well as data management and AI.

This is precisely where Germany retains a strength: its broad landscape of specialized companies, hands-on problem solvers, engineers, and technologically sophisticated Mittelstand companies. Artificial intelligence does not make this expertise obsolete, either. Quite the opposite: the ability to translate technologies into robust applications could become even more important in an increasingly automated and data-driven industry. The diversity of Germany’s Mittelstand therefore provides an important buffer for stability and the ability to adapt.

In 2026, German biotechnology has made international headlines with multibillion-dollar corporate transactions. At the same time, BioNTech, one of the sector’s flagship companies, plans to increasingly concentrate its activities in Mainz. Consolidation is therefore already underway. Beyond the big headlines, however, consolidation has long been part of doing business in Germany’s Mittelstand.

The guiding principle for the years ahead may therefore be less “more funding” and more: don’t be intimidated, build on your own strengths, and ask your customer. In other words, do precisely what German entrepreneurs have always done well.

© Knowbio GmbH, Berlin 2026

28th Guide to German Biotech Companies

Published by: Knowbio GmbH, Lessingstr. 12, 16552 Mühlenbecker Land, Germany
Tel. +49-30-264921-0, service@knowb.io, www.knowb.io

Executive Producer: Andreas Macht
Production: Martina Willnow
Graphic Design: Martina Willnow, Michaela Reblin

Printed at: Möller Pro Media® GmbH, Berlin

This book is protected by copyright. All rights including those regarding translation, reprinting and reproduction reserved. No part of this book covered by the copyright hereon may be processed, reproduced, and proliferated in any form or by any means (graphic, electronic, or mechanical, including photocopying, recording, taping, or via information storage and retrieval systems, and the Internet).

ISBN: 978-3-928383-99-8

Content

Editorial 3

The German Biotech Sector 2026 . . . 7

Prefaces from Industry Associations
Roland Sackers, BIO Deutschland e. V. 12
Dr. Kai Joachimsen, BPI e.V. 14
Dr. Björn Mathes, DECHEMA e.V. 16
Dr. Martin Walger, VDGH e.V. 18

Profiles of German Biotech Companies 21
ABclonal Germany GmbH 22
ACILA Dr. Weidner GmbH 24
Analytik Jena GmbH+Co. KG 26
AxoLabs GmbH 28
Biaffin GmbH & Co KG 30
BioCopy AG 32
Biofidus GmbH 34
Boehringer Ingelheim Biopharmaceuticals GmbH 36
BRAIN Biotech AG 38
CeGaT GmbH 40
Cellex Cell Professionals GmbH 42
Collaborative Drug Discovery 44
Eppendorf SE 46
EVONIK Operations GmbH 48
Evotec SE 50
Exyte Management GmbH 52
FGK Clinical Research GmbH 54
GENEWIZ Germany GmbH 56
HAMILTON AG 58
Heidelberg Pharma AG 60
IDT Biologika GmbH 62
IKA-Werke GmbH & Co. KG 64
Immunic AG 66
Indivumed GmbH 68
iOmx Therapeutics AG 70
Lucera GmbH 72
metabion international AG 74
Mettler-Toledo GmbH 76
Microcoat Biotechnologie GmbH 78
Milenia Biotec 80
Miltenyi Biotec 82
Navigo Proteins GmbH 84
Navigo Pure 86
Neovii Biotech GmbH 88
New England Biolabs GmbH 90
Nordmark Pharma GmbH 92
OPST 94
Omicron-Laserage® Laserprodukte GmbH 96
Polysciences Europe 98
ProBioGen AG 100
PROGEN 102
Project Pharmaceutics 104
Promega 106
ProtaGene 108
PSM GmbH 110
QIAGEN 112
Rentschler Biopharma SE 114
Richter BioLogics GmbH 116
SciRhom GmbH 118
Serumwerk Bernburg AG 120
Sirius Fine Chemicals SiChem GmbH 122
TRIGA-S GmbH 124
Vetter Pharma International 126
Wacker Biotech 128
WuXi Biologics Germany GmbH 130
YMC Europe GmbH 132
YUMAB GmbH 134

Startup
Praimera Biotech AG 136

Profiles of Service Providers 137
ALTRO Innovativ-Versicherungsmakler GmbH . . . 138
ambidex IP 140
BioM Biotech Cluster Development GmbH 142
biomindz Standortentwicklungsgesellschaft Mainz mbH 144
BIO.NRW 146
Daiwa Corporate Advisory GmbH 148
Germany Trade and Invest GTAI 150
Health Capital 152
HOX Life Science GmbH 154
iQ spaces Management GmbH 156
IZB mbH 158
Life Science Nord 160
Senn Resources AG 162
Technologiepark Weinberg Campus 164
TUM Campus Straubing 166

German Biotech Companies 168

Advertisements
Messe München 2
Grafiti 6
YMC Europe 20
IDT-Biologika CP4

Grafiti

SigmaStat

NEW SIGMASTAT V1

POWERFUL STATISTICS. SMARTER DECISION.

A powerful and intuitive statistical data analysis platform designed for the scientific and engineering community and academia—from undergraduate learning to advanced doctoral and post-doctoral research.

Move seamlessly from data → analysis → interpretation → visualization → reporting, accelerating the journey from complex datasets to clear and



ARAI -AI- POWERED STATISTICAL ASSISTANCE

Key Capabilities:

- Comprehensive Statistical Analysis
- Advanced Regression & Modelling
- Data Visualisation
- Statistical Reporting
- Flexible Data Integration
- Powerful Data Transformation

15% OFF

Purchase a new SigmaStat licence and save 15% !

Promo Code: LKSigmaStat1

SIGMAPLOT
Exact Graphs and Data Analysis

POWERFUL ANALYSIS. PUBLICATION-QUALITY GRAPHS.

EMPOWER YOUR RESEARCH WITH THESE COMPREHENSIVE GRAPHING FEATURES IN SIGMAPLOT V 16



- Butterfly Plots
- Violin Plots
- Support for Large Data Analysis
- Confidence & Error Bands
- Macro to import all Spreadsheets in Excel

Free Trial

Grafiti GmbH Phone: +49 (0) 211 5403 9646 Email: saves.kontakt@grafiti.com www.grafiti.com

German Biotech Sector 2025/2026

A mature sector at a critical juncture

Germany's biotechnology sector has entered a new phase. The industry is larger, its clinical pipelines are more mature and individual companies are increasingly capable of attracting global capital and strategic buyers. Yet the latest figures also expose a structural weakness: Germany is still much better at generating biotech innovation than at financing and scaling it.

According to the latest German Biotechnology Report 2026 from EY and BIO Deutschland, the number of biotechnology companies in Germany increased by 3% in 2025 to 1,052. Employment also grew by 3% to 59,607 people. At the same time, industry revenues slipped by around 0,7% to €12.0 billion, while R&D spending fell 4% to approximately €4.2 billion.

The figures underline a sector that is no longer a collection of young startups but an increasingly diverse industry with established companies, international subsidiaries, clinical-stage developers, platform businesses and industrial biotech players. The challenge is now to turn this growing base into sustainable global value creation.

More companies, but less growth capital

The most important warning sign comes from financing. German biotech companies raised around €1.8 billion in 2025, only about 5% less than in the previous year. On the surface, this looks remarkably resilient. The underlying picture is much less comfortable.

Venture capital fell by roughly one-third to €601 million. More importantly, capital became highly concentrated: the three largest VC rounds accounted for 71% of total venture investment. Tubulis alone raised €344 million in its Series C, the largest biotech VC round ever recorded in Germany.

The real bottleneck is further down the financing chain. Early-stage funding fell to €160 million in 2025. Series A remained comparatively stable at €75 million, but Series B financing collapsed from €169 million in 2024 to just €7 million — the lowest level in eight years.

This creates a classic German biotech dilemma. The country continues to produce new companies and promising technologies, but too few businesses receive the capital required to cross the gap from proof of concept to clinical validation, commercialization or industrial scale.

International money is therefore becoming increasingly important. EY estimates that only 12.5% of follow-on financing for German drug developers comes from

Key figures of the biotech sector in Germany

	2018	2019	2020	2021	2022	2023	2024	2025
Number of private and public biotechnology companies (national/+ subsidiaries**)	651	700	763	774	770	786	805/ 1,020**	807/ 1,052**
Number of employees in private and public companies (national/global'/+ subsidiaries**)	28,991	27,445/ *34,019	38,526*	44,565*	46,325*	47,140*	44,631*/ 57,741**	45,514*/ 59,607**
Turnover of private and public biotechnology companies	€4.44bn	€4.78bn	€6.95bn	€26.3bn	€24.9bn	€10.9bn	€10,2bn/ €12.1bn**	€9.96bn/ €11.9bn**
R&D expenditures of private and public biotechnology companies	€1.48bn	€1.79bn	€2.49bn	€3.84bn	€3.79bn	€4.17bn	€4.42bn	€4.23bn

Source: EY-Report, *national/global is the combination of sites of one company; **subsidiaries refers to German site of international companies

domestic investors, with 87.5% coming from abroad. The consequence is not necessarily a lack of capital but a growing risk that ownership, intellectual property and ultimately value creation migrate elsewhere.

The pipeline is getting deeper

The financing picture is considerably more encouraging when viewed against the development pipeline.

Therapeutics and diagnostics remain the dominant field of German biotech. In 2025, the number of Phase 2 clinical studies reached 118, up 18% from the previous year and 53% above the level recorded in 2012. Phase 3 remained stable at 21 studies.

This is significant because Phase 2 is where many technologies move beyond biological promise and begin to demonstrate efficacy in patients. The growing number of programs therefore points to a more mature development ecosystem, even as some Phase 1 programs disappeared through insolvencies, discontinuations or companies moving their assets into later stages.

The therapeutic landscape is also changing. Antibodies remain the dominant modality in later-stage development, but the early pipeline is increasingly populated by small molecules, nucleic-acid approaches and cell-based therapies. German companies are active in areas ranging from RNA therapeutics and gene editing to CAR-T and TCR-T cell therapies, radiopharmaceuticals and programmable cell depletion.

The next generation of German biotech is consequently not defined by a single technology platform. Its strength lies increasingly in the breadth of technologies being translated into clinical programs.

Global buyers are recognizing the value

The most striking evidence that German biotech can create global value comes from the transaction market. In 2025, German biotech M&A lost some of the momentum of the previous year in aggregate terms. But several transactions demonstrated the strategic relevance of individual companies. In 2026, this trend has already reached new heights in transaction dynamics.

In April, Gilead agreed to acquire Munich-based Tubulis for up to $5 billion, including an upfront payment of $3.15 billion. The transaction gives Gilead access to Tubulis' next-generation antibody-drug conjugate platform and clinical-stage assets. Wuppertal-based

Fig. 1: Financing of German biotech companies from 2018 to 2025



Source: EY-Report

Fig. 2: Venture capital as a share of GDP in 2024



Aicuris provides another example. Asahi Kasei completed its acquisition of the company in April 2026 in a transaction valued at around €780 million. Aicuris brings an antiviral portfolio including the late-stage candidate pritelivir and the marketed royalty-generating asset Prevymis.

These deals demonstrate both sides of the German biotech equation. German companies can generate technologies attractive enough to command substantial international valuations. At the same time, successful exits frequently mean that the ultimate ownership and economic benefits move outside Germany.

The question for the ecosystem is therefore changing. It is no longer simply whether Germany can produce globally relevant biotechnology. It is whether companies can be financed sufficiently to remain independent long enough to capture more of the resulting value.

From research excellence to industrial scale

This issue is now also reflected in German industrial policy. The High-Tech Agenda Germany identifies biotechnology as a strategic technology and sets explicit targets for increasing private investment, strengthening gene and cell therapy capabilities, improving access to research infrastructure and accelerating the translation of academic discoveries into companies and products.

Among its targets are a significant increase in biotech venture capital by 2030 and €5 billion a year in private investment in biotech R&D and scale-up by 2028. The agenda also aims to establish Germany as a leading location for gene and cell therapy and to improve its position in clinical research.

Artificial intelligence is another increasingly important part of the equation. EY sees AI and data-driven biology as potential productivity drivers across drug discovery and development, while the German policy agenda increasingly links AI with bioengineering and industrial biotechnology.

This could become a competitive advantage but only if Germany manages to connect its research infrastructure, data, industrial capabilities and capital markets more effectively.

A fragmented ecosystem

One of Germany's enduring strengths is also one of its weaknesses: its diversity.

Berlin-Brandenburg, Munich, the Rhine-Neckar region, Hamburg, North Rhine-Westphalia and other regional centers have developed substantial biotech capabilities. But unlike the UK's Golden Triangle or major Swiss clusters, Germany still lacks a single internationally dominant biotech hub.

Source: EY-Report

This fragmentation is not necessarily a problem for scientific excellence. It becomes one when companies need access to specialized infrastructure, clinical partners, experienced management and growth capital at the same time.

The next phase of Germany's biotech development will therefore depend less on creating yet another cluster than on connecting the existing ones more effectively.

The next test: scaling what already exists

The numbers in EY's 2026 German Biotechnology Report point to a sector at an inflection point.
Germany now has more than 1,000 biotech companies and almost 60,000 employees. Its companies are generating around €12 billion in annual revenue and spending approximately €4.5 billion on R&D. Its clinical pipeline is becoming deeper, while international investors and pharmaceutical companies are demonstrating that German technologies can command billion-euro valuations.

But the financing structure remains fragile. The sharp decline in Series B funding shows that the critical gap is no longer simply the creation of new companies. It is giving promising companies enough time and capital to become substantial businesses.

That makes the coming years, particularly 2027 less a question of whether German biotechnology has potential than of whether the ecosystem can convert that potential into scale.

The ingredients are there: world-class science, experienced industrial talent, growing clinical maturity and increasingly visible international success stories. The missing ingredient is the ability to connect these strengths with patient, long-term capital, faster translation and more consistent regulatory and political conditions.

Germany's biotech sector has reached maturity. The next challenge is to make that maturity economically sustainable and to ensure that more of the value created by German science is also captured in Germany.

But let's look beyond 2025, the year on which most of the figures presented here are based. In 2026, however, developments have already moved the picture another

Fig. 3: German biotech early-stage venture investment



Source: EY-Report

step forward. By autumn, also Munich-based ITM Isotope, a specialist in radiopharmacy manufacturing and radioligand therapeutics, was acquired by Telix Pharma for around $1.6 billion. The momentum may be returning to the German biotech scene, particularly in the country's southernmost region.

Germany's leading biotechnology hubs

This raises an obvious question: Where is most of the activity and dynamics in biotechnology located in Germany? The Institute for Deep Tech Innovation (DEEP) at ESMT Berlin (European School of Management and Technology), together with the Bertelsmann Stiftung, recently published the report "Assessing Deep-Tech Innovation Hubs in Germany: The Case of Biotechnology." The study assessed Germany's biotechnology innovation performance using a comprehensive index and examined the strengths and weaknesses of individual locations.

The analysis combines qualitative expert assessments with a quantitative biotechnology index covering five dimensions: basic research, R&D, company formation, public infrastructure and the business environment.

According to the study's Biotechnology Index, Berlin, Munich and Heidelberg are Germany's strongest innovation hubs. The index draws on indicators including research performance, patent activity and financing over an eight-year period, allowing the researchers to compare locations and identify longer-term trends. "Our index is the first to assess German biotechnology centres across the entire value chain," says Prof. Francis de Véricourt, Academic Director of the DEEP Institute.

Berlin ranks first among the five locations analysed, benefiting particularly from strong public infrastructure and clinical research. Munich follows, with strengths in startup support and later-stage financing for drug development. Heidelberg ranks third, supported by strong basic research. The three leading centres are relatively close in overall performance, followed by Stuttgart, with its diversified economic structure, and Nuremberg-Erlangen, which has a particular strength in medical technology.

The study also highlights a decline in innovation performance at most of the locations compared with 2016. Following the innovation boost during the COVID-19 pandemic, only Munich was able to maintain its momentum, while the other locations lost ground.

Germany's leading biotechnology regions



Source: Map created with AI according to the sources

According to de Véricourt, stronger collaboration between Germany's regional hubs could help combine their complementary strengths and create a more integrated biotechnology ecosystem. He also advocates concentrating excellence funding on a smaller number of particularly promising locations and extending collaboration to other European biotech centres.

And indeed, the German innovation hubs are starting to increasingly collaborate in networks, triangles and even newly built city partnerships to foster their ecosystems beyond borders. More to come in next year's Guide to German Biotech Companies.

Source: ESMT Berlin / Institute for Deep Tech Innovation (DEEP) and Bertelsmann Stiftung, Assessing Deep-Tech Innovation Hubs in Germany: The Case of Biotechnology (2025).

Georg Kääb

Foreword: German Biotech Guide

Roland Sackers
President of BIO Deutschland e. V.

Germany does not lack scientific excellence. The challenge is turning that excellence into companies that can scale, compete and remain in Europe.

Biotechnology has become a strategic industry. The COVID-19 pandemic showed how directly scientific innovation affects healthcare, economic stability and societal resilience. Since then, advances from cell and gene therapies to new diagnostic technologies have reinforced biotechnology's potential to improve lives while creating high-value jobs and economic growth.

Germany starts from a position of strength. In 2026, our biotechnology sector comprises more than 1,000 companies, including subsidiaries of international corporations, with 16 publicly listed companies. Dedicated biotech companies employ approximately 60,000 people. In 2025, the sector generated revenues of around €12 billion and invested €4.5 billion in research and development. More than 40 new biotech companies were founded during the year, an ongoing high level.

These figures are encouraging. But they also point to the central question for the next phase of German biotechnology: Can we turn excellent research and promising startups into globally competitive companies?

Financing remains one of the biggest constraints. By September 2026, German biotech companies had raised approximately €860 million in equity financing, well below the roughly €1.8 billion raised during all of 2025. Large financing rounds have been particularly scarce.

The challenge is structural. Germany and Europe still have less venture and growth capital available than the United States, the United Kingdom and Switzerland. That matters most when companies move beyond early-stage research and need much larger sums to finance clinical development, manufacturing and international expansion. If that capital is not available here, companies will look elsewhere, and Europe risks financing the early science while other regions capture much of the economic value.

Global competition is intensifying. The United States combines scientific strength with deep capital markets and established commercialization pathways. China is investing heavily and systematically in biotechnology and competing aggressively for capital, talent and innovation. Scientific excellence alone will not secure Europe's future position.

Picture: © QIAGEN

Policymakers have recognized the stakes. Biotechnology is one of six key technologies identified in Germany's High-Tech Agenda, with €2.9 billion earmarked for the sector during the current legislative period. At the European level, the EU Biotech Act and other initiatives are intended to improve the environment for research, scaling and manufacturing.

There has been progress. Germany has improved conditions for clinical research, expanded R&D incentives and introduced new financing instruments. Europe is also working to deepen its capital markets and improve access to financing for startups and scale-ups.

But strategies matter only if they are implemented with speed and consistency. Recent developments show why. A successful German funding program for small and medium-sized companies was suspended because of budget constraints. Similarly, despite having made promises to the contrary, Germany's government did not want to participate in the Important Project of Common European Interest in Biotechnology for budgetary reasons. Fortunately, following a concerted effort by stakeholders to keep our home country in the project, it now appears that Germany's participation will be made possible after all.

Such decisions create uncertainty at exactly the moment biotechnology companies need reliability. Investment decisions in our industry are measured in years, not quarters. Companies need predictable regulation, dependable funding structures and confidence that political priorities will survive the annual budget cycle.

This is about more than biotechnology. Germany is undergoing structural change across many traditional industries. Biotechnology and the broader life sciences sector can become important sources of future growth, highly skilled employment and regional investment.

Germany has the science, the people, the industrial base and a growing community of innovative companies. What it needs now is greater scale: better technology transfer, deeper growth capital, clear and predictable regulation, and faster, more consistent implementation. The global biotechnology race will not wait for Europe.

This German Biotech Guide shows the breadth of the foundation already in place. Our objective must be to ensure that the next generation of biotechnology innovation is not only discovered in Germany and Europe, but also financed, developed, scaled and manufactured here.

That is how scientific excellence becomes sustainable economic strength.

BIO DEUTSCHLAND

BIO Deutschand
Schützenstraße 6a
10117 Berlin

info@biodeutschland.org
www.biodeutschland.org

Germany's Biotech Strength: Creating the Conditions for Impact

Dr. Kai Joachimsen,
CEO BPI e.V.

Biotechnology is one of the defining forces in modern medicine. It is transforming how diseases are prevented, diagnosed and treated – from monoclonal antibodies and recombinant proteins to mRNA technologies, vaccines, gene and cell therapies. For patients, this means new options for difficult-to-treat diseases, more targeted therapies and, in some cases, treatments that can fundamentally alter, and even cure, diseases. For Germany, biotechnology is therefore a strategic asset for pharmaceutical innovation, patient care, industrial value and security of supply.

Its biotechnology ecosystem brings together research institutes, startups, established companies, service providers and global pharmaceutical manufacturers. In 2025, the German biotechnology sector comprised 1,052 companies and employed 59,607 people. In the German medicines market, biopharmaceutical sales reached €25.1 billion in 2025, compared with €22.1 billion in 2024. The sector invested €4.5 billion in research and development in 2025. These figures show how deeply biotechnology is embedded in Germany's medicines ecosystem.

The innovation pipeline is equally significant. In 2025, 37 medicines with new active substances were launched in Germany; 41% were manufactured using genetic engineering, and one further vaccine was produced biotechnologically without genetic engineering. Biotechnology is no longer a niche: it is an important part of the mainstream medicines pipeline, from vaccines and antibodies to advanced therapies. Oncology and immunology remain among the largest fields of application across biopharmaceutical care.

Biosimilars add another important dimension. In the ambulatory statutory health insurance market, biosimilar sales reached almost €3 billion in 2025, representing 6.0% of total market value at manufacturer prices. Their growing availability can broaden access to established biological therapies and create competition in a technologically complex market. Biotechnology therefore contributes to care through both pioneering treatments and established biological medicines.

Security of Supply

This growing role also changes what security of supply means. Reliable access to medicines depends not only on inventories and logistics, but also on resilient research, manufacturing and technological capabilities. Biopharmaceutical production requires specialised facilities, sophisticated analytical methods, highly qualified personnel

© BPI / Kruppa

and carefully controlled supply chains. Maintaining these capabilities in Germany and Europe can reduce strategic dependencies and strengthen the resilience of pharmaceutical value chains.

Advanced therapies demonstrate both the promise and the challenge of the next phase of biotechnology. Gene and cell therapies, RNA-based medicines and other innovative modalities can address diseases at a biological level that was previously inaccessible. They also require new capabilities across the value chain – from research and clinical trials to specialised manufacturing, hospital infrastructure and appropriate reimbursement. Germany has outstanding scientific and clinical capabilities. The task now is to connect them more effectively and make the path from discovery to patient benefit faster and more predictable.

Framework Conditions

This requires the right framework conditions. Companies must be able to found, finance, develop, manufacture and launch innovative medicines in Germany and Europe. Efficient regulation, faster clinical trials, dependable intellectual-property protection, access to growth capital and competitive production conditions are essential. Modern data infrastructures, skilled people and a healthcare system that recognises the long-term value of medical progress are equally important.

This is precisely what the German Pharmaceutical Industry Association (BPI) advocates for. We represent the full spectrum of the pharmaceutical industry, including biotechnology companies, research-based manufacturers, generics companies and service providers. With around 260 member companies employing approximately 78,000 people, we work to help shape conditions that strengthen innovation, secure supply and improve patient care.

The companies presented in this guide embody the breadth and ambition of German biotechnology, connecting science with entrepreneurship, innovation with manufacturing and progress with patient benefit. If Germany succeeds in creating the conditions in which scientific excellence can become clinical progress, industrial capability and reliable supply, biotechnology can make an even greater contribution to better health – and to a resilient, competitive life-sciences location in Germany and Europe.

BPI Bundesverband der Pharmazeutischen Industrie e.V.

Bundesverband der
Pharmazeutischen
Industrie e.V. (BPI)
Friedrichstraße 148
10117 Berlin
Phone: +49 (0) 30 2 79 09 0
E-Mail: info@bpi.de

www.bpi.de

Every Colour of Biotech. One Place. ACHEMA 2027.

Dr. Björn Mathes
CEO, DECHEMA Exhibitions

Red, white, green, yellow: whatever colour your biotechnology is, the equipment, machinery and know-how to scale it will be in one place in 2027. From 14 to 18 June, ACHEMA brings the entire biotech value chain to Frankfurt am Main, from lab bench to bioreactor and from single-use system to full-scale production plant. If you develop, produce or engineer biotech, this is the week that sets your agenda for the next three years.

ACHEMA 2027 goes further than ever. For the first time, ACHEMA takes the stage as the World Forum and Leading Show for Life Science and Process Industries. This is not a rebranding for its own sake. It answers what we see every day: the boundaries between chemistry and biotechnology are dissolving. Enzymatic steps in synthetic pathways, bio-based feedstocks in chemical plants, and microorganisms driving recycling have merged into one field of innovation, and ACHEMA is where that field comes together.

The numbers speak for themselves. In 2024, one third of our participants came from pharma and life sciences. Over 106,000 participants from 141 countries met close to 2,900 exhibitors from 56 countries. Nowhere else will you find this density of suppliers, users, researchers and decision-makers at one venue in one week. In 2027, two dedicated innovation themes, #pharma and #lab, sharpen this profile further. They are joined by the Action Area Digital Lab, which connects laboratory innovation with the digital transformation running from research to production.

Picture: © DECHEMA/Markus Püttmann

The congress, held right in the exhibition halls, puts biotech in the spotlight. Industrial biotechnology features within Green Innovation. Bioprocessing, next-generation therapeutics and single-use technologies for bio-based applications feature within Pharma Innovation. The full program will be published soon at www.achema.de/congress.

Want to see where biotech entrepreneurship is heading? Go to Hall 11.0, where the Start-up Area now sits alongside Research and Innovation. Ten finalists will compete for the ACHEMA Start-up Award, worth €15,000 and presented for the fifth time by DECHEMA, Business Angels FrankfurtRheinMain and High-Tech Gründerfonds. The partners and market leaders of tomorrow pitch here first.

Since 1920, ACHEMA has been where invention becomes innovation and academia meets industry. What makes 2027 special is that the stage has never been built so clearly for biotech. ACHEMA happens only once every three years. The partnerships, deals and ideas that start in Frankfurt will shape the industry until the next one. Make sure you are part of them.

I look forward to welcoming you in Frankfurt.

DECHEMA
Gesellschaft für Chemische Technik und Biotechnologie e.V.

DECHEMA Gesellschaft für Chemische Technik und Biotechnologie e.V.
Theodor-Heuss-Allee 25
60486 Frankfurt am Main
Germany

Phone: +49 69 7564-0
info@dechema.de

Biotechnology Needs Strong Bridges from Research to Application

Dr. Martin Walger
VDGH – Association of the Diagnostics Industry

With the 28th edition of the "Guide to German Biotech Companies," the German biotechnology sector once again presents itself to an international audience. The Guide highlights what sets our industry apart: scientific excellence, innovative companies, and a diverse industrial base. But it also demonstrates how important collaboration is throughout the entire innovation chain. After all, a good research idea only becomes progress when it finds its way into products, industrial applications, and the care of people.

This is where biotechnology, life science research, and diagnostics converge. The Association of the Diagnostics Industry (VDGH) represents both manufacturers of in vitro diagnostics (IVD) and the life science research industry (LSR). Our member companies supply the instruments, reagents, test systems, and technologies that enable research and development, support industrial processes, and advance modern medical diagnostics. Personalized medicine, in particular, demonstrates just how closely these fields are interconnected: New therapies require powerful research methods, reliable analytics, and precise diagnostic information.

Cell and gene therapy is a prime example of this. From researching new mechanisms of action to culturing and processing cells, all the way through to manufacturing and quality assurance, technologies from the LSR industry are indispensable. Diagnostics support the selection of suitable patients, treatment decisions, and the monitoring of treatment success. What is often perceived as separate industries is, in practice, part of a shared value chain.

With the High-Tech Agenda for Germany, the federal government has designated biotechnology as one of six priority key technologies. The biotechnology roadmap presented in May 2026 sets out key priorities: Germany is to become a leading international hub for the development and production of gene and cell therapies. The roadmap also includes the expansion of genome sequencing, AI-supported processes, and innovative medical technology. We expressly welcome the fact that research, diagnostics, and industrial application are considered together in this context. For it is precisely at these interfaces that it is determined whether scientific advances will find their way into practical application.

Now it comes down to implementation. To achieve this, companies need reliable research funding, access to high-performance infrastructure, and better conditions for transferring innovations from the scientific community. Startups and small and

© VDGH / Bildschön Berlin

medium-sized enterprises, in particular, must be able to develop and finance innovations and bring them into industrial production. At the same time, funding programs alone are not enough. Investments require predictable framework conditions, and new diagnostic procedures must be integrated into medical care more quickly.

Europe, too, has recognized the need for action. With its strategy for the European life sciences, the European Commission aims to make Europe the most attractive location for life sciences by 2030. The proposal for a European Biotech Act, to be presented by the end of 2025, is intended, among other things, to facilitate financing, clinical research, and the development of biotechnology production capacities. It is crucial for our companies that these initiatives give rise to a competitive European innovation space in which research results are not only developed but also successfully utilized and ultimately integrated into the value chain.

This requires regulation that ensures safety and enables innovation. With its proposal to revise the European Medical Devices and IVD Regulations, the European Commission has also opened the debate on more practical regulatory procedures. The VDGH advocates for less unnecessary bureaucracy and accelerated access to diagnostic innovations in standard care. The opportunities offered by automation, connected data, and artificial intelligence will only be realized if research, regulation, and healthcare work together.

As the VDGH, we bring the experience of our member companies to these debates. Our committees pool the industry's expertise; market analyses and the LSR FundFinder provide strategic guidance for companies; and our events foster dialogue with the scientific and political communities. At this year's LSR Spotlight Forum at analytica, for example, the focus was on organoids and artificial intelligence – two topics that demonstrate the potential inherent in collaboration across our industries. The life sciences research industry is thus regarded as a key sector for innovation and the future. That is why we are also committed to attracting qualified professionals and supporting the next generation of scientists.

The "Guide to German Biotech Companies" is part of this exchange. It highlights the innovative strength of German companies, fosters new connections, and underscores the importance of a strong biotechnology hub. As a cooperation partner, we are pleased to contribute to this effort. Let us bring together the strengths of research, life science research, and diagnostics even more closely so that innovations in Germany and Europe can emerge, grow, and deliver benefits to people.

VDGH
Verband der Diagnostica-Industrie

VDGH – Verband der
Diagnostica-Industrie e.V.
Neustädtische Kirchstr. 8
10117 Berlin
Tel. +49 30-2005 99-40
Germany

www.vdgh.de

LSR
Life Science Research
im VDGH

YMC

PRECISION

YMC – Consistency you can build on.

Reproducibility. Robustness. Reliability.

Consistent performance – every single day.
YMC-Triart columns ensure reproducible separations with outstanding stability, high resolution and exceptional analytical accuracy.

Curious to learn more? Discover us now.

ymc.eu

Profiles of German Biotech Companies

Name ›	ABclonal Germany GmbH
Address/P.O. Box ›	Emanuel-Leutze-Straße 8
Postal Code/City ›	40547 Dusseldorf
State ›	North Rhine-Westphalia
Contact Person ›	Dr. Jing Lu
Telephone ›	+49-211-1584-9841
Email ›	info@eu-abclonal.com
Website ›	abclonal.com
Social Media ›	
Number of Employees ›	500
Founded (year) ›	2011
Areas of Activity ›	I Develop and manufacture high quality reagents, including antibodies, recombinant proteins, molecular enzymes and NGS library preparation kits for research, IVD, CRO, and CDMO. I CRO service for antibody discovery, engineering, and production using hybridoma, single B cell, or phage display strategies. I CRO service for recombinant protein expression and peptide synthesis
External Collaborations ›	I The Michael J. Fox Foundation I YCharOS I mAb3D Atlas I Histologix Ltd

ABclonal Germany GmbH – Your European Partner in Global Life Sciences Innovation

ABclonal is an innovative growth company aiming to provide reliable and cost-effective products and services for both basic and translational research in cutting edge biomedical science. Innovation is our DNA, with worldwide R&D centres focusing on technical innovation and product development for protein science and molecular biology.

ABclonal Germany GmbH, a strategic branch of ABclonal Technology Co., Ltd., embodies the global vision and scientific excellence of its parent company while delivering localised expertise to researchers, biotech companies, and healthcare institutions across Europe. As part of ABclonal's international network – supported by R&D, production, and commercial hubs spanning North America, Asia, and Europe – we are committed to advancing life sciences innovation worldwide.

Global Strength, Local Precision

Leveraging ABclonal's global infrastructure, ABclonal Germany provides European clients with direct access to cutting-edge solutions in biological reagents, molecular enzymes, NGS automation, and antibody discovery services.

Why Partner with ABclonal Germany?

- Trusted Globally, Rooted Locally: Join 100,000+ international customers who rely on ABclonal's products, backed by our German team's commitment to responsiveness and regulatory excellence.
- End-to-End Solutions: From research antibodies to diagnostic materials, we provide products validated for global reproducibility, with logistics optimised for European timelines.
- Sustainability & Compliance: Aligned with EU regulations and sustainability goals, we prioritise ethical practices and eco-friendly innovation.



Our Milestones

- Antibody Production Services
  ABclonal was founded with a strong focus on providing customised antibody production services. Our mission has always been to enhance life science research by delivering better, high-quality antibodies.
- Every Protein Should Have an Antibody
  We launched the Human Genome Antibody Project, aiming to document and generate an antibody for every protein encoded in the human genome. By utilising recombinant protein antigens, we have successfully developed over 20,000 rabbit polyclonal and monoclonal antibodies.
- Next-Generation Sequencing (NGS)
  Leveraging the expertise of our molecular biologists and geneticists, we are developing cutting-edge NGS technology. Our goal is to produce innovative NGS library preparation kits while integrating advanced bioinformatics platforms. This will accelerate biomedical research and aid in the discovery of biomarkers for genetic and epigenetic diseases.

Our Mission

To become a global leader in biomolecular solutions.
Our Values:

- Customers Come First – We prioritise our customers' needs and success.
- Collaboration Over Individualism – We believe in teamwork and shared achievements.
- Clarity & Transparency – Honesty and openness drive our innovation.
- Embracing Challenges – We see obstacles as opportunities for growth.

ACILA
Dr. Weidner GmbH

Name › **ACILA Dr. Weidner GmbH**

Address/P.O. Box › **Opelstr. 14**
Postal Code/City › **64546 Mörfelden-Walldorf**
State › **Hesse**
Contact Person › **Mustafa Mentes**
Telephone › **+49-6105-9301-0**
Email › **info@acila.com**
Website › **acila.com/en**
Social Media › **in**
Number of Employees › **< 50**
Founded (year) › **1986**
Type of Laboratory › **Contract Laboratory, S1/S2, Clean Room Areas A/B/C, GMP, ISO 9001:2015, DIN EN ISO/IEC 17025:2018**

Areas of Activity ›
- **Bacterial Endotoxin Test Reagents & Accessory Products**
- **Sterile & Endotoxin-free Sample Vials**
- **Pharmaceutical Primary Packaging Material**
- **Animal Blood & Derivatives**
- **Microbiological and physico-chemical testing of medical devices, pharmaceuticals and active ingredients**

External Collaborations › **International Distribution Partnerships**

ACILA Dr. Weidner GmbH specialises in endotoxin-free and sterile laboratory products, pharmaceutical primary packaging materials, and animal blood and derivatives for use in pharmaceutical, biotechnological, and medical-device industries.

Founded by Dr. Peter Weidner in 1986 in Mörfelden-Walldorf near Frankfurt am Main, the company combines in-house production and an ISO 17025-accredited, GMP-regulated contract laboratory for microbiological and physico-chemical analysis under one roof, ensuring full traceability and compliance with Ph. Eur., USP, ISO and GMP standards.

Sample Vials, Bacterial Endotoxin Test Reagents & Accessory Products

With decades of expertise, ACILA produces high-quality reagents and consumables for Bacterial Endotoxin Test (LAL Test) and aseptic applications.

PYROKONTROL® stands for endotoxin-free sample vials, test tubes and high-purity diluents suitable for endotoxin and pyrogen testing.
STERICERT® represents ACILA's line of sample vials certified endotoxin-free and sterile, achieving a Sterility Assurance Level (SAL) of 10^{-6}.
Complementary products such as TrisSol® Tris Buffer, ACILA® LAL Reagent Water (LRW), and PYROCERT® LPS are produced under validated conditions and ensure consistent quality and reliability.

Pharmaceutical Primary Packaging Materials

Ready-to-use, sterile, and depyrogenated glass vials for pharmaceutical use.

PYROVAC® Vials have been specifically developed for the automated preparation of radiopharmaceuticals and can also serve as containers for drugs or diagnostic solutions, ensuring the highest standards of quality and safety.



Animal Blood and Derivatives

ACILA® supplies fresh sheep blood collected weekly from veterinarian-controlled donor animals via aseptic venipuncture.

The blood is processed under aseptic conditions – either gently defibrinated or treated with an anticoagulant such as heparin, sodium citrate, or EDTA. No preservatives or antibiotics are added.

This high-quality sheep blood is ideal for microbiological applications, including as an additive for culture media (e.g., blood agar), for the preparation of viable erythrocytes, simulation of contamination of e.g. surgical instruments, disinfectant efficacy testing and other diagnostic or research uses.

Contract Laboratory

ACILA operates an ISO 17025-accredited and GMP-regulated laboratory performing microbiological and physico-chemical testing of medical devices, pharmaceuticals and active ingredients in accordance with the European Pharmacopoeia (Ph. Eur.), the United States Pharmacopoeia (USP) and DIN EN ISO standards.

Among others, the following tests are routinely performed:

- Sterility Test
- Examination of Non-Sterile Products
- Bacterial Endotoxin Test (LAL Test)
- Particulate Contamination
- Determination of Chlorides

These services complement ACILA's in-house production – in full compliance with international standards – from a single source.

analytikjena
An Endress+Hauser Company

Name › **Analytik Jena GmbH+Co. KG**

Address/P.O. Box › **Konrad-Zuse-Strasse 1**
Postal Code/City › **07745 Jena**
State › **Thuringia**
Telephone › **+49-36-41-77-70**
Email › **info@analytik-jena.com**
Website › **www.analytik-jena.com**
Social Media ›
Number of Employees › **Around 900 worldwide**
Founded (year) › **1990**

Areas of Activity › **leading provider of technologies for molecular biology, liquid handling, laboratory automation, and analytical measurement**

Advancing Life Science Research through Precision and Automation

Analytik Jena is a leading provider of technologies for molecular biology, liquid handling, laboratory automation and analytical measurement. Founded in 1990 and headquartered in Jena, Germany, the company is part of the Swiss Endress+Hauser Group and serves customers in more than 100 countries worldwide.

As laboratories face increasing pressure to deliver faster, more reproducible results, automation is becoming essential for modern life science workflows. Analytik Jena helps biotechnology, pharmaceutical and research organizations boost productivity and standardize processes with advanced automation solutions. From automated DNA/RNA extraction, PCR and qPCR setup and NGS library preparation to cell-based assays, protein purification, single-cell applications and high-throughput drug discovery, our technologies enable reliable and scalable results across a wide range of life science workflows.

Liquid Handling and Assay Miniaturization

A core strength of Analytik Jena lies in liquid handling technologies. The company's portfolio spans a broad volume range, from picoliter dispensing to automated microliter-scale workflows. Solutions such as the CyBio liquid handling platforms enable precise and reproducible sample processing across a wide variety of applications.

To support assay miniaturization, Analytik Jena offers advanced non-contact dispensing technologies that accurately transfer extremely small volumes while reducing reagent consumption and preserving valuable samples. These capabilities are particularly beneficial for drug discovery, protein research, single-cell studies and high-throughput screening applications.

analytikjena
An Endress+Hauser Company

Automation for Modern Laboratories

Beyond stand-alone instruments, Analytik Jena develops integrated automation solutions tailored to customer requirements. By combining liquid handlers, thermocyclers, robotic transport systems and software tools, the company creates scalable workflows that improve laboratory productivity, consistency and traceability. Applications range from nucleic acid extraction and PCR setup to next-generation sequencing library preparation and sample processing.

Analytical Instrumentation for Industry and Research

Alongside its Life Science and Automation business, Analytik Jena is a well-established provider of analytical instrumentation for chemical analysis. The portfolio includes technologies for atomic spectroscopy, elemental analysis, molecular spectroscopy and TOC analysis. These solutions are used in environmental monitoring, pharmaceuticals, chemicals, food and beverage testing and industrial quality control.

Combined with dedicated consumables, application expertise and comprehensive services, Analytik Jena helps laboratories worldwide achieve precise, reliable results and efficient operations. By uniting analytical measurement technology, molecular biology, liquid handling and automation under one roof, the company supports customers from scientific discovery to routine laboratory applications.

Axolabs

Nucleic Acid Therapeutics by LGC

Name	**Axolabs GmbH**
Address/P.O. Box	**Fritz-Hornschuch-Str. 9**
Postal Code/City	**95326 Kulmbach**
State	**Bavaria**
Contact Person	**Dr. Ingo Röhl**
Telephone	**+49-9221-82762-0**
Fax	**+49-9221-82762-99**
Email	**info@axolabs.com**
Website	**www.axolabs.com**
Social Media	**in**
Number of Employees	**>400**
Founded (year)	**2000 (as Ribopharma; acquired by LGC in 2017)**
Type of Laboratory	**S1, S2**
Areas of Activity	**Research solutions for preclinical and clinical development with a focus on nucleic acid therapeutics (NAT), including bioinformatics-guided sequence selection, high quality oligonucleotide manufacturing, analytics (GMP), bioanalytics (GLP, GCP), lead molecule identification, and *in vitro* and *in vivo* pharmacology**
External Collaborations	**Axolabs collaborates with research groups around the world in the field of oligonucleotide therapeutics, including > 15 Big Pharma enterprises, > 200 biotech companies, and > 30 academic research institutes**

Your Complete Nucleic Acid Therapeutics Journey

Axolabs is a specialized CRO/CDMO dedicated to nucleic acid therapeutics. We support ASO, siRNA, sgRNA and mRNA programs from early discovery through commercial GMP manufacturing, helping clients accelerate development and reduce risk through an integrated end-to-end approach.

Why Axolabs?

- Specialized Expertise
  Over 20 years of experience focused exclusively on nucleic acid therapeutics.
- Integrated CRO/CDMO Services
  Discovery, development, analytics and manufacturing with one partner.
- Seamless Scale-Up
  Connected workflows and technical continuity from lead candidate to commercial production.

Research & Early Development

- Sequence design and optimization
- Lead identification and selection
- *In vitro* and *in vivo* pharmacology
- Cell-based efficacy and safety studies
- CRISPR/gRNA design and validation
- GLP/GCP bioanalysis and DMPK
- Sequencing and analytical development

Member of

BIO DEUTSCHLAND



Manufacturing & CMC

- Oligonucleotide and modified RNA synthesis
- Long oligonucleotide production
- LNP formulation and manufacturing
- Drug substance and drug product development
- CMC development and scale-up
- Technology transfer and process optimization
- GMP manufacturing and analytics

One Partner from Discovery to Commercialization

Axolabs integrates scientific, analytical and manufacturing expertise across the entire development pathway, enabling:

- Faster program progression
- Simplified technology transfer
- Data and process continuity
- Integrated CMC and analytical support
- Regulatory-ready documentation
- Efficient commercial scale-up

Trusted by Innovators Worldwide

Axolabs supports nucleic acid therapeutic programs through collaborations with leading pharmaceutical companies, biotechnology innovators and academic institutions worldwide.

Ready to advance your nucleic acid therapeutic?

Partner with Axolabs for specialized expertise across discovery, development and GMP manufacturing.

Name › **Biaffin GmbH & Co KG**

Address/P.O. Box › **AVZ 2, Heinrich-Plett-Str. 40**
Postal Code/City › **34132 Kassel**
State › **Hesse**
Contact Person › **Dr. Bastian Zimmermann**
Telephone › **+49-561-8044668**
Fax › **+49-561-8044665**
Email › **info@biaffin.com**
Website › **www.biaffin.com**
www.proteinkinase.biz
Social Media ›
Number of Employees › **8**
Founded (year) › **2001**
Type of Laboratory › **Analytical, ISO 9001:2015 certified**

Areas of Activity › **Service provider for biomolecular interaction analysis using SPR Biacore technology; supplier of recombinant proteins and reagents for kinase research and signal transduction**

External Collaborations › **Collaborations with academic research groups, CDMOs and commercial partners**

Request for Further Collaborations › **Biaffin is looking for strategic partners interested in complementing their analytical portfolio with SPR Biacore technology.**

Company overview

Biaffin GmbH & Co KG is an ISO 9001:2015 certified bioanalytical service provider specialised in the application of biosensors based on surface plasmon resonance (SPR) for biomolecular interaction analysis (BIA). BIA technology is ideally suited for highly accurate kinetic characterisation of any interacting molecules in real time in a label-free state. Biaffin has extensive knowledge and many years of experience in various application areas and supports biopharmaceutical drug development programme of pharma, biotech, and generic drug companies as well as scientific institutions worldwide as a competent partner. Our services are performed by a highly specialised team (PhD level scientists) in a laboratory well equipped with several state-of-the art SPR instruments (5x Biacore T200, 1x Biacore 8K+, 1x Biacore 1S+). Sufficient capacity of SPR instruments allows Biaffin to start interaction studies on short notice, quickly run multiple projects in parallel, and provide results in a timely manner. A qualified Biacore T200 instrument is available for SPR assay validation and GMP-like SPR analysis. The company's expertise is documented by many peer-reviewed publications in renowned scientific journals.

Analytical services for biopharmaceutical development

For the development of therapeutic antibodies, biopharmaceuticals, and biosimilars, Biaffin offers reliable SPR services for a highly accurate, quantitative kinetic characterisation, semi-quantitative kinetic ranking, or rapid qualitative screening of drug candidates. SPR assays have already been established for many target proteins and can be developed quickly by application of established protocols for reversible and site-directed coupling of biomolecules using specific capture surfaces. These assays can be applied for comparability and stability studies and batch-to-batch comparison during process optimisation. Available assay formats include dual-potency assays, pair-wise epitope mapping, and determination of active concentration based on binding activity (calibration-free methods). Assays can be validated and conducted under GMP-like conditions on a qualified Biacore instrument.

ADCC SPR assays

ADCC SPR assays are established for interaction analysis of antibodies with Fc gamma receptors (CD16, CD32, CD64) including receptor variants and different species, neonatal Fc receptor (FcRn), and complement C1q binding.

Small molecule drug development

Biaffin's services in small molecule drug development comprise customised SPR assay development for defined target proteins, fragment screening, hit validation, secondary screening, kinetic profiling, competition analysis, and lead optimisation of compounds to improve specificity, selectivity, and potency. Early ADME studies (serum protein binding) and studies on mode of action, cofactor requirements, and thermodynamic binding analysis further support the drug development process.

Catalogue products

Apart from analytical services, Biaffin offers a range of products serving customers' needs in kinase research and exploring cellular signal transduction pathways. Biaffin's product portfolio, available from the online shop www.Proteinkinase.biz, comprises recombinant proteins (kinases, cytokines, receptors, CD antigens), peptide substrates, specific inhibitors, and a biochemical ATP determination assay for customers' in-house research.

Quality statement

Biaffin has successfully implemented and maintains a Quality Management System certified according to the ISO 9001:2015 international standard, enhancing our ability to supply high-quality products and provide reliable, innovative services according to the highest quality standards, which consistently meet the needs and expectations of our clients.

Name › **BioCopy AG**

Address/P.O. Box › **Hochbergerstrasse 60F**
Postal Code/City › **CH-4057 Basel**
Country › **Switzerland**
Contact Persons › **Dr. Matthias Wiedenfels, CEO**
Email › **info@biocopy.com**
Website › **Biocopy.com**
Social media › **in**
Number of Employees › **40**

Areas of Activity › **Drug Discovery and Development**
Immuno-oncology
TCR-like Antibody Engineering
Development of next-generation Cancer Drug Candidates
AI-powered closed-loop Platform
pHLA complexes

The BioCopy Group

BioCopy is a German-Swiss biotech company headquartered in Switzerland with one R&D site in the south of Germany. BioCopy is breaking new ground in the development of next generation cancer drugs with its proprietary technologies joined in a unique AI-powered engineering platform.

The BioCopy platform

The BioCopy platform is designed to streamline and optimise the drug discovery and development process. It combines AI-powered workflows with wet-lab data in a closed-loop feedback system.

Streamlining Drug Discovery and Development

One of the most promising strategies in fighting cancer is the development of drugs that target specific markers typically concealed within cancer cells. While this approach holds great potential for therapeutic breakthroughs, it also presents significant challenges in identifying the ideal antibody and developing the optimal drug.

BioCopy focuses on the target class of so-called pHLA complexes. These are intracellular proteins presented as peptide fragments via HLA complexes on cell surfaces. Certain pHLA complexes are only found on cancer cells, making them ideal targets for cancer treatment – however, the difference to healthy cells is very small.

The engineering of therapeutic antibodies that target pHLA (so-called TCR-like antibodies) has been challenging and high-risk due to toxicity issues and the difficulties in the later manufacturing process.

BioCopy unlocks the transformative potential of TCR-like antibodies with a unique solution. We combine expertise in the pHLA space with high-throughput screening technologies, advanced protein engineering, and cutting-edge cell culture. This wet lab framework is integrated with databases and artificial intelligence, enabling accelerated learning through a closed-loop feedback system.

The generated proprietary data is fed into BioCopy AI-powered engineering workflows which identify the most promising antibody candidates for a particular kind of cancer.

The combination of bioinformatic workflows and advanced AI tools broadens the scope of off-target sequences, ensuring comprehensive coverage and precise analysis. This minimises off-target toxicity, which is one of the biggest challenges in the development of such drugs.

Parallel Assessment and Development

The BioCopy approach ensures exceptional efficacy and safety. Our platform allows us to work on multiple tasks and processes in parallel.

This paves the way for a streamlined, efficient and highly effective path from molecular concepts to drug candidates that are not only ready for clinical trials, but have a high probability of success.

At BioCopy, we herald a revolution in the discovery and development of drugs with pHLA targeting, and we are redefining the benchmark for time to market.

biofidus
A member of the Midas Group

Name › **Biofidus GmbH**

Address/P.O. Box › **Guetersloher Str. 54**
Postal Code/City › **33649, Bielefeld**
State › **North Rhine-Westphalia**
Contact Person › **Peter Spieth**
Telephone › **+49-521-329-363 40**
Email › **info@biofidus.com**
Website › **www.biofidus.com**
Social Media › **in**
Number of Employees › **>40**
Founded (year) › **2015**

Type of Laboratory › **Analytical CRO**

Areas of Activity › **Biopharma**

Redefining the CRO Partnership

Biofidus GmbH is a family-owned CRO powered by an interdisciplinary team of scientists who are redefining what a CRO partnership should look like. Combining scientific rigor with a hands-on, collaborative approach, Biofidus delivers tailored analytical solutions for precise, competent, decision-ready insights.

Holistic Analytics for Biologics

Biofidus has established a holistic analytical platform for the complex structural and functional characterization of new biological entities (NBEs) and biosimilars. From individual analytical questions to comprehensive characterization programs, Biofidus helps customers understand critical quality attributes (CQAs), identify potential risks and make informed development decisions.

Support Across the Development Lifecycle

From startups to global pharmaceutical companies, Biofidus provides flexible analytical support from early R&D through scale-up and commercialization. Its responsive scientific approach helps reduce development risks, solve complex analytical challenges and keep projects moving forward.

Core Capabilities

- Physicochemical characterization (LC, LC-MS, CE, CD, FTIR, DLS and DSC)
- Functional characterization (cell-based assays, SPR and ELISA)
- Method development, qualification and method transfer
- High-throughput developability studies
- Lead and clone selection assessments
- Comparability and biosimilarity studies
- Impurity characterization
- Forced degradation studies
- DNA/RNA sequencing

Member of

BIO DEUTSCHLAND

Extended Capabilities Through Midas Pharma

As part of the Midas Pharma Group, Biofidus gives customers access to complementary commercial-stage capabilities, including GxP-related services, regulatory expertise, starting materials and intermediates and combination-product solutions supported by an innovative device portfolio.

Together, Biofidus and Midas Pharma provide integrated support for biopharmaceutical projects from early development through clinical and commercial stages.

European Clinical and Commercial Infrastructure

For clinical and commercial phases, Midas Pharma and Biofidus provide an established European pharmaceutical infrastructure. Services include EU import and QP batch release, Marketing Authorization Holder services supporting launch readiness, pharmacovigilance with in-house EU QPPV oversight and EU wholesale distribution.

By combining Biofidus' analytical expertise with Midas Pharma's pharmaceutical infrastructure, customers benefit from coordinated support across the biopharmaceutical value chain.

Boehringer Ingelheim

Name ›	Boehringer Ingelheim Biopharmaceuticals GmbH
Address/P.O. Box ›	Binger Strasse 173
Postal Code/City ›	55216 Ingelheim
State ›	Rhineland-Palatinate
Contact Person ›	Rebekka Wuester
Telephone ›	+49-6132-77-0
Fax ›	+49-6132-72-0
Email ›	bioxcellence@boehringer-ingelheim.com
Website ›	www.bioxcellence.com
Number of Employees ›	54,000 in 2025
Founded (year) ›	1885 in Ingelheim, Germany
Type of Laboratory ›	S1
Areas of Activity ›	Focus on human pharmaceuticals, animal health and biopharmaceutical contract manufacturing
Net Sales ›	27.8 billion EUR in 2025
Relevant R&D Budget ›	6.4 billion EUR in 2025
Request for Further Collaborations ›	Boehringer Ingelheim BioXcellence™ is a dedicated partner for biopharma companies, providing comprehensive development and GMP manufacturing services. Renowned for its reliability, the company supports clients throughout the lifecycle of their products, thus transforming biologic innovations into commercial realities.

Member of

BIO DEUTSCHLAND

Company profile

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 54,000 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow.

BioXcellence Manufacturing – Tailored Capacities. Reliable Supply. Your Success, Our Commitment.

Boehringer Ingelheim BioXcellence™ is a leading biopharmaceutical contract manufacturer – a reliable partner that accompanies customers throughout the life cycle of their products. We provide E2E biopharmaceutical manufacturing based on mammalian cell culture and microbial fermentation.

We have extensive experience with a variety of different host cells, producing a broad range of molecules in accordance with cGMP manufacturing guidelines and covering all stages of development, including aseptic filling. Our focus is on creating value for our customers through robust processes, effective preparation for launch, and global clinical and commercial supplies of high-quality biopharmaceuticals.

We are committed to maintaining high-quality standards in all operations, with robust systems designed to meet stringent regulatory requirements, and strong quality control capabilities that ensure product quality at every manufacturing stage. Our team's extensive regulatory experience and impressive inspection track record demonstrate our ability to navigate complex regulations and integrate in-depth technological knowledge into our operations.

World-Class Expertise

With over 40 years of biotechnology experience and a team of dedicated and highly trained employees, we have helped our customers bring more than 45 biopharmaceutical medicines to the market, serving patients all

over the world. Our expertise spans across various host cells, enabling us to produce a wide array of molecules. Our commercial portfolio comprises monoclonal antibodies, recombinant proteins, antibody fragments, and recombinant vaccines, and is complemented by intensive experience in bi- and multispecific antibodies, Fc fusion proteins, scaffolds, peptide hormones, and pDNA.

World-class Facilities

Our network of manufacturing facilities spans US and EU, from Fremont, California to Biberach in Germany, and Vienna in Austria. With around 450 kL for mammalian cell culture and 12 kL for microbial fermentation in fully licensed multiproduct facilities we are your right partner for high-quality global supplies of biopharmaceuticals to patients. This is evidenced by our regulatory excellence. Our operations are based on fully licensed multi-product facilities for all major markets. One-quality, one-compliance, and one-regulatory form the foundation of our global network.

Your World-class Production Partner

For many of our customers, we are the preferred partner for reliable supplies. Seven of the top 10 pharmaceutical companies already trust us due to our extensive commercialisation experience. At Boehringer Ingelheim, we are deeply invested in the success of your product. Our shared passion is reflected in our commitment to providing the highest quality services and solutions to ensure your product reaches its full potential.

Aside from our extensive experience and technical expertise, which complements yours, there are several other compelling reasons to choose us as your trusted contract manufacturing partner. At Boehringer Ingelheim, we have learned over the generations that the challenging path towards health innovation requires long-term commitment, resilience, and transformative action.

Let's build a future together based on our history. We have capabilities to complement your expertise and are committed to turning your biologic innovation into commercial reality.

BRAIN BIOTECH

Name ›	BRAIN Biotech AG
Address/P.O. Box ›	Darmstädter Straße 34 – 36
Postal Code/City ›	64673 Zwingenberg
State ›	Hesse
Telephone ›	+49-6251-9331-0
Email ›	info@brainbio.com
Website ›	www.brainbiocatalysts.com
Social Media ›	
Number of Employees ›	~ 300
Founded (year) ›	1993
Type of Laboratory ›	S1, S2, L1, L2
Areas of Activity ›	Industrial Biotechnology Contract Research Services: I Enzyme technology I Microbial strain development I Bioprocess development I Scale-up Contract Manufacturing Services Products: Enzymes, ingredients
Request for Further Collaborations ›	We're looking for partners in the food, feed, chemicals, cosmetics and pharmaceutical industries to work with us to develop innovative, bio-based solutions.

Custom Enzymes, High-performing Production Strains & Scalable Bio-processes.

Under the new BRAINBiocatalysts brand, BRAIN Biotech AG brings together the expertise and services of BRAIN Biotech and Biocatalysts. The integrated offering spans enzyme discovery, strain development, manufacturing and application know-how, providing customers with seamless support from science to application.

R&D, Bioprocess and Manufacturing Services

- Enzyme discovery & engineering: We identify and develop enzymes through our proprietary screening platforms, rational design combining bioinformatics with AI predictions, as well as directed evolution. Clients benefit from unique metagenomic sequence resources and our broad range of microbial strains for gene expression.
- Microbial strain development: Industrial production strains (bacteria, yeast, fungi) are designed to produce enzymes, proteins and biomolecules in high yields. The group offers strain engineering using genome editing or classical methods as well as biosynthetic pathway engineering.
- Bioprocess development & scale-up: Customized bioprocess design helps customers to advance the production of microbial enzymes and proteins. The production of microbial biomass supports those lacking in-house microbiology expertise and production capabilities.
- Manufacturing: The production site in Cardiff, Wales has production capabilities of up to 2 x 10,000 liters, as well as full downstream processing capabilities. Facilities are food-grade, kosher and halal-certified, ensuring compliance with global markets.

Member of

DECHEMA Gesellschaft für Chemische Technik und Biotechnologie e.V.

BIO DEUTSCHLAND



End-to-end Solutions for Enzymes

Enzyme discovery and engineering, strain development and production at industry scale are all part of the BRAINBiocatalysts service.

The modular approach allows customers to select individual services or use BRAINBiocatalysts as an end-to-end development and manufacturing partner.

Biological Resources

The biological resources include the BioArchive, a collection of more than 50,000 microorganisms, and the MetXtra™ platform with extensive digital metagenomic sequence resources.

These resources provide starting points for discovering novel enzymes, microorganisms and production strains. They can also support customer-specific exclusivity and freedom-to-operate strategies, subject to the agreed contractual and licensing model.

Proprietary CRISPR-Cas-like genome-editing tools can be used in microbial strain development. These technologies enable targeted genetic modifications and can accelerate the creation and optimization of production strains. Access may be provided through customer development projects or licensing models, depending on the technology and intended field of use.

Name › **CeGaT GmbH**

Address/P.O. Box › **Paul-Ehrlich-Strasse 23**
Postal Code/City › **72076 Tübingen**
State › **Baden-Wuerttemberg**
Telephone › **+49-7071-565-44-55**
Fax › **+49-7071-565-44-56**
Email › **info@cegat.com**
Website › **www.cegat.com**
Social Media ›
Number of Employees › **500+**
Founded (year) › **2009**

Areas of Activity › **Genetic analysis, next-generation sequencing (NGS), proteomics**

About CeGaT

CeGaT is a global provider of genetic analyses for a wide range of medical, research and pharmaceutical applications.

Founded in 2009 in Tübingen, Germany, CeGaT combines state-of-the-art sequencing technologies with medical expertise to identify genetic causes of diseases and support patient care. For researchers and pharmaceutical companies, CeGaT offers a broad portfolio of sequencing services and tumor analyses. CeGaT generates the data basis for clinical studies and medical innovations and drives science forward with its own insights.

The owner-managed company stands for independence, comprehensive personal customer service and outstanding quality. CeGaT's laboratory is accredited according to CAP/CLIA, DIN EN ISO 15189 and DIN EN ISO/IEC 17025 and thus meets the highest international standards. This commitment to quality is complemented by certification according to DIN EN ISO/IEC 27001, the internationally recognized standard for information security management.

Your Partner for Next-Generation Sequencing (NGS)

Our vision is to make next-generation sequencing available to all life scientists and bring our expertise from genetic diagnostics into research applications.

As pioneers in NGS-based genetic diagnostics, we have extensive experience in sequencing and bioinformatic analysis. Based on this expertise, we provide sequencing services for research and pharmaceutical projects. We perform all processes in-house in Germany and use automation wherever possible to ensure consistently high quality.

Member of

BIO DEUTSCHLAND

Our interdisciplinary team brings together specialists from various scientific disciplines. A dedicated project manager serves as your single point of contact, providing advice and support from initial consultation to final data delivery. We offer sequencing solutions that match your specific research requirements.

A Comprehensive Service Portfolio to Match Your Project's Requirements

To support scientists in projects of different scopes, we offer a broad portfolio of sequencing services, including:

- Whole Genome Sequencing
- Whole Exome Sequencing
- Transcriptome Sequencing
- Ready to Load Sequencing

The portfolio is complemented by analyses for microbiome, immunology, translational oncology, epigenomics and proteomics studies. We also support NGS projects within clinical studies. Based on your project's requirements, we identify the most suitable services from our portfolio, with options for nucleic acid isolation, data output formats and further bioinformatic analyses.

Advanced Sequencing Infrastructure

CeGaT continuously invests in advanced equipment and technologies to ensure high-quality data and analyses. In-house, we operate five Illumina NovaSeq™ 6000 and four NovaSeq™ X Plus systems for high-throughput short-read sequencing. For high-quality long-read sequencing, we use the PacBio Revio platform. Our technological infrastructure also includes 10x Genomics platforms for single-cell applications and Olink technology for proteomics analyses. Together, these capabilities support a broad range of research and pharmaceutical projects.

cellex.
Cell Professionals

Name › Cellex Cell Professionals GmbH

Address/P.O. Box › Melli-Beese-Str. 9-11
Postal Code/City › 50829 Cologne
State › North Rhine-Westphalia
Telephone › +49-221-2509-0
Email › businessdevelopment@cellex.me
Website › www.cellex.me/en
Social Media › in
Number of Employees › 200+
Founded (year) › 2001

Type of Laboratory ›
- GMP manufacturing area
- EU Cleanroom Grade A/B/C/D
- Cryostorage area
- Development and QC labs
- Apheresis unit

Areas of Activity ›
- Regulatory strategy support and consultancy
- GMP manufacturing & quality control
- Technology transfer from preclinical
- Analytical & process development
- Transport & logistics services
- Apheresis collection & supply of cellular starting materials
- Batch certification

From Cell Sourcing to Cell Therapy Manufacturing

Your trusted European CDMO for Cell Therapy

Cellex has strong expertise in manufacturing final and intermediate drug products for Cell and Gene Therapy. Benefit from our comprehensive solutions to get your innovative drug products from early preclinical stage to clinic and commercialization. As a reliable and trusted partner of international pharma and biotech companies, with extensive knowledge in autologous and allogeneic development and manufacturing, Cellex is a full-service CDMO partner.

Manufacturing of CGT Products / ATMPs

Our state-of-the-art facility offers GMP-compliant services across the entire product lifecycle – from process development to clinical and commercial manufacturing.

- 11,000+ manufactured ATMP batches
- 100% batch acceptance rate and 99%+ in-spec performance
- Autologous and allogeneic CGT products / ATMPs
- In-house QC labs, cryostorage and QP release
- Experienced team including highly qualified operators, project managers and consistent leadership
- Track record of supplying 4 commercial products

Why Partner with Cellex?

- Full regulatory compliance (e.g. EMA, FDA, ICH, GMP), consultancy and audit capabilities
- High capacity with the flexibility to scale on demand
- Broad portfolio of analytical methods to ensure product quality
- Manufacturing process development and optimization
- GDP-compliant, customized logistics & transport solutions
- End-to-end support related to CGT products: Project Management, QP Services, and Product Labelling
- In-house cellular starting material supply

Human Cellular Starting Materials

Cellex offers high-quality starting materials for R&D, clinical and commercial use. With >50,000 collections performed, Cellex has deep expertise in collecting allogeneic and autologous cellular blood products. Cellex's comprehensive portfolio of human starting materials for cell therapy includes Leukopaks, G-CSF Mobilized Leukopaks, Bone Marrow and Whole Blood.

Why Choose Cellex as a Supplier?

- Located in Cologne with direct access to highways, high-speed trains and several airports for fast delivery worldwide
- Highly diverse donor database, with healthy and diseased donor material
- Donor prescreenings and recallable donors available
- Specialized collection centre for CGT collections
- Customized cell products according to client-specific needs
- Autologous patient collections for clinical use

Name › **Collaborative Drug Discovery, Inc.**

Address/P.O. Box › **Nine Hills Road**
Postal Code/City › **CB2 1GE Cambridge**
Country › **United Kingdom**
Contact Person › **Dr. Mariana Vaschetto**
Telephone › **+44-1223-803830**
Email › **mariana@collaborativedrug.com**
Contact Person Germany › **Mel Berg, European Marketing Lead**
Email › **mberg@collaborativedrug.com**
Website › **www.cddvault.com**
Social Media ›
Number of Employees › **>100**
Founded (year) › **2004**

Areas of Activity ›
- **Drug discovery collaboration**
- **Collaborative data management**
- **Cloud-based research tools**
- **Data analysis and management**
- **Workflow automation**
- **AI/ML integration in drug discovery**
- **Cross-team collaboration**

CDD Vault - Software for Scientific Data Management

Collaborative Drug Discovery (CDD) is a software company advancing pharmaceutical research through powerful tools for managing chemical and biological data. Founded in 2004, its flagship platform, CDD Vault, was built to meet FAIR data standards and designed to scale - helping teams accelerate research, reduce administrative burden, and create a secure foundation for AI-driven discovery and investor-ready reporting.

CDD Vault supports both small molecule and biologic research, enabling integration and analysis of diverse datasets within one platform. Researchers can manage chemical structures, reaction pathways, and biological assay data while also working with complex modalities such as peptides, antibodies, nucleic acids, and bioconjugates including antibody-drug conjugates (ADCs). The platform includes enhanced sequence-based registration with chemically aware structures and a built-in macromolecule editor for accurate biologics representation and structure-activity analysis. By unifying chemical and biological data management, CDD bridges a key gap in modern drug discovery workflows.

The Flagship Product: CDD Vault

CDD Vault is a secure, cloud-based system for managing, visualising, and sharing drug discovery data. Designed for scientists, it provides a collaborative environment to store, analyse, and interpret research data. Key capabilities include:

- Structure-Activity Relationship (SAR) Tools: Correlate chemical and biologic structures with activity data.
- Data Visualisation: Intuitive graphs and plots for interpreting complex datasets.
- Collaboration Controls: Role- and project-based permissions for secure internal and external sharing.
- Integrated Assay & Activity Management: Centralised assay definitions and biological data analysis.
- Electronic Lab Notebook (ELN): Flexible experimental data capture linked to compounds and assays.
- Inventory & Sample Management: Tracking of compounds, biologics, and samples.







Driving Collaboration

CDD supports seamless collaboration among medicinal chemists, biologists, and computational scientists by enabling shared insights and transparent communication. Integration with external tools and a RESTful API allow efficient data exchange and comprehensive analysis.

Industry Applications

CDD Vault is widely used by pharmaceutical companies, academic institutions, and research organisations to support:

- Target identification and validation
- Lead optimisation
- Preclinical research
- Small molecule and macromolecule development

Security and Compliance

CDD maintains rigorous security standards and regulatory compliance, including 21 CFR Part 11, ensuring data confidentiality and integrity in regulated environments.

Future-Focused Innovation

Built for scalability and FAIR principles, CDD Vault continues to evolve with AI-assisted generation and analysis tools that enhance SAR interpretation across chemical and biologics datasets. Structured data tagging makes datasets machine-readable and AI-ready. These capabilities help researchers extract actionable insights, reducing the time and cost of bringing new therapeutics to market.

Conclusion

Collaborative Drug Discovery is transforming how teams manage and collaborate on chemical and biological data. Through its unified, intuitive platform, CDD accelerates drug discovery and supports the development of better therapies worldwide.

eppendorf

Name › **Eppendorf SE**

Address/P.O. Box › **Rudolf-Schulten-Str. 5**
Postal Code/City › **52428 Jülich**
State › **North Rhine-Westphalia**
Email › **bioprocess-info@eppendorf.de**
Website › **www.eppendorf.link/bioprocess**
Social Media ›
Founded (year) › **1945**

Areas of Activity › **bioprocess, lab consumables, lab automation, pipettes, centrifuges, incubators**

Moving science through excellence, let's bioprocess together!

Since 1945, Eppendorf has been developing tools that help scientists work with confidence and precision. From our first pipette to today's broad portfolio of laboratory devices and consumables, our history is shaped by a clear purpose: improving human living conditions through science. We combine technical expertise with an understanding of the people who rely on our products every day.

Bioprocessing brings this purpose to life. It supports the development and manufacturing of products that can improve health and well-being, including vaccines, antibodies, cell and gene therapies, and modern food. Our upstream bioprocess portfolio includes scalable bioprocess systems, single-use bioreactors, software solutions, and services.

Together, these solutions help you monitor and control your processes efficiently, automate routine tasks, and use data to build process understanding - from the initial idea to a robust process, from the laboratory to manufacturing.

Quality and innovation guide every step. We know that bioprocessing is unique to every business and no two processes are the same. So, with our customers in mind, we focus on what matters in the laboratory and on the manufacturing floor: dependable function, intuitive usability, consistent performance, and making demanding work more manageable.

Member of

VDGH
Verband der Diagnostica-Industrie

Scalable bioprocess systems.

We focus on what matters most in the laboratory and on the manufacturing floor.

Moving science forward, together.

But we don't stop at the equipment stage. Our application services, training, and dependable technical support are here to help you overcome cultivation bottlenecks and process challenges. You can count on knowledgeable people who understand your goals and work with you to find the best solution for your request.

We also believe that progress grows through open exchange. At our regular open house bioprocess events, we bring scientists and industry professionals together to share experiences, discuss current challenges, and gain practical insights. These interactions keep us close to the reality of our equipment users and help turn their questions into better solutions.

In a nutshell, here are some examples where Eppendorf Bioprocess supports you:

- Cell and gene therapy development
- Antibody production
- Vaccine development
- Modern food process development
- Microbial fermentation
- Clinical and commercial manufacturing

Let's bioprocess together. Whether you're developing a vaccine, antibody, cell or gene therapy, modern food, or another product, we're ready to support your specific process. Together, we move science forward through excellence.

Name	**EVONIK Operations GmbH**
Address/P.O. Box	**Kirschenallee**
Postal Code/City	**64293 Darmstadt**
State	**Hesse**
Contact Person	**Dr. Tim Pohlmann**
Telephone	**+49-151-120-260-80**
Email	**tim.pohlmann@evonik.com**
Website	**www.evonik.com**
Social Media	
Number of Employees	**>1,000**
Founded (year)	**1982**
Type of Laboratory	**L1/L2/S1/S2,**
Areas of Activity	**I CDMO, Microbial Fermentation** **I Manufacturing: cGMP, FSSC 22000, EFfCI, ISO 9001, FAMI-QS** **I Strain and process development** **I Piloting and Scale-up**
External Collaborations	**CDMO, Joint Development, Supply Agreements, Joint Venture, Venture Capital**
Request for Further Collaborations	**Long-term business orientation**

A global precision fermentation leader from strain development to large-scale production

The Business Line Health Care at Evonik operates a global network of biotechnological production sites at different scales with up to 250 m³ fermentors. This network includes a versatile multi-product site in Slovakia, designed for process scale-up and market launch of new and innovative products, which is available to our industrial partners.

Evonik has leveraged its expertise in fermentation and biocatalysis technologies, including strain development, process optimisation, piloting, and large-scale manufacturing to bring a wide range of products to market. These products span various application fields, such as APIs, pharma intermediates, biomaterials, food ingredients, excipients, and cosmetics. With a total CDMO fermentation capacity exceeding 4,000 m³, Evonik's network of sites in the U.S. and Europe is well positioned to support customer projects and products, regardless of scale or process complexity.

Evonik CDMO services – a one-stop shop

In addition to development and production services, Evonik can support customers in techno-economical assessments (TEA) and life cycle assessments (LCA). Leveraging Evonik's extensive engineering experience, Evonik can also facilitate the realisation of brownfield or greenfield concepts in case the volume demand should exceed current capacities.

As such, Evonik positions itself as a comprehensive, one-stop shop and full-service provider.

Sustainability as a growth driver for biotechnology services

Industrial biotechnology is a crucial driver for growth and innovation, enabling the development of novel, nature-inspired products that are inaccessible through chemical synthesis, thereby complementing Evonik's existing technologies and services. Advances in synthetic biology and a shift towards sustainable manufacturing methods are increasing the demand for Contract Development and Manufacturing Organizations (CDMOs) with best-in-class microbial fermentation capabilities. For over four decades, Evonik has been a dependable partner to pharmaceutical companies and other innovators aiming to industrialise disruptive biofabrication technologies.

The Evonik biotechnology platform

The Evonik Biotech Hub serves as a central hub for various scientific disciplines within the global biotechnological network. With more than 100 scientists at three international sites, the Biotech Hub is the competence centre for industrial biotechnology at Evonik, providing everything from groundbreaking ideas to industrial bioprocesses, facilitating the transformation of business opportunities into commercially feasible processes.

The profound understanding of biological systems, like the interactions in different target systems or the elucidation of the mode of action, as well as the differentiating capability in designing and operating efficient and sustainable manufacturing processes for biomolecules and microbial solutions, enables the Biotech Hub to develop tailored and competitive solutions allowing its customers to assume a leading position in their respective markets.

Name ›	**Evotec SE**
Address/P.O. Box ›	**Manfred Eigen Campus Essener Bogen 7**
Postal Code/City ›	**22419 Hamburg**
State ›	**Hamburg**
Contact Person ›	**Sarah Fakih (EVP Head of Global Communications & Investor Relations)**
Telephone ›	**+49-40-560810**
Email ›	**info@evotec.com**
Website ›	**www.evotec.com**
Social Media ›	**in**
Number of Employees ›	**~4,500**
Founded (year) ›	**1993**
Areas of Activity ›	**Drug discovery & preclinical development; integrated R&D services; small molecules & biologics; cell therapies; AI-driven discovery; PanOmics & iPSC-based disease modeling; ADME-Tox(Cyprotex); biologics development & manufacturing (Just – Evotec Biologics); oncology; neuroscience/CNS; metabolic & cardiovascular diseases; immunology; infectious diseases.**
Annual turnover ›	**€ 788.4 m (2025)**
Relevant R&D budget ›	**€ 37.5 m (2025)**
Biological Patents ›	**A broad portfolio of patent families relating to compounds, targets, and assays.**
External Collaborations ›	**Evotec is working with more than 800 pharma and biotech companies, academic institutions, and healthcare stakeholders globally.**
Request for Further Collaborations ›	**Our sales teams are happy to discuss our end-to-end R&D solutions, in- and out-licensing opportunities, and how we can assist you in meeting your drug discovery and preclinical development needs.**

Member of

BIO DEUTSCHLAND

Evotec is a globally operating life science company advancing drug discovery, preclinical development, and manufacturing through highly integrated, technology-enabled partnerships. Headquartered in Hamburg, Germany, Evotec delivers comprehensive solutions that translate deep molecular disease understanding into innovative, high-quality therapeutics across multiple modalities.

Evotec's activities cover the full continuum from target identification to clinical and commercial manufacturing, enabling flexible collaboration models for pharmaceutical, biotechnology, academic, and non-profit partners worldwide. By combining advanced science, leading technologies, and data-driven innovation, Evotec accelerates the discovery and preclinical development of differentiated medicines across a broad range of therapeutic areas. The company's partnership approach goes beyond traditional service delivery by offering access to proprietary platforms, extensive multimodal data resources, and shared scientific risk and reward.

Discovery & Preclinical Development

A core strategic pillar of Evotec's business is its Discovery & Preclinical Development (D&PD) segment, which integrates biological expertise with proprietary technology platforms to make early-stage R&D more predictive and effective. At the intersection of science, technology, and data, Evotec applies industrialised, multimodal approaches to understand disease biology and translate insights into high-quality development candidates. Key capabilities include the PanOmics multi-omics platform, extensive molecular patient databases, and iPSC-based disease modelling, enabling highly translational, patient-relevant research across diverse indications.







A defining feature of D&PD is the integration of AI and machine learning throughout discovery workflows. Scalable data infrastructures, advanced analytics, and AI-enabled models support faster hypothesis generation and validation, deeper target characterisation, and smarter compound and modality design. By systematically linking biological data with predictive algorithms, Evotec enhances decision-making, reduces attrition risk, and improves the probability of clinical success.

Just – Evotec Biologics

Evotec's second strategic pillar, Just – Evotec Biologics, extends the company's capabilities into biologics development and manufacturing. Built on its proprietary continuous manufacturing platform and pioneering expertise, Just – Evotec Biologics combines molecular optimization, process development, and advanced bioprocessing technologies to deliver efficient, scalable production of modern biotherapeutics. Compared with conventional fed-batch approaches, its continuous manufacturing technology can significantly increase productivity while reducing manufacturing footprint and cost, including for complex biologics that may be challenging to produce using traditional methods. Having manufactured more than 90 distinct products, including 50 complex biologics, across clinical and commercial development, Just – Evotec Biologics offers capabilities from development through commercial supply. In addition to end-to-end CDMO services, the business also provides an asset-light technology licensing model, enabling customers to access and deploy the platform with flexibility.

Through the combination of integrated discovery platforms, strong AI-enabled analytics, and next-generation biologics manufacturing, Evotec positions itself as a long-term innovation partner committed to improving efficiency, predictability, and success rates of drug development to bring new therapies to patients faster.

Name › **Exyte**

Address/P.O. Box › **Loewentorstrasse 42**
Postal Code/City › **70376 Stuttgart**
State › **Baden-Wuerttemberg**
Telephone › **+49-711-8804-0**
Email › **info.BLS@exyte.net**
Website › **www.exyte.net**
Social Media ›
Number of Employees › **12,000**
Founded (year) › **1912**

Areas of Activity › **EPC/EPCM for the planning, design and delivery of high-tech facilities in the biopharma and life sciences, semiconductor, battery, and data center sectors**

Engineering the future of technology

Exyte is a global leader in the design, engineering and delivery of facilities for the pharmaceutical, biotechnology and wider life sciences industries. Combining decades of process engineering and GMP expertise with comprehensive project execution capabilities, the company supports clients from research and development through to large-scale commercial manufacturing. By combining advanced engineering with digital technologies and cleanroom expertise, Exyte helps bring new therapies and medicines to market faster.

Exyte combines deep life sciences expertise with global engineering and delivery capabilities to execute complex pharmaceutical and biotechnology projects. The company offers both EPC and EPCM delivery models, enabling clients to select the approach that best fits their project requirements.

Engineering and delivery expertise

Exyte's expertise spans the full spectrum of pharmaceutical and biotechnology facilities, including biologics, vaccines, cell and gene therapies, xRNA technologies, viral vectors, radiopharmaceuticals and small molecule production. The company also delivers advanced aseptic fill-and-finish facilities, oral solid dosage plants, continuous manufacturing environments, laboratories, pilot plants, research and development centers, quality control facilities and manufacturing science and technology (MSAT) environments. This expertise is reflected in Exyte's track record of contributing to multiple Facility of the Year Award (FOYA)-winning projects.

Innovation, digitalization and sustainable facilities

A broad portfolio of services supports clients throughout the project lifecycle, including process engineering, facility design, cleanroom solutions, compliance and qualification services, automation, digitalization and operational readiness. Exyte integrates technologies such as digital twins, advanced visualization tools and data-driven facility concepts to enhance efficiency, accelerate project delivery and support Pharma 4.0

strategies. Modular design approaches and off-site manufacturing capabilities further help shorten project timelines while maintaining the highest standards of quality, safety and regulatory compliance.

Beyond pharmaceuticals and biotechnology, Exyte also serves companies in food and nutrition, consumer care and specialty chemicals, delivering sophisticated production and research facilities that require highly controlled environments and demanding technical standards. Sustainability is embedded throughout the company's approach, with a focus on energy-efficient buildings and resource-conscious design that support future-ready manufacturing facilities.

About Exyte

Exyte is a global leader in the design, engineering and delivery of ultra-clean and sustainable facilities for high-tech industries. With cutting-edge expertise developed over more than a century, the company serves clients in the sophisticated markets of semiconductors, battery cells, pharmaceuticals, biotechnology and data centers. Exyte offers a full range of services, from consulting to managing the implementation of built complete solutions with the highest standards in safety and quality, to its customers worldwide. Exyte creates a better future by enabling key industries to enhance the quality of modern life.

FGK
CLINICAL RESEARCH

Name ›	**FGK Clinical Research GmbH**
Address/P.O. Box ›	**Heimeranstr. 35**
Postal Code/City ›	**80339 Munich**
State ›	**Bavaria**
Contact Person ›	**Martin Krauss**
Telephone ›	**+49-89-893-119-0**
Email ›	**martin.krauss@fgk-cro.com** **rfp@fgk-cro.com**
Website ›	**www.fgk-cro.com**
Social Media ›	**in**
Number of Employees ›	**240+**
Founded (year) ›	**2002**
Areas of Activity ›	**Full service CRO for conduct of clinical studies, offering support in** **| Regulatory Affairs** **| Project Management/Monitoring** **| Medical Safety** **| Data Management/Biostatistics** **| Medical Writing** **| eSolutions** **| Quality Assurance** **all over Europe.** **Our daughter companies create special added value for our clients:** **| "FGK Representative Service":** **EU Representation Services which are legally required for non-European sponsors conducting clinical studies in the EU (EEA).** **| "FGK Pharmacovigilance":** **Post-Market PV services including QPPV and PSMF.**
External Collaborations ›	**BVMA - Federal Association of Contract Research Organisations**
Request for Further Collaborations ›	**Small to mid-sized biotech, device or pharmaceutic seeking flexible support in their clinical development**

Company overview

FGK Clinical Research is an owner-managed CRO of an ideal size for cooperation with smaller and mid-sized biotech, medical device or pharmaceutical companies. Covering all phases and areas of clinical development in Europe, we have experience in every major medical indication, including oncology, cardiology, neurology, dermatology, and gastroenterology. Broad knowledge in rare diseases, ATMPs and Cell Therapy completes our expertise.

Most staff is located in our headquarters in Munich and our branch office in Berlin, Germany. We have operational subsidiaries in the Czech Republic, Hungary, Poland, the Netherlands, the United Kingdom as well as the US (Boston).

Our approach to a project

The main philosophy for FGK is to prepare and conduct studies in close cooperation with the sponsor.
Our operational team works hand-in-hand with all other departments involved. This also applies for the project manager, who is the central contact person delivering all required information to the sponsor.

Timely approvals and efficient troubleshooting are achieved through a combination of centralized project management and local monitoring, as well as local expertise and regulatory submissions within the country of study conduct.

Services

Clinical Operations

- Project management, primary liaison for sponsor communication, status reports, etc.
- Feasibility, site management, monitoring, etc.

FGK CLINICAL RESEARCH

Regulatory Affairs

- Consulting on regulatory topics
- Review of study documents (e.g. protocol, informed consent form, labels)
- Clinical Trial Application with submission to EU and non-EU regulatory bodies
- Legal representative – also visit www.fgk-rs.com

Medical Safety/Pharmacovigilance

- Adverse Event Management and assessment/reporting
- Drug safety, medical monitoring and coding of medical terms
- Pharmacovigilance – also visit www.fgk-pv.com

Medical Writing

- Investigator's brochures, study protocols, ICF and subject information
- Clinical expert reports, clinical publications, IMP and submission dossiers

Data Management

- CRF design and review, clinical trial databases
- Data validation, processing and cleaning, external data handling, CDISC SDTM

Biostatistics and Programming

- Study design, sample size calculations
- Statistical consultancy, analysis plan, programming and reporting
- CDISC ADaM

Quality Assurance

- Audits of investigator site, database and system audits, internal audits
- SOP composition and implementation

eSolutions

- eCRF/ePRO, RTSM, eTMF, CTMS, DCT elements

FGK CLINICAL RESEARCH

FGK PHARMACOVIGILANCE

FGK REPRESENTATIVE SERVICE

GENEWIZ
From Azenta Life Sciences

Name › **GENEWIZ Germany GmbH**

Address/P.O. Box › **Bahnhofstrasse 86**
Postal Code/City › **04158 Leipzig, Germany**
State › **Saxony**
Contact Person › **Lennart Mackies; Dora Quest**
Telephone › **+49-151-525-699-25;**
+49-151-729-125-17
Email › **Lennart.Mackies@azenta.com;**
Dora.Quest@azenta.com
Website › **www.genewiz.com**
Social Media › in 𝕏
Number of Employees › **100+**
Founded (year) › **2017**

Areas of Activity ›
Next generation sequencing (NGS)
Plasmid sequencing and PCR services
Gene synthesis and gene editing
Full-length plasmid sequencing
RNA / transcriptome sequencing
Whole-genome sequencing
Microbiome and metagenomics
Proteomics and spatial biology
Oligo synthesis
Plasmid preparation services
Custom antibodies
Viral packaging
Preclinical and clinical services

GENEWIZ, a world-leading genomics service provider, is a trusted partner for academic, biotech and pharma researchers requiring multiomics and synthesis services. With a global network of laboratories supporting you locally, we deliver integrated genomics and analytical solutions that accelerate discoveries with greater confidence.

At the heart of Europe, our laboratory in Leipzig, Germany, is a 1,500 m^2 high-tech facility equipped with cutting-edge sequencing technologies. Our experienced project management team and advanced automation enable us to deliver scalable solutions – from single samples to complex studies involving thousands of samples – within very short turnaround times and great support in many European languages, including German.

Next Generation Sequencing (NGS)

In Leipzig, we provide a comprehensive portfolio of NGS services, including all common short-read and long-read sequencing technologies. We support transcriptomic and genome sequencing focusing on human, animal and microbial samples. We also have an expert team experienced in extracting and processing complex samples, including plant, bacterial, fungal and viral samples. With large-scale expert extraction capacity and accreditation to process infectious and genetically modified organisms, our facility is prepared to handle projects of all sizes and complexities. This includes large pharma studies with thousands of samples. To enable deeper insights, we also offer advanced multiomics capabilities such as single-cell sequencing and spatial transcriptomics (10x Genomics), and Olink proteomics.

Member of

BIO DEUTSCHLAND



Sanger Sequencing

Sanger sequencing services in Leipzig, including plasmid, PCR and colony sequencing, are designed to provide fast, reliable, and cost-efficient results. We can process a wide variety of sample types and complexities, from single tubes to high-throughput projects. Leveraging the newest long-read NGS technologies, we also provide whole-plasmid sequencing and PCR product sequencing without the need to design or supply primers. All samples are processed in a highly automated laboratory with barcode-based tracking, ensuring precision and reliability. With flexible logistics, including customised sample pick-up across Europe, we deliver sequencing results quickly, often overnight or within one business day in Europe.

Gene Synthesis and More

While gene synthesis is performed through the global GENEWIZ network, customers in Europe benefit from seamless access to high-quality synthetic DNA (oligos, DNA fragments, cloned constructs, mRNAs, ssDNAs and others) supported by our local team of experts. In addition, the network provides plasmid prep services, viral packaging, antibody expression, as well as GLP- and CLIA-compliant solutions for preclinical and clinical studies. Our specialist Leipzig team ensures smooth project coordination, helping researchers integrate these services with their local sequencing workflows.

Part of Azenta Life Sciences

GENEWIZ Germany GmbH is part of Azenta Life Sciences, a global leader in life sciences solutions. Azenta supports innovators across drug development, clinical research, and advanced cell therapies with a comprehensive portfolio of multiomics services and trusted cold-chain sample management. Together, we help bring scientific breakthroughs to market faster.

For additional information, please visit www.genewiz.com.

HAMILTON

Name ›	**Hamilton Germany GmbH a subsidiary of Hamilton Company**
Address/P.O. Box ›	**Lochhamer Schlag 11**
Postal Code/City ›	**82166 Gräfelfing**
State ›	**Bavaria**
Contact Person ›	**Ebel Thorsten – District Manager Central Europe**
Telephone ›	**+49-89-248-804-804**
Email ›	**info.de@hamilton.ch**
Website ›	**www.hamiltoncompany.com**
Social Media ›	**in**
Number of Employees ›	**3,000+ globally**
Founded (year) ›	**Late 1940s**
Areas of Activity ›	**Automated liquid handling, laboratory automation, software, consumables, OEM liquid handling solutions, application support, life sciences, biotechnology, pharmaceutical and biopharmaceutical workflows, clinical diagnostics, forensics, genomics, cell-based workflows, integrated laboratory processes.**
Request for Further collaborations ›	**In addition to our direct offer to customers, we partner with kit manufacturers to automate their methods under various collaborations and partnership models, including OEM.**

Member of

VDGH
Verband der Diagnostica-Industrie

Hamilton Germany GmbH represents Hamilton in the German market, providing customers in life sciences, biotechnology, pharmaceutical and biopharmaceutical research, clinical diagnostics, forensics and related laboratory environments with access to automated liquid handling and laboratory automation technologies.

Automation for evolving laboratory needs

Hamilton combines liquid handling platforms, software, consumables, small devices and OEM solutions in a broad automation portfolio. The liquid handling platforms include Microlab VANTAGE, Microlab STAR V, Microlab STAR, Microlab NIMBUS and Microlab Prep. Customers can choose between ready-to-use solutions for rapid implementation and customized systems developed around the requirements of an individual project.

Local expertise and customer support

From its location in Gräfelfing near Munich, Hamilton Germany GmbH supports customers across Germany with local commercial and technical expertise. The team works closely with Hamilton specialists and the company's international organization to help laboratories evaluate automation opportunities, define suitable workflows and select solutions aligned with their scientific and operational needs.

Supporting science from discovery to routine workflows

Hamilton solutions support applications ranging from sample preparation and assay set-up to genomics, cell-based workflows and integrated laboratory processes. By bringing instruments, software, consumables and application expertise together, Hamilton helps laboratories standardize methods, reduce manual intervention and create reproducible, traceable processes.



Precision, partnership and long-term service

Hamilton's approach is based on close collaboration with customers and partners. Application expertise, training, field service and custom engineering complement the technology portfolio and support laboratories from initial workflow design through implementation and routine operation. This combination allows customers to select the level of automation that fits their scientific, operational and regulatory requirements.

Innovation backed by global experience

Hamilton has delivered precision solutions for more than 75 years. Important components are manufactured in-house, and the wider Hamilton organization combines engineering, application knowledge and service capabilities across its international locations. Hamilton products and services support laboratories and scientific institutions worldwide.

Innovation for a better world

Hamilton Germany GmbH connects customers in Germany with Hamilton's global automation expertise. Its goal is to help laboratories make their work more precise, reproducible and scalable, enabling scientists to focus on discovery while establishing robust processes for the laboratories of today and tomorrow.

Heidelberg PHARMA

Name ›	Heidelberg Pharma AG
Address/P.O. Box ›	Wallstadter Straße 59
Postal Code/City ›	68526 Ladenburg
State ›	Baden-Wuerttemberg
Contact Person ›	Dr. George Badescu
Telephone ›	+49-6203-1009-0
Email ›	investors@hdpharma.com
Website ›	www.heidelberg-pharma.com
Social Media ›	in
Number of Employees ›	35
Founded (year) ›	1997
Areas of Activity ›	ADC technology
External collaborations ›	I Takeda

The leader in next-generation ADC payloads

Heidelberg Pharma is a publicly listed clinical-stage company working on a unique treatment approach in oncology and developing innovative Antibody Drug Conjugates for the targeted and highly effective treatment of cancer. ADCs combine the specificity of antibodies with the efficacy of toxins to fight cancer. Selected antibodies are loaded with cytotoxic compounds, the so-called payloads, which are transported into diseased cells. Inside the cells, the toxins then unleash their effect and kill the diseased cells.

First to use compound Amanitin

Heidelberg Pharma is pioneering the payload Amanitin from the green death cap mushroom in cancer therapy. The biological mechanism of action of the toxin represents a new therapeutic modality. It is used as a compound in the Amanitin-based ADC technology, the so-called ATAC technology. Amanitin is cross-linked to different antibodies designed to transport the compound to the cancer cell, where it is absorbed and the Amanitin is released and results in programmed cell death, or apoptosis. RNA polymerase inhibition is a novel principle in cancer therapy and offers the possibility of breaking through drug resistance and destroying dormant tumor cells.

Two Amanitin-based candidates in clinical development

The lead Amanitin-based candidate, pamlectabart tismanitin (HDP-101), is currently being evaluated in a Phase I/IIa clinical trial for the treatment of multiple myeloma, the second most common blood cancer worldwide. The Phase I part of the study was completed and the recommended dose for the Phase IIa part of the study was determined. Currently, the Phase IIa part of the study is progressing as planned.

A second ATAC candidate, HDP-102, is being developed for non-Hodgkin lymphoma (NHL) and tested in a Phase I study. Due to cost-cutting measures, the clinical trial was stopped. Heidelberg Pharma is exploring partnership opportunities to support the continued development of the program.

ADC collaborations

Based on a hybrid business model, the ADC technology platform is being used to develop proprietary therapeutic candidates as well as in research collaborations with partners to create new product candidates. The partners utilize the ADC technology to combine their own antibodies with Heidelberg Pharma's payload.

New strategic focus

Heidelberg Pharma reprioritized its own research activities and wound down early research activities. The development focus is on the clinical development of the lead ATAC candidate, pamlectabart tismanitin.

To ensure a comprehensive product portfolio, the company deepens its collaboration with its strategic shareholder Huadong Medicine in research and early-stage development by combining and leveraging their complementary technologies, expertise, and resources. This includes Heidelberg Pharma's proprietary ATAC technology platform and other novel toxin payloads, together with Huadong's state-of-the-art R&D capabilities. The partnership aims to create synergies and drive the development of innovative next-generation ADCs, including bispecific and multispecific ADCs.

Mission

Heidelberg Pharma is striving to eradicate cancer through its ATAC pipeline driven by a unique payload technology. The toxin Amanitin offers the chance to break through therapy resistance and also eliminate dormant tumor cells. For patients who no longer respond to any other treatment, this would represent a significant advance in treatment.

ATAC® is a registered trademark of Heidelberg Pharma Research GmbH.

Name › **IDT Biologika**

Address/P.O. Box › **Am Pharmapark**
Postal Code/City › **06861 Dessau-Rosslau**
State › **Saxony-Anhalt**
Contact Person › **Antje Seidler**
Telephone › **+49-34901-8850**
Email › **info@idt-biologika.com**
Website › **www.idt-biologika.com**
Social Media ›
Number of Employees › **1,600**
Founded (year) › **1921**

Areas of Activity › **End-to-End Services in Contract Development and Manufacturing of Cell Culture & Microbial Proteins, Monoclonal Antibodies, Vaccines, Gene & Immune Therapeutics, Biosimilars and other Sterile Injectables**

About IDT Biologika

IDT Biologika, as part of SK bioscience, is a globally operating biopharmaceutical contract development and manufacturing organization (CDMO) specializing in cell culture and microbial-based proteins, monoclonal antibodies, vaccines, gene and immune therapeutics, biosimilars and other sterile injectables.
With more than a century of expertise in biopharmaceutical manufacturing, we provide solutions that combine maximum flexibility, uncompromising quality, and complete regulatory compliance. Beyond delivering technical reliability and scalability, we understand the unique requirements of our customers—from early clinical phases through to commercial supply. Our dedicated teams ensure seamless process development and efficient product transfer, always upholding the highest regulatory standards.

Our services

We offer our customers seamless end-to-end solutions and the ability to nimbly scale projects from development through to commercialisation. This includes process and analytical development, drug substance manufacturing up to BSL-2, fill-finish, labelling & packaging, quality control & analytics for clinical and commercial batches. At our customers request we supply their products in vials, pre-filled syringes (with and without safety devices), autoinjectors, or as combination products.

Our site

At our site in Dessau-Rosslau, Germany, IDT Biologika operates one of Europe's premier integrated facilities. With state-of-the-art infrastructure, reliable supply chain, strict quality systems, and experienced teams, we ensure flexibility, reliability, and full compliance with international regulatory standards - helping our customers bring their products to market efficiently and with confidence.

Member of

Contact us:

Proven expertise and strong track record

Our fully integrated services are underscored by our commitment to quality and the operational excellence that flows through our best-in-class process and cGMP (up to BSL-2) manufacturing capabilities, meeting FDA, EMA, and ANVISA standards.

IDT Biologika has made a significant contribution to global health by manufacturing products for international biopharma companies that are used to fight infectious diseases worldwide. In the rapidly emerging area of oncolytic virus-based therapies, we have established ourselves as a trusted partner by manufacturing one of the first commercial oncolytic virus products approved by EMA and FDA.

With more than 35 years of proven expertise, we have earned the trust of our customers not only in mammalian and microbial manufacturing, but also in the fill-finish of sterile injectables in general. These achievements reflect the dedication, quality, and long-standing commitment of our company and its people.

Our Technology Excellence

Our industry-leading knowledge of bacterial and viral manufacturing and our next-generation platforms build on years of successful partnerships with our customers and continue to drive innovation in biopharmaceutical manufacturing. Our broad technology portfolio includes proprietary cell lines as well as deep expertise with a variety of other cell lines. In addition, we have extensive know-how in handling and manufacturing bacterial strains and viral vectors across diverse production platforms. This covers the entire value chain—from drug substance upstream and downstream processing to final drug product manufacturing. Complementing these capabilities, we also provide our own well-characterized seed and cell banks, ensuring reliability, consistency, and flexibility for our customers' projects. To further support our partners, we offer a full range of in-house analytical services, enabling seamless integration, highest quality standards, and efficient project execution.

Please contact us for further information.

Name › IKA-Werke GmbH & Co. KG

Address/P.O. Box › Janke & Kunkel-Str. 10
Postal Code/City › 79219 Staufen im Breisgau
State › Baden-Wuerttemberg
Contact Person › Dr. Dennis Stibane,
Global Business Development Manager
Telephone › +49 7633 831-284
Email › dennis.stibane@ika.de
Website › www.ika.com
Social Media ›
Number of Employees › 900
Founded (year) › 1910

Areas of Activity › Laboratory and process technology, bioprocessing solutions, battery solutions

About IKA

For more than 115 years, IKA has been developing and manufacturing innovative solutions for laboratories and the process industry. Headquartered in Staufen, Germany, the family-owned company combines engineering excellence, advanced technology and forward-thinking design to help customers achieve reliable and efficient results. Today, more than 900 employees contribute to IKA's globally recognized expertise in laboratory, analytical and processing technology, serving customers in over 160 countries through an extensive network of subsidiaries and partners.

Innovation at IKA is driven by close collaboration with scientists, researchers and industry experts. This customer-focused approach ensures that new products not only address current laboratory challenges but are also prepared for the increasingly digital and connected environments of the future.

Smart Bioprocessing for Modern Life Science Laboratories

As biotechnology and biopharmaceutical development continue to evolve, laboratories require equipment that delivers both performance and flexibility. Drawing on decades of expertise in mixing, temperature control, automation and process engineering, IKA has introduced a new generation of bioreactor systems designed specifically for modern bioprocess development.

The HABITAT bioreactor series provides researchers with an advanced platform for applications ranging from microbial fermentation and cell cultivation to phototrophic processes. Combining ergonomic design with intelligent automation, the system enables precise process control while supporting efficient workflow management and reproducible results.

Flexible hardware configurations, intuitive software and extensive integration capabilities allow users to adapt the system to their individual process requirements. Pumps, sensors and automation tools can be seamlessly incorporated, creating a scalable environment

that supports both early-stage research and advanced process development.

Parallel Process Development Made Easy

The latest addition to the HABITAT portfolio is HABITAT DUO, a dual-bioreactor platform that significantly increases laboratory productivity by enabling parallel experimentation.

Two bioreactor vessels can be operated simultaneously through a single control unit, allowing researchers to compare process conditions directly, accelerate optimization studies and improve throughput while minimizing laboratory footprint. The system supports both glass and single-use vessels for cell culture and fermentation applications, which can be used independently or in parallel.

A single user interface provides complete visibility and control over both reactors. Advanced operation modes include batch, fed-batch and perfusion processes, supported by features such as exponential feeding, profile mode and recipe management.

Comprehensive Solutions for Life Science Laboratories

Today, IKA's bioprocessing solutions perfectly complement its established Life Science portfolio, enabling laboratories to source a wide range of technologies from a single trusted partner. From routine sample preparation and liquid handling to advanced bioprocess development, IKA delivers integrated solutions that support efficient, reproducible and user-friendly workflows across the entire research process.

Immunic THERAPEUTICS

Name › Immunic Therapeutics

Address/P.O. Box › Lochhamer Schlag 21
Postal Code/City › 82166 Gräfelfing
State › Bavaria
Headquarters: New York City, USA
Contact Person › Jessica Breu
(Vice President Investor Relations and Communications)
Telephone › +49-89-2080477-09
Email › info@imux.com
Website › www.imux.com
Social Media ›
Number of Employees › approx. 120
Founded (year) › 2016

Areas of Activity ›
- Immunology
- Neurology

External Collaborations ›
- Ludwig-Maximilians-University (LMU) Munich, Germany: Department of Pharmacy
- City of Hope, California, USA: Beckman Research Institute, Dept. of Immunology & Theranostics
- University of Turin, Italy: Neuroscience Institute Cavalieri Ottolenghi
- Kyoto University, Japan: Institute for Life and Medical Sciences

Member of

BIO DEUTSCHLAND

Immunic (Nasdaq: IMUX) is in a transformative phase as the company prepares to evolve from a late-stage biotechnology company into a fully integrated commercial organization focused on novel oral therapies for neurologic diseases. At the center of this strategy is vidofludimus calcium (IMU-838), an oral small molecule being developed for relapsing and progressive forms of multiple sclerosis (MS). Building on a decade of scientific innovation and clinical development, Immunic is now focussing to advance vidofludimus calcium toward potential regulatory submission, regulatory approval and commercialization, while continuing to explore the broader potential of nuclear receptor-related 1 (Nurr1) as an emerging target for neurodegenerative diseases.

Vidofludimus Calcium: Addressing Multiple Drivers of Neurodegeneration in Multiple Sclerosis

Vidofludimus calcium is an orally available, next-generation selective immune modulator that acts as a potent, first-in-class Nurr1 activator and as a selective dihydroorotate dehydrogenase (DHODH) inhibitor. Nurr1 is a neuroprotective transcription factor and an emerging target in neurodegenerative diseases.

Vidofludimus calcium is currently being investigated in the twin phase 3 ENSURE trials in relapsing MS (RMS). Immunic announced a positive outcome of an interim analysis, confirming the trials can continue without changes, including no sample size expansion. Top-line data for both ENSURE trials is expected by the end of 2026.

For progressive MS (PMS), Immunic announced encouraging results from its phase 2 CALLIPER trial of vidofludimus calcium. Exploratory MRI outcomes revealed consistent, directionally favorable signals, although the primary percent brain volume change (PBVC) endpoint was not met. The drug showed consistent reductions in disability progression in the overall PMS and all subpopulations, including primary and non-active secondary PMS – both areas with high unmet medical needs. Safety and tolerability remained favourable, with no new safety signals identified. Building on these results,

Immunic plans to initiate a phase 3 clinical program in PMS, expected later this year.

Neuroprotective, Anti-Inflammatory, and Anti-Viral Effects

Immunic believes that vidofludimus calcium has the potential to demonstrate important advantages over approved MS treatments through its combined neuroprotective, anti-inflammatory, and anti-viral effects, potentially making it a differentiated treatment option for all forms of MS. The collective findings support the concept that Nurr1 activation may represent a novel mechanism to prevent neurodegeneration in MS. To date, vidofludimus calcium has shown consistent clinical effects and favourable safety/tolerability in more than 3,500 patients across trials and formulations.

The molecule selectively targets hyperactive immune cells without suppressing normal immune function. In phase 2 clinical testing, it demonstrated strong suppression of MRI lesions, showed encouraging signs of reducing confirmed disability worsening, and lowered serum neurofilament light chain (NfL) levels. In addition, vidofludimus calcium's broad-spectrum anti-viral activity may support lowering the rate of viral infections and reactivations, including Epstein-Barr virus (EBV), potentially resulting in slowing EBV-related neurodegenerative processes.

Leading Immunic's Next Stage of Growth

Subject to positive clinical and regulatory outcomes, Immunic aims to bring vidofludimus calcium to patients in key MS markets, initially in North America. Led by Chief Executive Officer Erik Lundgren, Chief Medical Officer Michael A. Panzara, M.D., M.P.H., Chief Scientific Officer & Co-Founder Hella Kohlhof, Ph.D., and President & Chief Operating Officer Jason Tardio, Immunic is building the capabilities required to support the potential commercialization of vidofludimus calcium. The company combines scientific innovation, clinical development and regulatory expertise, operational excellence and commercial readiness to prepare for its next phase of growth and to address the evolving needs of people living with MS.

INDIVUMED

Name ›	Indivumed GmbH
Address/P.O. Box ›	Falkenried 88 I Bldg. D
Postal Code/City ›	20251 Hamburg
State ›	Hamburg
Contact Persons ›	Prof. Dr. Hartmut Juhl (CEO)
Telephone ›	+49-40-4133-83-0
Fax ›	+49-40-4133-83-14
Email ›	info@indivumed.com
Website ›	www.indivumed.com
Social Media ›	in
Number of Employees ›	~100
Founded (year) ›	2002
Type of Laboratory ›	S2, S1
Areas of Activity ›	Patient-centric R&D approach I Data-driven target discovery I Patient stratification I Modality fit Innovative pipeline I Therapeutically novel targets I Biologics and small molecules I CRC and other solid tumors Partnering opportunities I Partner on novel therapeutic targets I Co-develop innovative therapeutics I Co-create new pipelines
External Collaborations ›	Clinical cooperations and scientific collaborators I Global clinical network of leading cancer clinics in Europe, US and Asia I Scientific collaborators, such as I University of Rochester Medical Center, US I Salk Institute, US I Georgetown University Medical Center, US I A*Star Institute for molecular and cell biology, Singapore I National Cancer Center Hospital East, Japan I University of Tor Vergata, Italy I Institut de Recerca Biomèdia Lleida, Spain
Member of	BIO DEUTSCHLAND

Every cancer target we find already knows its patient.

Indivumed is a biotech company focused on precision oncology. Our patient-centric, data-driven R&D approach enables the discovery of therapeutically novel targets to develop therapeutics where patient, target and modality align.

With over 20 years of experience in collecting tissue and data of unmatched quality and variety, we have built a unique multi-omics database that connects molecular and clinical data, unlocking a deep cancer disease understanding. Our translational pipeline is focused on colorectal cancer (CRC) and other solid tumors with high unmet clinical need, advancing differentiated therapeutic programs across biologics and small molecules.

Most cancer programs fail in the clinic. Ours are designed not to.

Patient, target and modality, defined together – rooted in tumor biology, captured in the operating room. That is where our R&D approach begins.

First, we measure patient biology. We collect matched tumor and normal tissue from the same patient, standardized across all global collection sites with a median cold ischaemia time of under 12 minutes. This ensures exceptional tissue quality and preserves molecular integrity. We pair it with clinical data from the same patient with over 300 clinical data points per patient including a follow-up of up to 10 years.

Next, we stratify. Based on the high-quality material, we deploy a comprehensive multi-omics approach, including whole genome sequencing, transcriptomics, proteomics, phospho-proteomics, and microRNAs. This allows us to identify the biology that separates patient populations. By combining that molecular picture with clinical data, we define clinically relevant subgroups and prioritize targets with more confidence.

Then, we test. Targets are de-risked and validated in our in-house patient-derived 3D models generated from the same tissue used for molecular profiling – offering superior translational relevance for target assessment.

Finally, we match. Each target is evaluated against the parameters that determine whether a modality works on it: tumor-versus-normal selectivity, epitope accessibility, receptor density, internalization rate and format matching across ADCs, bispecifics or small molecules. We integrate AI across this workflow to support target identification, patient-target matching and modality selection.

A pipeline built on the right Patient x Target x Modality fit

Our portfolio of innovative programs across biologics and small molecules is selected and developed based on high therapeutic relevance, robust biological validation and expected patient impact, as well as market potential.

Our current focus is on CRC, a high-impact disease with limited treatment options. Our database also includes extensive patient cases in non-small cell lung cancer (NSCLC) and other solid tumors, providing a strong foundation for future innovation across multiple cancer types.

We partner with ambitious teams to develop cancer therapeutics where patient, target and modality align.

- Partner on novel therapeutic targets: intracellular and surface-bound targets (functional, locator targets for ADCs, bispecifics)
- Co-develop innovative therapeutics: small molecules and antibody-based modalities
- Co-create new pipelines: addressing unmet medical needs in solid tumors

Name › iOmx Therapeutics AG

Address/P.O. Box › Fraunhoferstr. 22
Postal Code/City › 82152 Martinsried
State › Bavaria
Contact Person › Dr. Apollon Papadimitriou
Telephone › +49-89-8999-7090-0
Email › info@iomx.com
Website › www.iomx.com
Social Media › in
Number of Employees › >50
Founded (year) › 2016

Areas of Activity ›
- Next-generation cancer therapies
- Drug development
- Immuno-oncology

Next-Generation Immuno-Oncology Therapeutics for Resistant Solid Tumors

iOmx Therapeutics is a biotechnology company developing next-generation immuno-oncology therapeutics designed to overcome resistance in solid tumors. The company combines deep tumor immunology expertise with strong biologics development capabilities to advance a diversified pipeline of novel therapeutics, including multifunctional antibodies and T cell engagers.

Addressing the Next Challenge in Immuno-Oncology

Immuno-oncology has transformed the treatment of many cancers, yet a large proportion of patients with solid tumors still fail to achieve durable responses. Tumors can employ multiple biological mechanisms to suppress or evade an effective immune response, creating a need for therapeutic approaches that go beyond established cancer immunotherapies.

iOmx addresses this challenge by targeting differentiated biological pathways and tumor antigens involved in tumor resistance and combining complementary modes of action within a single therapeutic molecule. Its programs are selected with the goal of achieving meaningful efficacy as standalone therapies in major solid tumor types.

A Differentiated, Risk-Balanced Pipeline

iOmx is building a multi-asset portfolio across clinically validated and novel targets. The company develops a range of antibody-based therapeutic formats, including T cell engagers as well as bispecific or multifunctional antibodies.

Member of

BIO DEUTSCHLAND

Its pipeline includes approaches designed to simultaneously target multiple immunosuppressive pathways that contribute to tumor immune evasion, as well as T cell engagers directed against tumor-specific antigens to enhance the selective recruitment of T cells to tumor cells.

Biomarker-supported patient enrichment strategies are integrated from the outset of development to identify the patients most likely to benefit and provide a clear translational path from biological rationale to clinical proof of concept.

Backed by Leading International Life Science Investors

iOmx is supported by a strong international investor syndicate, including Athos, Sofinnova Partners, Wellington Partners, MIG Capital, M Ventures and Arvantis Social Foundation Impact Investment.

With its combination of tumor immunology expertise, biologics development capabilities and a differentiated multi-asset strategy, iOmx is working to advance a new generation of immuno-oncology therapeutics for patients whose tumors remain resistant to today's treatment options.

LUCERA

Name ›	Lucera GmbH
Address/P.O. Box ›	Kurfürstenanlage 21
Postal Code/City ›	69115 Heidelberg
State ›	Baden-Wuerttemberg
Contact Person ›	Dr. Friedrich von Bohlen Dr. Stephan Brock
Telephone ›	+49-6221-43851-0
Email ›	info@lucera.eu
Website ›	lucera.eu
Social Media ›	in
Number of Employees ›	25
Founded (year) ›	2026
Areas of Activity ›	Biomedical data intelligence, precision drug development, translational medicine, AI in drug development, knowledge graph, Dataome, systems biology, target validation, mechanism validation, disease biology, patient stratification and patient selection
External Collaborations ›	Axxam

Biomedical Intelligence Supporting Precision Drug Development

Lucera helps biopharma teams determine where a therapeutic mechanism is most likely to translate into patient benefit – and what it takes to turn that insight into successful drug development.

Precision medicine made disease heterogeneity actionable, linking treatment to individual molecular makeup. Built on 15 years of biomedical expertise, Lucera applies this principle to drug development. We connect mechanistic biology, patient context and clinical development evidence to provide a clear biological rationale and recommendation for the next development decision, answering the critical questions that shape a drug development program.

Where can the mechanism impact disease?

Lucera's mechanistic disease and drug models distinguish disease-driving biology from association. They reveal where the intervention acts, how biology changes across states and stages, and in which context the mechanism could plausibly modify the course of disease.

What is the most relevant patient population?

Our Digital Molecular Twins, where we translate individual patient-level clinical records into molecular representations, make patient heterogeneity interpretable without requiring deep molecular profiling for every patient. This approach reveals where intervention relevance, risk and outcomes may differ among a given patient population.

Stephan Brock (left) / Friedrich von Bohlen (right)



Does the therapeutic effect translate clinically?

Lucera assesses whether the trial context is aligned with the expected mechanism. We evaluate how treatment settings, recruitment criteria, comparators and endpoints influence the ability to detect the expected therapeutic effect and, ultimately, whether a clinical development program is likely to have the desired outcome.

A solid track record

Lucera builds on a history of success, enabling clients to make well-informed, evidence-based decisions. For example, in a specific form of heart failure, Lucera precisely modeled distinct disease-driving pathomechanisms and assessed candidate interventions against them. Digital Molecular Twins independently confirmed the findings, while identifying GLP-1R, SGLT2 and PCSK9 as top contenders, before their later clinical validation. The result was a convergent, real-world data-supported prioritization of therapeutic mechanisms.

In another project, Lucera separated a single heterogeneous patient population into molecularly differentiated event-risk subpopulations, creating a direct bridge from molecular evidence to recruitment criteria, enabling a faster, smaller clinical trial.

For another client, Lucera modeled DM1 spliceopathy in detail, mapped the molecular effects of the intervention and evaluated molecular models of candidate endpoints against the resulting disease-state changes. The analysis produced a mechanistically ranked endpoint strategy that was validated in an independent clinical trial.

Lucera gives decision makers the precise information they need to take the next development step with confidence.

metabion

Name › **metabion international AG**

Address/P.O. Box › **Robert-Koch-Straße 1**
Postal Code/City › **82152 Planegg**
State › **Bavaria**
Contact Person › **Diana Yulafci**
Telephone › **+49-89-899-363-0**
Email › **info@metabion.com**
Website › **www.metabion.com**
Social Media › **in**
Number of Employees › **70**
Founded (year) › **1997**

Areas of Activity › **Small-, mid- and large-scale oligonucleotides and components for in vitro diagnostics (IVD)/analyte-specific reagents (ASRs), as well as small-/mid-/large-scale oligos for R&D and therapeutic applications (GMP grade).**

Custom Third Party and OEM Services: Contract Manufacturing & Kitting in the Diagnostics and RUO space.

metabion is a biotechnology company headquartered in the greater Munich area, and globally renowned as a "boutique" and best-in-class provider of custom high-quality oligos. With three decades of experience, metabion specialises in the production of a wide range of synthetic DNA and RNA oligonucleotides tailored to customers' requirements, alongside the supply of standard life science products.

metabion's state-of-the-art production facility in Kirchheim b. München is specifically designed for high-quality manufacturing, from small-scale R&D oligonucleotides and oligo components for diagnostic/IVD/ASRs, to mid-/large-scale oligos for R&D/therapeutic applications. metabion is certified according to DIN EN ISO 9001:2015, ISO 13485:2016, aligned with GMP standards.

Successfully translating the highest quality standards into everyday practice is at the core of metabion's corporate philosophy and the key to its popularity at the same time. We are dedicated to enhance scientific excellence and to support diagnostic and therapeutic solutions. Quality to trust!

Custom Synthesis of High-Quality Diagnostic/IVD Oligonucleotides

- Small-, mid- and large-scale production of diagnostic/IVD oligos – from nmoles to mmoles
- ISO 13485 and cGMP compliant manufacturing
- Unmodified and modified primers – a wide range of modifications available
- qPCR and dPCR probes (DLPs and DQPs) including an extensive portfolio of reporters and quenchers
- nGS oligonucleotides for diagnostic applications
- Hybridisation probes for FISH applications.

Custom Synthesis of High-Quality Therapeutic Oligonucleotides

- From R&D to GMP grade manufacturing of small-, mid- & large-scale oligos, oligonucleotide-based vaccine adjuvants and APIs
  - Lead Discovery and Optimisation
  - Preclinical Development
  - Clinical Trials (phase I and II)

METABION

- Support and Services:
  - Design of Experiment (DOE)
  - Process Characterisation, Development and Validation
  - Scale-up and Process Transfer
  - IND & NDA Filing support
- Therapeutic oligonucleotide portfolio includes:
  - Immune-stimulating CpG oligonucleotides
  - Antisense oligonucleotides (ASOs)
  - siRNAs, miRNAs, sgRNA
  - Gapmers/RNA-DNA Chimeras
  - Aptamers
  - Oligonucleotide-peptide/lipid/sugar conjugates for tissue-specific API delivery
- Exhaustive panel of QC Analytical methods and services
- Custom formulation, Fill & Finish support and services

Custom Synthesis of High-Quality R&D Oligonucleotides and Gene Fragments

- Oligonucleotide “boutique” with most complete standard portfolio (ss and ds DNA/RNA, single tube plates, low/medium/high throughput, modifications)
- Highly customised oligo manufacturing capabilities upon inquiry
- ds gene fragments and gene fragment libraries (m-blocks) up to 2 kb

Custom Third Party/Contract Manufacturing and OEM Services

- Formulations and aliquotation/replication in tubes or plates
- Filling of diagnostic assay components including third party reagents and components
- Complete assay/kit assembly and labelling
- Logistics including drop-shipping to customers
- Application programming interface for ordering and billing systems integration

METTLER TOLEDO

Name › Mettler-Toledo GmbH

Address/P.O. Box › Ockerweg 3
Postal Code/City › 35396 Gießen
State › Hesse
Contact Person › Carmen Wiederuh
Telephone › +49-641-507401
Email Address › Carmen.Wiederuh@mt.com
Internet Websites › www.mt.com
Social Media ›
Number of Employees › ~18.100
Founded (year) › 1989

Areas of Activity › **Manufacturer and marketer of precision instruments and services for many applications in research and development, quality control, production, logistics, and retail to customers around the world.**

Advanced solutions to optimise every step of your life science workflow

OneDrop UV/VIS Spectrophotometry: The Life Sciences Specialist UV5Nano micro-volume spectrophotometer from METTLER TOLEDO stands out with its innovative technology and intuitive usability coupled with modern design. FastTrack™ technology combines a long-lasting light source with state-of-the-art array technology and enables very fast, accurate, and precise measurements.

Real-time cell counting without staining

CytoDirect's intuitive operation makes cell counting seamless, accelerating your workflow and reducing time to results. Powered by digital holographic microscopy and machine learning, CytoDirect delivers stain-free viability measurements, eliminating the need for dyes or reagents.

Viability Map offers a deep dive into cell health, helping you fine-tune experimental conditions and ensure continuity with existing protocols. Compact and fully portable, CytoDirect fits effortlessly into any lab environment – even under the hood – giving you the flexibility to work wherever science takes you.

RAININ liquid handling solutions by METTLER TOLEDO

Rainin by METTLER TOLEDO delivers precision liquid handling solutions tailored for life sciences. From ergonomic pipettes with Lite Touch System (LTS) technology to BioClean Ultra tips and expert pipette services, the Pipetting 360° concept ensures accuracy, comfort, and reliability across the lab.

PipetteX 4.0 software streamlines asset management with real-time tracking, calibration alerts, and instant access to service records and certificates – making compliance effortless and efficient.

Rainin MicroPro 20 and 300 are the smallest 96-channel benchtop pipetting systems available. MicroPro delivers precision and speed for 96- and 384-well plate workflows. Compact, powerful, and designed for high-

throughput efficiency, MicroPro offers wireless control and intuitive functions like aliquoting, dilution, and mixing – enhancing reproducibility and reducing errors.

And more...

- Precise pH and conductivity measurements from small sample volumes with a single keypress for fast and reliable results
- Analytical balances deliver consistent, high-precision weighing with durable, easy-to-use tools that support efficient lab routines
- Excellent workflow support with PlateDirect – an intuitive microplate reader designed for smooth, user-friendly operation
- Seamless workflows and secure data management with our software systems LabX and PipetteX

Process Analytics Across Your Bioprocess

Reliable process data is essential for product quality, process consistency, and efficient scale-up in biopharmaceutical manufacturing. METTLER TOLEDO provides process analytical solutions across conventional stainless-steel systems, single-use bioreactors, and downstream processing.

Reusable Ingold sensors support critical measurements such as pH, dissolved oxygen, dissolved carbon dioxide, and conductivity from process development through commercial manufacturing. Intelligent Sensor Management (ISM®) technology provides advanced diagnostics and supports efficient sensor maintenance and documentation.

For single-use upstream processes, factory-calibrated InSUS™ sensors extend proven measurement capabilities for parameters including pH and dissolved oxygen into disposable bioreactors and bags.

PendoTECH® expands real-time process monitoring into downstream operations, from harvest and clarification through filtration, chromatography, and formulation towards filling. Its single-use portfolio covers pressure, flow, UV absorbance, turbidity, conductivity, temperature, pH, and air-in-tube detection, complemented by monitoring, data-acquisition, and filtration control solutions.

Name › **Microcoat Biotechnologie GmbH**

Address/P.O. Box › **Am Neuland 3**
Postal Code/City › **82347 Bernried**
State › **Bavaria**
Contact Person › **Dr. Ingrid Wanninger**
(Business Development)
Dr. Michael Kroder
(Business Development)
Telephone › **+49-8158-9981-0**
Fax › **+49-8158-9981-10**
Email › **info@microcoat.de**
Website › **www.microcoat.de**
Social Media › in

Number of Employees › **>200**
Founded (year) › **1992**
Type of Laboratory › **S1/S2, GLP, GCP, GMP, ISO 9001, EN ISO 13485 ISO 14001**

Areas of Activity ›
- **Contract manufacturing**
- **Custom development**
- **Laboratory services**
- **Endotoxin and pyrogen testing service**

External Collaborations › **Business-to-business with industrial partners in the pharmaceutical industry, diagnostic industry and life science industry**

Request for Further Collaborations › **Microcoat seeks joint projects and service partnership with pharmaceutical, biotech and diagnostic companies, as well as with players in the field of food safety testing, crop science and instrumentation (medical devices).**

Member of

BIO DEUTSCHLAND

Company profile

Microcoat offers a wide range of individual and specialised services for the diagnostic and pharmaceutical industry. In close cooperation with our customers, we aim for best performance, building on a complete range of advanced technologies and uncompromised quality standards.

For pharmaceutical companies, we leverage our profound expertise in in-vitro diagnostics and assay development in order to become a preferred partner in early development, pre-clinical and clinical phases of drug development and patient sample testing.

For food safety, environmental testing and other specialised diagnostic fields, Microcoat aims to be the preferred OEM-partner for the development and manufacturing of reliable test components and kits.

Contract manufacturing diagnostics

Microcoat is an approved original equipment manufacturer (OEM) for diagnostic test kits, bulk and finished components. We manufacture according to ISO and IVD standards. Since all critical test components are produced and modified in house, we are able to control quality at all stages of the production process.

Production technologies:
- Fermentation (30 litre scale)
- Downstream processing
- Protein chemistry
- Microplate and particle coating
- Dispensing/filling/labelling
- Freeze-drying
- Kit assembly

Product categories:
- Coated microplates
- Lateral flow test strips
- Recombinant proteins/antigens
- Antibody/protein conjugates
- Liquid components
- Dried/lyophilized components
- Diagnostic kits

B2B Diagnostics

Custom development diagnostics

Microcoat offers unique expertise in diagnostic assay and product development. A broad spectrum of methods, skilled staff and intensive communication with the customer are the cornerstones of successful project execution.
Development projects are based on detailed milestone plans and follow standardised development guidelines through the five project phases (feasibility, development, verification, validation and manufacturing).
We develop for you:

- Immunological assays
- Molecular assays
- Sample and matrix preparation protocols
- Depletion protocols

Functional Service Provider Laboratory services

In our certified facilities, we conduct a broad spectrum of GLP/GCP services to support drug development starting from early discovery to post-marketing surveillance. As an independent contract research organisation and preferred provider we serve pharma and life science industries worldwide. Based on long lasting experience in endotoxin and pyrogen testing, Microcoat offers a set of proprietary methods and skilled scientific personnel for GMP release testing as well as non-routine projects. Services are run as flexible customer-specified projects including the search for root causes, exploration of realization alternatives, development of product-specific adaptions and GMP compliant validation of newly established methods.
Our services include:

- Assay development and validation
- Biomarker testing
- Immunogenicity/PK assays
- Endotoxin and pyrogen testing

Business model

Microcoat is focused on business-to-business with industry customers, seeking a reliable and long-lasting partnership for outsourcing projects such as contract manufacturing (OEM), assay and product development, and bioanalytical testing in the context of pre-clinical and clinical studies.

milenia biotec
Lateral Flow Rapid Tests
and more

Name › **Milenia Biotec GmbH**

Address/P.O. Box › **Versailler Str. 1**
Postal Code/City › **35394 Gießen**
State › **Hesse**
Contact Person › **Dr. Ivo Bertalan**
Jan Tillmann
Telephone › **+49-641-948883-0**
Email › **info@milenia-biotec.de**
Website › **milenia-biotec.com**
Social Media ›
Number of Employees › **< 50**
Founded (year) › **2000**

Areas of Activity ›
- **Lateral flow technology**
- **Development, production, distribution, CDMO**
- **Tools and expertise for biomarker detection**

From Biomarker to Lateral Flow Test – Lateral Flow Assay Development & Manufacturing

Milenia Biotec GmbH is a German specialist in lateral flow technology with more than 25 years of experience in assay development, manufacturing and commercialization. We support biotechnology companies, diagnostic developers and research organizations in transforming innovative biomarkers and detection concepts into robust, easy-to-use lateral flow solutions. As an independent, family-owned and run company, we deeply value personal relationships and long-term commitment.

Custom Lateral Flow Development & OEM

Looking for a partner to turn your biomarker or assay concept into a lateral flow test?

Whether you have an early-stage biomarker concept, an established assay requiring transfer to lateral flow or a product ready for scale-up, Milenia can support the next development step. Our expertise covers the complete process:
assay feasibility → strip development → optimization → scale-up → manufacturing → OEM/private label

Customers may involve us throughout the entire development process or select individual services according to their specific project needs. This flexible approach allows us to support projects ranging from initial proof-of-concept studies to routine manufacturing.

HybriDetect – Universal Lateral Flow Platform

Our HybriDetect platform provides researchers and assay developers with a flexible solution for converting labeled reaction products into rapid visual or reader-based results. It can be combined with a broad range of molecular detection technologies, including PCR, LAMP, RPA, CRISPR-Cas systems, hybridization assays and aptamer-based approaches. The platform can also be adapted to conventional antigen and antibody detection.

HybriDetect strips are available for the detection of one, two or three analytes and can also be integrated into user-friendly cassette formats. More than 400 peer-reviewed publications demonstrate the broad scientific use of HybriDetect across molecular biology, diagnostics and life science research.

For rapid isothermal amplification without the need for a thermocycler, Milenia also provides solutions for Recombinase Polymerase Amplification (RPA) and Loop-Mediated Isothermal Amplification (LAMP). The myilab research reader complements these technologies by enabling objective, reader-based evaluation of lateral flow results.

Proven Diagnostic and Industrial Expertise

Milenia's experience extends beyond research applications. We successfully developed and manufactured lateral flow IVDs for demanding applications in human diagnostics, including tests for heparin-induced thrombocytopenia (HIT), human anti-mouse antibodies (HAMA) and interleukin-6.

Our lateral flow expertise also covers industrial and food-testing applications. One example is the GenLine Lactobacillus/Pediococcus Screen, which combines PCR amplification with lateral flow detection for the rapid identification of beer-spoilage organisms.

Development and manufacturing at Milenia are supported by an EN ISO 13485:2016-certified quality management system, providing a reliable framework for diagnostic, life science and OEM projects.

Let us turn your detection concept into a lateral flow solution.

We welcome collaborations with biotechnology companies, diagnostic developers and research organizations seeking to translate novel biomarkers, molecular assays or detection concepts into practical lateral flow formats.

Miltenyi Biotec

Name ›	Miltenyi Biotec
Address/P.O. Box ›	Friedrich-Ebert-Straße 68
Postal Code/City ›	51429 Bergisch Gladbach
State ›	North Rhine-Westphalia
Contact Person ›	Svea Lübcke
Telephone ›	+49-2204-8306-0
Fax ›	+49-2204-85197
Email ›	MACSsales@miltenyi.com
Website ›	www.miltenyibiotec.com
Social Media ›	
Number of Employees ›	> 4,500 worldwide
Founded (year) ›	1989
Type of Laboratory ›	| S1/S2 | L1/L2 | cGMP | clean room facilities A/B/C/ | fully automated laboratory (collaboration with Tecan® Group Limited)
Areas of Activity ›	| Sample preparation | Cell separation | Cell culture and stimulation | Flow cytometry | Imaging and spatial biology | Cell processing | Cell and gene therapy enabling services | Viral vector design and manufacturing | Process development and manufacturing | Commercialization support
External Collaborations ›	Customised Applications Check out our collaborations on our website www.miltenyibiotec.com/grant-management-and-collaboration

Member of

BPI Bundesverband der Pharmazeutischen Industrie e.V. BIO DEUTSCHLAND VDGH Verband der Diagnostica-Industrie

Miltenyi Biotec is a global leader in innovating technologies and services for patient-specific cell and gene therapies, transforming scientific discoveries into practical treatments for personalised medicine. With over 35 years of expertise, it supports biomedical discoveries and translates them into clinical applications, enhancing patient access to new therapies. Miltenyi Biotec focuses on offering integrated solutions for complex challenges in treating cancers, autoimmune diseases, and inherited disorders. Headquartered in Bergisch Gladbach, it employs more than 4,500 people across 24 countries.

MACS® Sample Preparation

Start smart with innovative solutions for your tissue preparation. gentleMACS™ Dissociators and MACS® Tissue Dissociation Kits enable standardised sample preparation from almost any tissue source.

MACS® Cell Separation

With over 63,000 citations, the MACS Cell Separation portfolio is the most trusted technology for isolating target cells. Combining proven magnetic isolation with flexible workflows, it supports manual to fully automated processing. Our MicroBeads and instruments provide reliable solutions tailored to your research needs.

MACS® Flow Cytometry

The MACSQuant® Instruments include ultra-compact flow cytometers and the MACSQuant® Tyto®, a microchip-based cell sorter, and provide unrivalled ease of use for multisampling and multiparameter analysis and sorting. Our large portfolio of antibodies, including REAfinity® Recombinant Antibodies and Vio® Dyes, comprise a family of conjugates with high fluorescence intensities and stain indices.

Technology platforms

Expertise

Research & therapeutic areas



Miltenyi Bioindustry services

MACS® Imaging and Spatial Biology

The MACSima™ Platform, powered by MICS (MACSima Imaging Cyclic Staining) technology, enables researchers to fully explore spatial biology with its advanced protein multiplexing capabilities. The UltraMicroscope Blaze™ Platform allows automated 3D imaging at a cellular level, from rodent organs or organoids to samples as big as a human kidney or whole mouse models. To complement these technologies, we offer a growing collection of recombinant antibodies that have been pre-tested for fluorescence microscopy.

MACS® Cell Culture and Stimulation

Our cell culture media, cytokines, growth factors, and reagents for stimulation, expansion, and differentiation of a variety of mammalian cells are also available up to GMP grade, thus enabling GMP-compliant, cellular product manufacturing.

Clinical products and services

Miltenyi Biotec's comprehensive portfolio for advancing translational research and therapy includes the FDA approved CliniMACS© CD34 Reagent System as well as a range of CliniMACS© Reagents for cell separation and processing and MACS GMP products for cell culture and stimulation. The CliniMACS Prodigy® platform is a unique cell processing solution that enables the fully automated and integrated manufacture of a GMP-compliant cell product in a closed environment. Miltenyi Bioindustry is our global CDMO service department helping biopharmaceutical companies and advanced clinical centres from process development into commercial scale, GMP-compliant manufacturing of viral vectors and cell and gene therapies. The CliniMACS Cell Factory® facilities are located across North America, Europe, and China and in close proximity to customers.

NAVIGO PROTEINS

Name ›	Navigo Proteins GmbH Business Unit: Navigo Precision
Address/P.O. Box ›	Heinrich-Damerow-Straße 1
Postal Code/City ›	06120 Halle/Saale
State ›	Saxony-Anhalt
Contact Person ›	Michael Hamm (Head of Business Development Navigo Precision)
Telephone ›	+49-345-27996-330
Email ›	info@navigo-precision.com
Website ›	www.navigo-precision.com
Social Media ›	in
Number of Employees ›	90-100
Founded (year) ›	2017
Type of Laboratory ›	S1
Areas of Activity ›	Precision medicine, oncology, ophthalmology
Patents ›	Extensive patent portfolio in proprietary affinity ligand technology
External Collaborations ›	ITM, Optigo Biotherapeutics, GAIASO Theranostics, Veraxa, SCK CEN, AI-DT, Nostrum Biodiscovery, Universität Leipzig
Request for Further Collaborations ›	Licensing, partnerships, research collaborations

Next-Generation Precision Medicine

Navigo Precision, part of the Navigo Proteins Group, is a German, fast-growing, near-clinical-stage biopharmaceutical company developing next-generation targeted therapies for precision medicine.

We integrate artificial intelligence with wet-lab capabilities to support the development of highly specific therapeutic proteins. Our technology combines AI-powered protein engineering, automated laboratory workflows and experimental validation for the discovery of targeted therapeutic and diagnostic approaches.

Our Mission

Navigo Precision aims to advance precision therapeutics by combining artificial intelligence, automation and protein engineering.
We translate scientific innovation into targeted therapies for patients worldwide, with a focus on addressing areas of unmet medical need in oncology.

AI-Powered Protein Engineering

Our proprietary AI-orchestration engine links prediction and experiment for faster, data-driven validation. Together with high-throughput automation, it supports the rapid and scalable screening of therapeutic candidates.

Navigo Precision also applies advanced AI models for generative protein design. This approach supports the design of functional proteins and expands the accessible sequence space for protein engineering.

Member of

BIO DEUTSCHLAND

NAVIGO PRECISION

From Protein Design to Targeted Therapeutics

Navigo Precision applies its technology to develop next-generation targeted therapeutic and diagnostic approaches, with a focus on oncology, radiotheranostic applications and ophthalmology.

Our work is directed toward programs that address disease-relevant questions through targeted, protein-based solutions.

Partnerships for Innovation

Navigo Precision is building a growing portfolio of proprietary targets and therapeutic programs available for partnering. We work with pharmaceutical, biotechnology and research partners, including ITM, SCK CEN, GAIASO Theranostics, Optigo Biotherapeutics, AI-DT, Nostrum and the University of Leipzig.

These collaborations bring together expertise in targeted therapies, diagnostics, radiotheranostics and cancer research to advance the development of innovative therapeutic programs.

NAVIGO PURE

Name ›	Navigo Proteins GmbH Business Unit: Navigo Pure
Address/P.O. Box ›	Heinrich-Damerow-Straße 1
Postal Code/City ›	06120 Halle/Saale
State ›	Saxony-Anhalt
Contact Person ›	Anna Bogdanova (Director Sales) Joséphine Hammerlindl (Business Development Manager Navigo Pure)
Telephone ›	+49 345 27996-330
Email ›	info@navigo-pure.com
Website ›	www.navigo-pure.com
Social Media ›	in
Number of Employees ›	90-100
Founded (year) ›	2017
Type of Laboratory ›	S1
Areas of Activity ›	Downstream processing Ligand and Resin development for affinity chromatography (custom and off-the-shelf)
Biological patent ›	Extensive patent portfolio around proprietary affinity ligand technology

Reinventing purification for biologics

Precision Capturing® is Navigo Proteins' pioneering affinity chromatography platform within the Navigo Pure business unit that redefines the way biologics are purified. Traditional downstream processing often requires multiple sequential chromatography steps, each of which adds time, cost and complexity to biologics manufacturing. Precision Capturing® addresses these challenges by consolidating purification into a single, highly efficient capture step. This streamlined approach significantly accelerates process development, improves product quality and enhances manufacturing efficiency across a wide spectrum of biologics.

At the heart of the platform are proprietary engineered scaffold ligands, derived from artificial Protein A scaffolds. These ligands are small, robust and highly specific, designed to selectively bind even the most challenging biologic molecules. Unlike conventional technologies that are often limited to antibodies with Fc regions, Precision Capturing® enables purification of a diverse range of therapeutic modalities including antibodies, enzymes, blood factors, vaccines, viral vectors and non-Fc proteins. This flexibility makes it a truly universal solution for next-generation bioprocessing.

Navigo Pure: from innovation to implementation

Our NaviCapture® ligands and resins are already applied in EMA- and FDA-approved bioprocesses, proving their regulatory acceptance and industrial reliability. These products are used throughout the entire value chain, from preclinical development to clinical supply and large-scale commercial manufacturing.

Member of

BIO DEUTSCHLAND







To bring this platform to market on an industrial scale, Navigo Proteins has established Navigo Pure, the dedicated business unit focused on delivering custom ligands and resins for use under GMP standards. Navigo Pure ensures that customers benefit from:

- Simplicity & Speed: Fewer purification steps mean shorter timelines, reduced process complexity and accelerated time-to-market for novel therapies.
- Robustness & Yield: The high specificity of Navigo's ligands enables excellent product quality, improved yields and more predictable performance under industrial conditions.
- Scalability & Regulatory Readiness: With GMP-compliant production and extensive regulatory expertise, solutions are designed to seamlessly support clinical and commercial manufacturing.
- Cutting-edge Ligands & Resins: Advanced affinity tools are created for drug classes most in need of efficient chromatographic processes, helping overcome current bottlenecks in biologics production.

25+ years of experience

Backed by over 25 years of experience in bioprocessing innovation, Navigo Pure has become a trusted global partner for affinity purification. Today, the company proudly supports more than 40 organizations, from fast-moving biotech startups to established Top-10 global pharmaceutical leaders, in developing and commercializing life-changing therapies. With the Navigo Pure business unit, Navigo Proteins is shaping the future of biologics manufacturing by delivering smarter, faster and more reliable purification solutions.

Name ›	Neovii Biotech GmbH
Address/P.O. Box ›	Am Haag 6+7
Postal Code/City ›	82166 Gräfelfing
State ›	Bavaria
Contact Person ›	Sebastian Hofmann
Telephone ›	+49-89-898888-0
Fax ›	+49-89-898888-16
Email ›	info.germany@neovii.com
Website ›	www.neovii.com
Number of Employees ›	180
Founded (year) ›	2003
Type of Laboratory ›	BioStoffV S3** cGMP certified production facilities, EU (Annex 1 EU-MP guideline) up to grade A respectively ISO5 (according to EN-ISO 14644-1)
Areas of Activity ›	I Transplantation Medicine I Haematological Oncology
External Collaborations ›	Academic research institutions and other companies

The company

The company Neovii Biotech GmbH – as part of the Neovii Group – is dedicated to delivering targeted biopharmaceutical treatment options in transplantation medicine and haematological oncology. The focus of its activities is the development and commercialisation of immunologically active biopharmaceutical therapeutics based on innovative antibody technologies. All the manufacturing activities are located in Gräfelfing/Germany.
Neovii has a presence in more than 40 countries worldwide.

For further details please visit:
www.neovii.com

Research and Development

Neovii supports research and development activities in the fields of solid organ transplantation, stem cell transplantation, and immune and haemato-oncological disorders. Neovii actively seeks in-licensing and acquisition opportunities. We are looking to expand our portfolio of products with novel life-transforming therapies that address severe unmet medical needs, in particular in the areas of transplantation, haemato-oncology, and immune disorders.

Areas of interest

Since its inauguration Neovii Biotech has been manufacturing and commercialising a medicinal product for the prevention of graft-versus-host disease after stem cell transplantation and prevention/treatment of acute organ rejection following solid organ transplantation.

The main fields of our operations are:

- Stem Cell Transplantation
- Solid Organ Transplantation
- Aplastic Anaemia
- Autoimmune Diseases

Transplantation: ATLGs (Anti-human T-lymphocyte immunoglobulins) – polyclonal antibodies
ATLGs are antibody-based medicines for the targeted suppression of immune responses (immunosuppressants).

They suppress immune responses by multiple mechanisms, such as immune cell depletion, inhibition of T-cell function, and induction of regulatory immune cells. Their immunosuppressive properties are used mainly in solid organ transplantation and stem cell transplantation. In stem cell transplantation (SCT) polyclonal antibodies are indicated for the prevention of graft-versus-host disease (GVHD).

GVHD is recognised as a severe complication following SCT that negatively impacts on the patient's quality of life and is a major cause of morbidity and mortality. In GVHD, transplanted immune cells attack the recipient's body, causing tissue and organ damage. By suppressing these immune reactions, ATLGs significantly lower the incidence of GVHD (Finke J, et al, Lancet Oncol 2009;10(9)1855—64).

In solid organ transplantation (SOT), polyclonal antibodies are indicated either for the prevention of organ rejection or to suppress active, acute rejection reactions. The rejection of a transplanted organ is primarily caused by immune cells of the recipient that start attacking the grafted organ, because it is recognised as foreign. By suppressing these immune reactions, ATLGs limit organ damage and prevent graft loss (Kaden J, et al. Ann Transplant. Jan 10 2013;18:9-22).

ID-Number: ATM.00003-3.0

Name › New England Biolabs GmbH

Address/P.O. Box › Brüningstr. 50 – Geb. B852
Postal Code/City › 65926 Frankfurt am Main
State › Hesse
Contact Person › Dr. Carsten Lanwert
Telephone › +49-69-305-23140
Fax › +49-69-305-23149
Email › customersupport.de@neb.com
Website › www.neb.com
Founded (year) › 1981

NEB – Passion for Science

Created by scientists for scientists, New England Biolabs is proud to be a world leader in the discovery and production of enzymes and reagents for molecular biology applications. Since our establishment in 1974, we have remained committed to developing high-quality, innovative products that empower not only your research but also our own. Our profits have always funded an extensive research programme, which we believe is critical for staying connected to our customers and helping to drive scientific breakthroughs. From our founding principles to our unique corporate culture, NEB's philosophy can be distilled down to three core values: passion, humility and being genuine.

Latest Innovation in Enzyme Technology

Our outstanding expertise in protein engineering and evolution has led to the creation of unrivaled enzymes and unique workflows in library preparation and target enrichment for the NGS space. These products set the benchmarks for optimal performance and ease of use in modern molecular biology laboratories. Moreover, NEB's specialised offerings for alternative DNA assembly, isothermal amplification as well as novel reagents for CRISPR/Cas9-based genome editing make us a first-choice supplier for today's molecular biologists.

Customised Solutions/GMP–grade & Lyophilisation

NEB's customised solutions unit has been delivering tailor-made enzyme formulations and packaging solutions to biotech, pharma and diagnostic customers. Building on an extensive experience, our GMP-grade manufacturing capabilities offer a range of customised products at scale, enabling commercial customers and partners to use NEB's world-class products in their specific applications and to support them in their efforts to access regulated markets. The recently established subsidiary NEB Lyophilisation Sciences combines expert knowledge in the design, development and manufacture of innovative enzyme solutions for ambient store products to meet our customers small- to large-scale lyophilisation needs.

Member of

VDGH
Verband der Diagnostica-Industrie



ISO-certified Quality

NEB is dedicated to providing research products of the highest quality. Our integrated quality management systems are certified to meet the requirements according to the standards ISO 13485 and ISO 9001.

Social Responsibility & Sustainability

While our passion for science helps us to drive discovery, we continue to be guided by our responsibility to each other and our community. We continuously strive to promote ecologically sound practices and environmental sustainability in order to protect our natural resources. As an additional measure, NEB has received ISO 14001 certification, a quality standard for environmental management systems. We also recognise that we must work together to build a more equitable society and improve diversity, equity and inclusion in our workplace.

Basic and Applied Science

We believe that basic research and the cultivation of scientific knowledge are critical for us to stay connected with our customers and to drive scientific breakthroughs. At NEB, over 30 labs participate in research projects, which are aided by post-doctoral fellows and students in Masters and PhD programmes. NEB researchers have authored or co-authored over 1,500 publications to date. With a dual focus on basic and applied research, NEB's culture is both collaborative and academic.

Scientific Customer Service

Our support model is unique as it utilises technical support scientists, scientist responsible for product development or manufacturing, and product line experts. As such, customers are supported by scientists and often experts in the product or its application.

New England Biolabs GmbH

The NEB subsidiary in Germany represents the service hub for Central Europe. From our location in Frankfurt, we serve scientists and industry customers in Germany and Austria and support our network of distribution partners across Europe.
For further information please visit our website at www.neb.com.

Nordmark Biotech

Name ›	Nordmark Pharma GmbH
Address/P.O. Box ›	Pinnauallee 4
Postal Code/City ›	25436 Uetersen
State ›	Schleswig-Holstein
Contact Person ›	Dr. Jörg Stute
Telephone ›	+49-521-430602-45
Email ›	projects@nordmark-biotech.de
Website ›	www.nordmark-biotech.de
Number of Employees ›	~ 700
Founded (year) ›	1927
Areas of Activity ›	I Process development I Microbial fermentation I Mammalian cell culture
Annual Turnover ›	€160m

Member of

BIO DEUTSCHLAND

Founded in 1927, Nordmark is an internationally leading specialist for the development, manufacturing, and commercialisation of active pharmaceutical ingredients (APIs) and drug products of biological and biotechnological origin under GMP conditions. Headquartered in Uetersen near Hamburg (Germany), and family owned again after a management buyout from the BASF group in 2001, Nordmark today employs around 700 employees and generates revenues of around EUR 160 million.

Inspired by the organisation and high-quality standards of our former parent company, as an independent pharmaceutical enterprise, we successfully develop and produce biological active pharmaceutical ingredients and drug products through all stages of the value chain.

Nordmark Biotech, the biotechnological division of Nordmark, is a specialist for providing tailor-made solutions for the development and manufacturing of biopharmaceuticals from lab to production scale. In this context, we are able to offer expertise in both systems – microbial as well as mammalian – to our customers.

Services cover the entire value chain from process development to marketed drugs:

- Strain and Cell Line Development
- Microbial Fermentation – Upstream Process Development
- Mammalian Cell Culture – Upstream Process Development
- Downstream Process Development
- Formulation and Filling – Pharmaceutical Development
- Biomanufacturing under GMP Conditions
- Analytical Services
- Regulatory Service
- Process Transfer
- Market Supply

NORDMARK

Nordmark Biotech connects flexible partnerships with a unique expertise and know-how in developing and delivering drugs to market. As a family-owned business we work with maximum care and attention and with fast and simple decision-making processes. We are focused on success – regardless of project size.

Nordmark can refer to a significant track record in the industry with different successful process development and manufacturing projects in various stages of clinical development as well as approved and marketed products for more than 40 international partners. With more than 90 years of excellence and commercial success, Nordmark is the ideal partner to bring your ideas to market.

OPST
OLIGO PEPTIDE SERVICE TECHNOLOGY

Name › **OPST GmbH**

Address/P.O. Box › **Wettersteinstr. 1**
Postal Code/City › **82024 Taufkirchen**
State › **Bavaria**
Contact Person › **Marc Niwar**
Telephone › **+49-1514-491-77-30**
Email › **info@opst.solutions**
Website › **www.opst.solutions**
Social Media › **in**
Number of Employees › **6**
Founded (year) › **2023**

Areas of Activity ›
- **AKTA service and support**
- **Chromatography / purification systems (new and refurbished)**
- **Synthesizers and liquid handling equipment (new and refurbished)**
- **Refurbishment and resale of laboratory systems**
- **Service, maintenance and repair support**
- **Spare parts supply**
- **Oligonucleotide synthesis building blocks and reagents**
- **User training and project support**

Ensuring laboratory systems run smoothly – from servicing to consumables

Who we are

OPST GmbH (Oligo Peptide Service Technology) supports laboratories and production facilities with technical service, laboratory equipment and synthesis materials. Our team has more than 30 years of experience in oligonucleotide and peptide production, as well as in servicing and repairing laboratory equipment. We aim to keep established systems running for as long as it makes technical and economic sense.

Service beyond the OEM lifecycle

Many laboratories rely on proven platforms that still work well, although the manufacturer has restricted or discontinued support for them. Premature replacement often means new investment, revalidating methods and additional staff training. OPST keeps these systems operational through fault diagnosis, maintenance, repairs, spare parts supply and technical support. A key focus of our work is AKTA systems, both for chromatographic purification and for oligonucleotide synthesis. These include the AKTA Explorer and AKTA Purifier, which remain widely used despite discontinued OEM support and the AKTA Oligopilot plus 10 and 100, for which Cytiva support is scheduled to end in March 2027. OPST continues to service and support all of these systems.

Refurbished and new equipment

We supply refurbished and new equipment – whether a laboratory needs to expand capacity or replace an existing instrument. Second-hand systems are inspected and refurbished in accordance with the manufacturer's specifications. Depending on their condition, we repair or replace individual components, and every system is tested before delivery. This makes refurbished equipment a reliable and cost-effective alternative to buying new. As we also service existing systems, our advice is not tied to any one solution: we recommend what suits the laboratory best, help select the appropriate configuration, assist with installation and train users directly on the equipment.

Equipment portfolio

A selection of our range:

- Oligonucleotide synthesizers: AKTA Oligopilot plus 10 and 100, OligoPilot 400, Dr. Oligo, ABI 394 and 3900, Expedite 8909, K&A H-8 and H-16, and others upon request
- Chromatography systems: AKTA Start, Go, Pure, Avant, Explorer, Purifier, Pilot 400 and 600, and Process
- Filtration and concentration: AKTA Crossflow and Flux systems, TurboVap 96
- New instruments: i.prep pipetting robot, plus oligonucleotide synthesizers and purification systems for different scales and throughputs – on request

Building blocks and reagents

OPST also supplies synthesis building blocks and reagents, including modified phosphoramidites and supports, dyes and labels, as well as click-chemistry reagents. Customers can therefore source equipment, service and consumables from a single partner who understands the chemistry just as well as the instruments on which it is used.

Name › Omicron-Laserage Laserprodukte GmbH

Address/P.O. Box › Raiffeisenstrasse 5e
Postal Code/City › 63110 Rodgau
State › Hesse
Contact Person › Natalie Stockinger
Telephone › +49-6106-8224-0
Email › sales@omicron-laser.de
Website › www.omicron-laser.de
Social Media ›
Number of Employees › 99
Founded (year) › 1989

Areas of Activity › Laser, LED, Light Sources, Diode Lasers, Medical Lasers, Medical Systems, CW Light Sources, Customised Laser Systems, Photonics, Laser Development, Laser Solutions, Customised Light Sources, Biotech, Life Sciences, Microscopy, Spectroscopy

Flexible Laser & LED Light Sources for Industry & Science with 36 Months Warranty

Omicron-Laser has been developing, manufacturing, and distributing innovative laser and LED light sources since 1989 and is one of the leading manufacturers for demanding applications in biotechnology, microscopy, microlithography, medicine, and many more.

Based in Germany, Omicron is specialised in customised solutions in addition to its broad product portfolio. Product development and production comply with European and US guidelines and are conducted according to the ISO9001 and ISO13485 quality standards. Omicron offers CW light sources as well as high-speed modulated systems in the nanosecond and picosecond range, both as single and multi-wavelength solutions.

Important developments based on ISO 9001 and ISO 13485 include:

- the LightHUB® laser beam combiner series
- the LedHUB® high-power LED light engine
- the QuixX® picosecond pulsed diode laser
- the PDT medical laser system for cancer treatment
- the BrixXLAB multichannel desktop laser for laboratory applications
- BrixXHUB Ultra® Highly Integrated Multimode High-Power Light Engine

Highly Integrated Multimode High-Power Light Engine: BrixXHUB Ultra®

As the first highly integrated multimode high-power laser light engine on the market, the BrixXHUB Ultra is the perfect fit for applications in widefield laser illumination. The new device is a highly integrated multimode high-power laser light engine with up to 6 high-power BrixX lasers at its core, offering a wide range of wavelengths between 375 and 1550nm at up to more than 5 Watts per wavelength. This, combined with 6 analog and digital modulation inputs, provides unique flexibility to meet dynamic project needs. The system is designed for user-friendly operation and comes fully equipped with all essential accessories, enabling users to promptly

start their projects without any delay. In addition, its user-upgradeable design allows for easy customisation, enabling individuals to adapt to evolving project requirements effortlessly.

Flexible Multi-Wavelength Solutions: LightHUB+®, LightHUB Ultra®, LedHUB®

Omicron's innovative LightHUB+® and LightHUB Ultra® laser light engines represent a new form of laser light sources for science, research, and industry based on the ultra-compact LuxX (LuxX+) laser series. The high-performance systems can be equipped with one to six (LightHUB+®) or seven (LightHUB Ultra®) laser modules of different wavelengths from UV to the near IR range and offer rapid analogue intensity modulation with up to 1.5MHz (3MHz and 250MHz digital) and digital full ON/OFF modulation with a switching time of <1µs for each channel. The individual laser modules can easily be exchanged and added by the user. Hence the systems can be adapted to changing application requirements and are future-proof.

The Omicron LedHUB® is a high-power LED light source for biotech, industrial, and analytical applications. With up to 6 different wavelengths between 340 and 940nm it can be used in applications like widefield microscopy, optogenetics, chemical analysis, forensics, and many more. The modular principle of the LedHUB® provides the possibility to start with only one or two wavelengths initially and upgrade by further wavelengths at a later stage. The capability of rapid switching between wavelengths and high-speed analogue modulation of intensity is a key feature for demanding applications.

Name › Polysciences

Address/P.O. Box › Badener Str. 13
Postal Code/City › 69493 Hirschberg an der Bergstrasse
State › Baden-Wuerttemberg
Contact Person › Melanie Bailey-Treiber
Managing Director
Tughan Akbasak, PhD
Sales and Marketing Director
Telephone › +49-6201-845-20-0
Fax › +49-6201-845-20-20
Email › info@polysciences.de
Website › www.polysciences.com
Social Media ›
Number of Employees › 300
Founded (year) › 1961

Areas of Activity › Bioprocessing & cell and gene therapy
- Transfection reagents (research to cGMP)
- Excipients for viral vectors & mRNA

Microspheres & instrument standards
- Polymer, silica & magnetic microspheres
- NIST-traceable size standards & count standards
- Instrument calibration & QC

Monomers, polymers & biomaterials
- Functional PEGs & biodegradable polymers
- Ophthalmic & medical device materials

Diagnostics & histology
- ELISA & lateral flow assay manufacturing
- Histology & pathology stains

Electronic chemicals
- Encapsulants for microelectronics

Custom synthesis & CDMO
- Custom polymer & fine chemical synthesis
- Contract manufacturing

Science-driven chemistry for the life sciences

Polysciences is part of the Ott Scientific group, which brings together four specialist companies – Polysciences, Bangs Laboratories, Kyfora Bio and Ethos Biosciences – with expertise spanning specialty monomers and polymers, transfection and bioprocessing, microparticles and instrument standards, diagnostic reagents and electronic chemicals. Founded in 1961, Polysciences is the oldest company in the group. Polysciences Europe GmbH, established in 1993 and based in Hirschberg an der Bergstrasse near Heidelberg, serves as Ott Scientific's gateway to Germany and the wider European market. Customers benefit from direct, single-source access to the group's complete portfolio – from catalogue products and custom synthesis to quality control – supported by local technical expertise.

A broad portfolio from one source

We combine research-grade products with materials for regulated applications. Biotech and pharmaceutical developers rely on functional PEGs, biodegradable polymers and crosslinkers for bioconjugation, hydrogels and drug delivery. Ophthalmic and medical device manufacturers use specialty monomers for contact and intraocular lenses, as well as polymers for device coatings, available in ultrapure and cGMP grades. For cell and gene therapy, our transfection reagents – including PEI MAX®, Transporter 5® and SmashGene™ – together with our enhancers, support viral vector, antibody and recombinant protein production from early research through to cGMP manufacturing.

Particles and standards you can trust

Drawing on more than three decades of experience, we develop polymer, silica and magnetic microspheres used as solid phases in immunoassays, lateral flow tests, nucleic acid isolation and cell separation. Magnefy™ particles, for example, are designed for SPRI-based DNA isolation and CUT&RUN workflows. NIST-traceable size standards, count standards, calibration beads and Fluoresbrite® fluorescent microspheres provide reliable



references for flow cytometers, particle counters and imaging systems, supporting method verification in line with ISO, ASTM and CEN guidelines.

Diagnostics and electronics

For diagnostics manufacturers, we support ELISA and lateral flow assays from feasibility through scalable production, including OEM and private-label kits and components such as conjugates and membranes. We also offer nephrology biomarker tests as well as histology and pathology stains. In electronics, specialty resins and encapsulants are used in microelectronic packaging, while electronics-grade poly(acrylic acid) serves as a raw material for CMP slurries.

Custom synthesis and CDMO services

When no catalogue product fits, we develop one. With more than 60 years of synthesis experience, an FDA-registered production site in Warrington, Pennsylvania, cGMP capabilities and ISO 13485:2016 certification, Polysciences develops and manufactures custom monomers, polymers and fine chemicals for medical device, biopharmaceutical and electronics customers. Formulation, filling, packaging and kitting complete a flexible path from early R&D to commercial scale.

Let’s work together

From Hirschberg, our team works closely with research institutes, startups and industrial partners across Germany and the rest of Europe. Whether you need a catalogue product, a custom material or an OEM component, we look forward to understanding your project and finding the right solution together.

ProBioGen

Intelligent Biopharmaceutical Solutions

Name	**ProBioGen AG**
Address/P.O. Box	**Herbert-Bayer-Str. 8**
Postal Code/City	**13086 Berlin**
State	**Berlin**
Contact Person	**Dr. Alfred Merz (CEO)**
Telephone	**+49-30-322-935-100**
Fax	**+49-30-322-935-400**
Email	**info@probiogen.de** **cdmo@probiogen.de**
Website	**www.probiogen.de**
Social Media	
Number of Employees	**300**
Founded (year)	**1994**
Type of Laboratory	**S1, S2, GMP**
Areas of Activity	**Biopharmaceutical development and GMP manufacturing** **Proprietary technologies to enhance product characteristics and process efficiency** **Designer cell lines** **Vector platforms**
Biological Patents	**ProBioGen holds numerous international patents on technologies to improve product quality/potency and enhance cellular productivity.**
External Collaborations	**With many international companies and research organisations, e.g. Boehringer Ingelheim, Bayer, Charité, Novartis, etc.**
Request for Further Collaborations	**ProBioGen works with biotech and pharma companies that develop (complex) therapeutic proteins, antibodies, vaccines or viral vectors.**

Member of

BIO DEUTSCHLAND

Intelligent Biopharmaceutical Solutions

ProBioGen is an experienced Berlin-based CDMO specializing in the development and manufacturing of biopharmaceuticals, viral vectors, vaccines and advanced therapies. Built on scientific depth, proprietary technologies and broad multi-modality capabilities, ProBioGen delivers integrated development services and GMP-compliant manufacturing to optimize product quality and performance.

Unique Services

Cell line & process development for therapeutic proteins

- CHO.RiGHT® expression system
- DirectedLuck® transposase for efficient gene delivery & high titers
- Proprietary chemically defined (CD) media platform/ multiple suppliers
- Robust and economic platform processes
- Classic and intensified processes
- Reports to support investigational new drug (IND) filing
- Modular services and open source concept

(GMP) Manufacturing for therapeutic proteins

- Cell banking (MCB/WCB)
- Up to 1000 L TOX manufacturing
- 2x up to 1000 L GMP manufacturing
- Disposable, stirred tank bioreactors

Development services for viral vectors

- Tailor-made solutions for the production of e.g. lentiviral and adenoviral vectors, AAV and MVA
- Suitable cell substrates for the propagation of various viral vectors in suspension processes using CD medium
- Robust upstream and downstream processing supported by comprehensive analytical tools
- Cost-effective non-GMP production for preclinical development phase

(GMP) Manufacturing for various viral vectors

- Cell banking (MCB, WCB) and virus banking (MSV/WSV)
- Up to 200L TOX manufacturing
- Up to 200L GMP manufacturing (up to biosafety level 2)
- Aseptic filling of drug product and diluent under GMP conditions

Your Biologics. Elevated.®

Analytics, bioassays & quality management

- Integrated analytical development
- Validation according to bioanalytical guidelines (EMA/FDA)
- Stability studies in accordance with ICH Q1
- Wide range of cell based and binding activity assays
- Various cell based and instrumental analyses for content and identity testing of viral vectors and vaccines

Innovative Technologies

GlymaxX® ADCC enhancement & glyco-engineering

- Prevents antibody fucosylation
- Boosts ADCC cell-killing activity against tumors and infected cells
- Applicable to both novel and existing producer cell lines
- Allows adjustment of fucose, galactose, and sialic acid levels in glycoproteins

DirectedLuck® – Transposase system

- Proprietary transposase for efficient gene delivery
- Generates high-titer clones (up to 8 g/L)
- Superior heterodimer rates for bi-specific mAbs

Lenti.Right pools and producer cell line

- GMP qualified starter cell bank based on HEK 293
- Efficient LV production in CD medium (107-108 TU/ml)
- No requirement of GMP-grade plasmid DNA or transfection reagent
- Straightforward purification of lentiviral particles for e.g. CAR-T therapies

AGE1.CR.ReX® designer cell line & MVA vaccine manufacturing platform

- Avian suspension cell line permissive for numerous human and veterinary viral vaccine strains
- Equipped with the proprietary TetherexX™ system for higher titers, increased genetic stability, and production-ready virus in less time
- GMP-compliant chemically defined media and scalable suspension processes
- Proprietary MVA strain, transgene expression design, and technology for rapid generation of recombinants

PROGEN

Name ›	PROGEN
Address/P.O. Box ›	Maassstrasse 30
Postal Code/City ›	69123 Heidelberg
State ›	Baden-Wuerttemberg
Contact Person ›	Ruth Roschatt
Telephone ›	+49-6221-8278-0
Fax ›	+49-6221-8278-24
Email ›	info@progen.com
Website ›	www.progen.com
Social Media ›	in
Number of Employees ›	40+
Founded (year) ›	1983
Type of Laboratory ›	S1 class laboratories, DIN ISO 13485 certification for the production of in vitro diagnostic kits and research reagents.
Areas of Activity ›	AAV gene therapy analytical tools and antibodies, antibodies and reagents for biomedical research, in vitro diagnostics, ELISA, antibody phage display technology, density gradient media
External Collaborations ›	Strong network with industrial and academic institutions
Request for Further Collaborations ›	PROGEN is actively seeking partners for the advancement and distribution of its gene therapy and antibody-based products & services.

Member of

BIO DEUTSCHLAND

Making Gene Therapy Better. Together.

PROGEN develops analytical tools to support research and development in the fields of gene therapy and life sciences. Our core expertise lies in Adeno-Associated Virus (AAV) analytics, where we provide standardised reagents and assays that help scientists characterise, quantify, and monitor viral vectors across all stages of therapy development, from discovery to quality control. We work with biotech and pharmaceutical companies, commercial manufacturers, and academic institutions worldwide. Our focus is on tools that improve reproducibility, simplify workflows, and meet regulatory requirements. By building on more than four decades of antibody expertise, we deliver reliable solutions for today's challenges in viral vector characterisation while preparing for the needs of tomorrow.

Looking Ahead

Founded in 1983 in Heidelberg, PROGEN is one of Germany's first biotech companies. Today, we operate globally as a subsidiary of R-Biopharm AG, with ISO 13485 and My Green Lab® certifications.

We collaborate closely with scientists and industry partners to ensure our tools reflect real research needs and evolving regulatory expectations. Beyond supplying products, we provide technical expertise and maintain active collaborations with academic institutions, biotechnology companies, and pharmaceutical companies. PROGEN is open to partnerships to advance and distribute its products and services.

Our goal is to deliver reliable, high-quality tools that enable safe and efficient therapeutic development in gene therapy and beyond.

Since
1983

Reliable Tools for Gene Therapy

Our Portfolio

AAV Analytical Tools

PROGEN offers a comprehensive portfolio to support AAV vector characterisation, monitoring, purification, and assay validation throughout the gene therapy workflow:

- Pan AAV Capsid Titer Assay for quantifying standard, engineered, or novel AAV capsids with one single fast and wash-free assay.
- ELISA kits and controls for reproducible capsid titer quantification across all major serotypes, with express formats for faster results.
- Dip'n'Check lateral flow tests for rapid, equipment-free detection of assembled capsids during production.
- Antibodies against AAV particles, capsid proteins, and replicase proteins, which are widely used for detection, in-process monitoring, and assay development.
- Reference standards and proteins, including empty, full, and Renilla-filled capsids and VP1/2/3 proteins, to support assay comparability and regulatory readiness.
- OptiPrep™ iodixanol for efficient AAV purification and full/empty capsid separation.

Non-Viral Gene Therapy Tools

Alongside our AAV expertise, we also provide lipid nanoparticle (LNP) delivery kits, supporting the growing non-viral approaches in gene therapy.

Analytical Tools
for Every Gene Therapy,
for Every Lab.

ProJect pharmaceutics
formulations for pioneering drugs

Name › ProJect Pharmaceutics GmbH

Address/P.O. Box › Fraunhoferstrasse 22
Postal Code/City › 82152 Martinsried
State › Bavaria
Telephone › +49-89-45-22-89-700
Fax › +49-89-45-22-89-717
Email › info@project-pharmaceutics.com
Website › www.project-pharmaceutics.com
Social Media › 𝕏 in

Founded (year) › 2010

Type of Laboratory › Contract research and development (CRO); cytotoxic (≤OEL5); BSL-1; BSL-2; fee-for-service business model; 2-4 weeks start up time; slim and reliable timelines; GLP-like quality standards; submission-compliant documentation

Areas of Activity › Analytical characterisation; pre-formulation screening; formulation development; freeze drying cycle development; lyophilisation process scale-up; tech transfer to GMP

Biological Patents › Several patents in freeze drying and formulation

External Collaborations ›
- Network for seamless development from pre-clinic to fill/finish and market.
- Formulation specialist partnered with DS and DP CMOs worldwide.
- Local company representation in APAC and U.S.A.
- Credited laboratory for Wyatt Technology in Europe.
- Application laboratory for Thermo Fisher LC-MS (Orbitrap Exploris 240) technology

Request for Further Collaborations ›
- Small biotechnology/mid-size pharma companies, large top players in pharma/biotechnology.
- From DSP development to early and late drug product phases up to life cycle management.
- Customised solutions for challenges in formulation, analysis or process.

ProJect Pharmaceutics is a leading independent European CRO specialised in formulation and manufacturing process development for injectables: biologics (rec. proteins, antibodies, fusion proteins), peptides, ADCs, cytotoxics, small molecules, generics, viral therapeutics, ATMPs, VLPs and other nanoparticular drug delivery systems. We apply innovative, quality-by-design based, rational concepts of pharmaceutical development according to ICHQ8 and other guidelines. We support our global customers in developing a consistently high-quality pharmaceutical product that is transferable, scalable and manufacturable under GMP conditions. ProJect Pharmaceutics is managed by experts with >35 years of experience in the pharmaceutical industry. In about 850 m^2 we operate special laboratories for biologics, cytotoxics and a BSL-2 unit, equipped with dedicated industrial HOF pilot freeze dryers.

Protein formulation

- Predictive formulation analytics: a QbD-based high-throughput approach for accelerated development
- Pre-formulation, early state & late phase formulation
- Liquid & lyophilised formulation (DoE-based)

High concentration protein formulation

- Low viscosity formulation for s.c. application
- UF/DF process development
- Injectability & syringeability evaluation

Cytotoxic small molecules

A deep understanding of the challenges when processing highly potent drugs, such as limited solubility in water and rapid degradation, paired with long-lasting experience and comprehensive know-how of lyophilisation from various organic solvents enables us to provide specific solutions for high potency & cytotoxic drugs.

Antibody-drug conjugates (ADCs)

- ADCs & related complex conjugated moieties
- Predictive, high-throughput formulation development
- High-end freeze-drying technology
- s.c. ADC formulation up to e.g. 50-100 mg/mL
- Complementary formulation & process development of intermediate mAb and linker-payload bulk
- Tailored development rather than a CMO's default





Peptide formulation

- Formulation and lyophilisation cycle development

Innovative liposome technology

- High encapsulation efficiency (hydro- & lipophilic APIs)
- GMP-compatible manufacturability with standard equipment

Viral-based therapeutics

- Lyophilised formulation and cycle development

In-use stability & clinical application

- Evaluation of DP compatibility with IV line equipment

Freeze drying

- In vials, dual chamber systems, syringes, cartridges, bulk trays or bags, containers in nest&tub configuration
- Out of organic solvents
- Rational cycle development (robust, collapse-safe, cost & time efficient, tailored to the formulation)
- Bulk lyophilisation (solid or powder)
- SEM structural analysis of lyo cake
- Time lapse video & IR thermal camera monitoring
- Aseptic pre-clinical batch manufacturing
- Robustness & design space evaluation
- Smooth technology transfer to GMP

Process development and manufacturing

- DSP: Smart optimisation of UF/DF & purification steps targeting a common DS/DP formulation
- Container closure system compatibility
- Forced stress, in-use & accelerated stability studies
- Detergent & excipient quantification
- Sterile filtration study
- Manufacturability assessment
- Fill&finish process mock-up
- Aseptic pre-clinical batch manufacturing

Fill&finish

As state-of-the-art development experts we are teamed up with state-of-the-art contract manufacturing experts to provide high-quality parenterals from pre-clinical to clinical and commercial scale.

Name › Promega GmbH
(a branch of Promega Corp.)

Address/P.O. Box › Gutenbergring 10
Postal Code/City › 69190 Walldorf
State › Baden-Wuerttemberg
Contact Person › Dr. Caroline End
Telephone › +49 6227 6906-0
Email › Promega_Info@promega.com
Website › www.promega.com
Social Media ›
Number of Employees › 168
Founded (year) › 1997

Areas of Activity ›
- High-quality reagents and kits for DNA, RNA and protein analysis; cell-based and biochemical assays for studying cellular processes and characterizing therapeutic candidates.
- Instruments and compatible reagents for automated laboratory workflows.
- Custom manufacturing and R&D services for customer-specific requirements
- On-site Stocking for convenient access to frequently used products
- Technical support for assay selection, workflow optimization and laboratory automation

Patents › Promega holds hundreds of patents in the areas of:
- Bioluminescence
- Cellular Analysis
- Cell biology
- Drug Discovery

Member of

VDGH
Verband der Diagnostica-Industrie

Promega – Supporting Science from Research to Application

For over four decades, Promega has been advancing science by providing innovative tools for life science research, diagnostics, pharmaceutical development, and applied testing. The portfolio includes over 4,000 products for genomics, protein analysis, cell biology, genetic identity and molecular diagnostics. From PCR and qPCR to luciferase-based assays, cell-free protein expression, CRISPR analysis and STR-based human identification, Promega products support a wide range of molecular biology applications.

Where Science Meets Simplicity

We design technologies that make complex processes more efficient. Whether you're quantifying gene expression, detecting protein interactions, isolating high-quality nucleic acids, or analysing metabolic activity – Promega's smart assay systems and reagents save time and increase reproducibility. Our Maxwell® instruments automate DNA and RNA extraction, while GloMax® detection systems deliver reliable readouts for luminescent, fluorescent, and absorbance-based assays. Technologies like NanoBRET™, HaloTag®, and HiBiT® support advanced cellular analysis and high-throughput screening.

Serving Science across Sectors

Promega products are trusted by scientists in academic research, pharma and biotech companies, clinical diagnostics, forensics, food safety, and environmental monitoring. Our solutions support research areas such as cancer biology, neuroscience, immuno-oncology, microbiology, epigenetics, and personalized medicine. Whether in early-stage basic research or regulated environments, Promega tools help transform ideas into insights.

Training Facility in Walldorf, Germany

1. **Spectrum CE Systems**
   DNA Sequencer/Analyzer
2. **Glomax®**
   Multimode Plate Readers
3. **Glomax® Galaxy**
   Bioluminescence Imager
4. **Maxwell® & Maxprep™**
   Automated Nucleic Acid Purification Systems
5. **Quantus™**
   Fluorometric DNA/RNA Quantification System

Customised Solutions & Scientific Partnerships

Promega offers a wide range of services to meet specific customer needs – from small-scale customisation to large-scale collaborations. These include:

- Custom Assay Development & R&D Services: Assay development and optimisation for specific applications.
- Custom & Bulk Manufacturing: Modified formulations, private labeling, and scalable production.
- OEM Partnerships: Seamless integration of Promega technologies into partner products and platforms.
- Regulatory Support & Quality Standards: Product-specific documentation and manufacturing options, including ISO 13485 and GMP, depending on the product and intended use.
- Global Distribution & Local Support: Available in over 100 countries with scientific and technical expertise close to our customers.

Rooted in Values. Growing through Responsibility.

At Promega, we believe science serves the greater good. We encourage a culture of curiosity, authenticity, collaboration, and personal development. We actively support education, creativity, and inclusiveness – both inside and outside the laboratory. These values shape not only how we innovate, but also how we work with our customers, colleagues, and communities.

Sustainability: Progress and Commitments

Promega aligns its global operations with the UN Sustainable Development Goals (SDGs) and has been part of the UN Global Compact since 2010. Our emissions reduction targets were validated by the Science Based Targets initiative (SBTi) in April 2026. We work to reduce the environmental impact of our products and operations: Selected sites, including the headquarters in Madison have been certified with ISO14001.

ProtaGene
Analytical Excellence

Name › ProtaGene GmbH

Address/P.O. Box › Inselwiesenstr. 10
Postal Code/City › 74076 Heilbronn
State › Baden-Wuerttemberg/NRW
Otto-Hahn-Str. 15, 44227 Dortmund
Im Neuenheimer Feld 582
69120 Heidelberg
Site Burlington:
4 Burlington Woods Drive
Burlington, MA 01803, USA
Contact Person › Dr. Roland Moussa; Michael Stump, Ph.D.
Telephone › +49-7131-74504-0
Fax › +49-7131-74504-299
Email › contact@ProtaGene.com
Website › www.ProtaGene.com
Social Media › in

Number of Employees › 220
Founded (year) › 1997
Type of Laboratory › Protein analytical laboratories (GMP-compliant, biosafety level 2)
Genetic analysis laboratories (GCP/GLP, biosafety level 2)
Areas of Activity › Analytical services for biopharmaceutical development: antibodies, antibody drug conjugates (ADCs), antibody oligonucleotide, conjugates (AOCs), bispecific/multispecific antibodies, biosimilars, FAB fragment, fusion proteins, vaccines, other protein formats, new biological entities (NBEs), oligonucleotides, mRNA, cell and gene therapy analytics: viral particles, LNPs, GeneWerk integration site analysis, vector characterisation, bioinformatics, sequencing data analytics, On-/Off-Target analysis, immune repertoire analysis, gene expression analysis
| Comparability demonstration
| HCP analytics
| Method validation and verification
| Forced degradation studies
| Stability testing | Release testing
| Cell-based bioassays

Member of

BIO DEUTSCHLAND

ProtaGene is a world-leading analytical CRO partner for developing biotherapeutics and advancing therapy medicinal products. For almost 30 years, the group has worked alongside clients worldwide ranging from startups to top ten pharmaceutical companies to bring medicines to market. They have been part of the story for novel blockbuster products, as well as rare and orphan drugs. ProtaGene is rooted in deep science and hands-on execution, which allows for an intelligent and agile approach to meet the needs of the increasingly complex medicines being developed today. Their experience is demonstrated best with their biosimilar analytical strategies that cut years off creating the required analytical data package. They also operate the gold standard of gene safety testing methods (Integration Site Analysis), which has generated critical data for gene and cell therapy market authorization. ProtaGene is the deep-science partner for modern medicines and analytical development, empowering our partners to bring innovative therapies to market by supporting a broad range of cutting-edge modalities and complex formats, including:

- New biological entities (NBE)
- Bi- and multispecific mAbs (msAbs)
- Fusion proteins
- Antibody-drug conjugates (ADC)
- Antibody-oligonucleotide conjugates (AOC)
- Peptide-based drugs
- Oligonucleotides (e.g. ASO, siRNA)
- mRNA-based (LNP) vaccines
- Viral vectors (e.g. AdV, LVV, AAV)

ProtaGene supports all phases of drug development by operating at every quality level, with a strong focus on GMP, alongside GCP, GLP and R&D, ensuring data meets rigorous regulatory standards while applying lean, agile processes to accelerate delivery. Analytical reports are regularly accepted by multiple regulatory authorities worldwide, including the FDA (USA), EMA

(EU) and others, spanning all stages of development from scientific advice to Phase I-III and up to market authorization. By means of standard and innovative analytics, customized and applied by our highly experienced teams within the FDA and EMA territories, we focus on delivering GMP-compliant analytical excellence in advancing, de-risking and accelerating all stages of drug development.

ProtaGene provides you with the full range of analytical services from drug discovery and development to GMP release testing and regulatory compliance under Biosafety Level 1 and 2 (BSL1/BSL2):

- Characterization and structural analysis
- Physicochemical testing
- Purity and impurity testing
- Bioassays and potency testing
- Stability and forced degradation studies
- Analytical method development
- Method validation
- GMP, GLP and R&D testing
- Bioinformatics

Our analytical services for gene therapy-based products provide best-in-class molecular diagnostics and analysis services to ensure the safety of novel cell and gene therapies focusing on insertional mutagenesis and genotoxicity. Highly sensitive platforms and bioinformatics tools determine fusion sequences adjacent to known DNA or RNA fragments in minimal tissue samples down to the single-cell level. Applications include clonality and safety of (viral) vectors in gene therapy, on-target specificity of designer nucleases, immune repertoire studies in T cells and B cells and next generation sequencing (NGS). Drawing on our unique worldwide experience in gene therapy studies, bioinformatics, NGS and associated regulatory demands, we help our customers by designing solutions entirely tailored to their needs.

PSM Your Pharma CDMO for Aseptic Fill & Finish Services

Name › **PSM GmbH**

Address/P.O. Box › **Am Nusskopf 39**
Postal Code/City › **66578 Schiffweiler**
State › **Saarland**
Contact Person › **Thorsten Haefner**
Telephone › **+49 6821 2959 60**
Email › **service@psm-saar.de**
Website › **www.psm-saar.de**
Social Media ›
Number of Employees › **~ 110**
Founded (year) › **2020**

Type of Laboratory › **Contract Development Manufacturing Services (CDMO) for biopharmaceuticals including monoclonal antibodies, biosimilars, small molecules and diluents.**

Capabilities to process pre-fillable syringes (PFS), vials, and cartridges.

Areas of Activity › **Our End-to-End CDMO Services**
- **Analytical services**
- **Method and process development**
- **Cold-chain logistics, including low-temperature handling down to -70°C**
- **Compounding**
- **Non-GMP Fill & Finish Service for Technical Tests**
- **Aseptic filling or filling with terminal sterilization**
- **Visual inspection and secondary packaging**
- **GMP storage and GDP transport**

Member of

BPI Bundesverband der Pharmazeutischen Industrie e.V.

Your Pharma CDMO for Aseptic Fill-and-Finish services

PSM GmbH is a family-run German company that operates as a Contract Development and Manufacturing Organization (CDMO) in the pharmaceutical industry, located in Schiffweiler in the state of Saarland in Germany.

From clinical development to commercial manufacturing

As an end-to-end CDMO, we provide services for the entire implementation process and lifecycle of your drug, from clinical phases to commercial GMP manufacturing.

Our portfolio includes method and process development, analytic, non-GMP fill and finish services for technical tests, aseptic fill and finish services, visual inspection with CCIT, secondary packaging with serialization, as well as GMP storage and GDP transport.

State-of-the-Art EU GMP Annex 1 Approved Facility

With our state-of-the-art facility, we are proud to be one of the first European CDMOs to have passed the inspection by the local authorities under the new EU GMP Annex 1. Our facility has been inspected and approved by the local regulatory authorities in 2024.

All the equipment, from fill and finish to secondary packaging, is designed to process all common ready-to-use primary packaging containers, including pre-fillable syringes up to 10 mL, vials up to 50 ml, and cartridges up to 10 mL, made of glass or polymer.

This flexibility enables us to offer fill-and-finish services for biopharmaceutical drugs like monoclonal antibodies, biosimilars, small molecules and diluents (e.g. WFI). Our current processes can accommodate batch sizes of up to 600 litres.

Highest Product Yields for Orphan Drugs

For very high-value biological drugs like monoclonal antibodies, we use the most sophisticated human-free robotic fill-and-finish technologies with isolator tech-

nology to minimize product loss throughout the entire processing cycle for batch sizes of up to 100 litres. Our services include the handling of low-temperature drugs of -70°C and the controlled thawing process of frozen API.

Your benefits in working with us

Fast decision-making processes: Flat hierarchies in our family-owned business ensure fast decision-making processes, making your project a success within the agreed timeline.

Focused collaboration and customized solutions: We are approachable, easy to work with, and offer customized solutions to integrate your project requirements into our processes and equipment.

Agility and flexibility: Changing requirements during a project are embraced rather than rejected.

Reliability and transparency: We want to be your reliable partner and ensure the highest level of transparency in all processes relevant to your product.

Relationship-based decision-making: We base our decisions not simply on short-term commercial aspects, but also on your product's long-term success.

Our mission

In order to support patients and improve their quality of life, we put passion into our daily work, focus on pharmaceutical excellence and use the latest fill-and-finish technologies and processes. We offer the most advanced, agile and, above all, GMP-compliant end-to-end solutions for aseptic contract manufacturing.

psm-saar.de

Watch our video showcasing biopharmaceutical fill-and-finish processes.

Name › QIAGEN

Address/P.O. Box › QIAGEN Strasse 1
Postal Code/City › 40724 Hilden
State › North Rhine-Westphalia
Contact Person › John Gilardi
Telephone › +49 2103 29-0
Email › pr@qiagen.com
Website › www.qiagen.com
Social Media ›
Number of Employees › 5,500
Founded (year) › 1984

QIAGEN – From Sample to Insight

Life faces many urgent challenges: combating cancer, diagnosing infectious diseases, ensuring public safety, and securing a reliable food supply. Meeting these challenges begins with unlocking the insights hidden in DNA, RNA, and proteins – the building blocks of life. That is where QIAGEN plays a vital role. As a global leader in Sample to Insight solutions, we provide the tools that help scientists and healthcare professionals turn biological material into valuable molecular information. Our portfolio spans sample technologies, assays, automation platforms, and bioinformatics, enabling customers to work with speed, accuracy, and confidence. Serving more than 500,000 customers in over 170 countries, QIAGEN supports both Life Sciences research and Molecular Diagnostics in clinical healthcare. Academic institutions, pharmaceutical and biotechnology companies, government agencies, and diagnostic laboratories rely on our technologies to accelerate discovery, guide treatment decisions, and improve public health.

Core areas of expertise

QIAGEN's offering is anchored by five growth pillars:

- Sample technologies that provide trusted solutions for nucleic acid collection, stabilization, and preparation.
- QuantiFERON, the leading blood-based test for latent tuberculosis infection, endorsed worldwide by health-care authorities.
- QIAcuity digital PCR for precise quantification of nucleic acids in both research and clinical settings.
- QIAstat-Dx for syndromic testing, delivering rapid answers in infectious disease and beyond.
- QIAGEN Digital Insights to analyze and interpret complex genomic datasets with AI-powered, curated bioinformatics.

Member of

BIO DEUTSCHLAND VDGH Verband der Diagnostica-Industrie





Making a difference

QIAGEN's technologies address pressing challenges in science and medicine. They support research into cancer, infectious diseases, and personalized medicine, while enabling clinicians to detect pathogens rapidly and identify patients who may benefit from targeted therapies. Beyond healthcare, QIAGEN contributes to forensics, food safety, and environmental testing.

Responsibility

Headquartered in Venlo, the Netherlands, QIAGEN brings together about 5,500 employees from 75 nationalities and operates 35 subsidiaries worldwide. In 2025, sales reached $2.09 billion, with 90% coming from consumables, a sign of the stability and recurring strength of our business.

We are also committed to operating responsibly. In 2025, we cut Scope 1 and 2 emissions by 4%, used 39% renewable energy and saved 35 tons of plastics.

Outlook

The market for QIAGEN's solutions is valued at around $12 billion today and is expected to grow to $13-14 billion by 2028. This growth is being driven by ongoing investment in research, broader use of molecular diagnostics in everyday healthcare, and the increasing need for bioinformatics tools to make sense of complex genomic data.

QIAGEN is ready to grow with these changes. Our strong consumables base gives us steady footing, while innovations in digital PCR, syndromic testing, and bioinformatics open new opportunities. Partnerships with pharmaceutical companies strengthen our role in precision medicine, where companion diagnostics are becoming more essential to targeted therapies. With our global presence and focus on sustainability, we are well placed to continue growing while helping advance science and improve healthcare worldwide.

Rentschler Biopharma

Name › Rentschler Biopharma SE

Address/P.O. Box › Erwin-Rentschler-Str. 21
Postal Code/City › 88471 Laupheim
State › Baden-Wuerttemberg
Contact Person › Dr. Latika Bhonsle-Deeng, VP Global Marketing and Corporate Communications
Telephone › +49-7392-701-0
Fax › +49-7392-701-300
Email › communications@rentschler-biopharma.com
Website › www.rentschler-biopharma.com
Social Media › in

Number of Employees › 1,400
Founded (year) › 1872
Type of Laboratory › S1

Areas of Activity › Contract development and manufacturing organization (CDMO) for biopharmaceuticals, including complex therapeutic proteins, mRNA and viral vectors

External Collaborations › Strategic collaboration with Vetter, headquartered in Ravensburg, Germany, for high quality aseptic filling and secondary packaging

Request for Further Collaborations › Rentschler Biopharma offers bioprocess development and cGMP manufacturing solutions from development to commercialization and beyond for pharma and biotech companies in long-term collaborations and strategic collaboration settings.

Member of

BIO DEUTSCHLAND

A world-class biopharmaceutical CDMO

Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO) focused exclusively on client projects. Rentschler Biopharma's high quality is proven by its long-standing experience and excellence as a solution partner for its clients. A high-level quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality and productivity at each development and manufacturing step. Rentschler Biopharma is a family-owned company with about 1,400 employees, headquartered in Laupheim, Germany, and operations in Milford, MA, USA. The company is part of the United Nations Global Compact, emphasizing it's focus on sustainability.

Reliability you can trust

The company offers process development and manufacturing of biopharmaceuticals, as well as related consulting activities, project management and regulatory support. Rentschler Biopharma is highly experienced in the development and cGMP manufacturing of recombinant proteins and antibody therapeutics in compliance with international standards (EMA/FDA). Working collaboratively with its clients, Rentschler Biopharma provides customised solutions with optimized work packages for each development stage. State-of-the-art cGMP facilities and cell culture processes are leveraged for manufacturing for both, clinical studies and commercial supply. Consistent monitoring of the international regulatory landscape and in-depth understanding of the necessary regulatory documentation (CMC), ensures that each project is properly documented in accordance with international regulatory requirements. The company works in a strategic collaboration with Vetter for aseptic manufacturing and packaging. The desired goal of the collaboration with Vetter is the alignment of manufacturing approaches that enable clients to bring their products to patients more easily and faster.

Bioprocess development

- Fast and efficient supply for multiple candidate screening
- Robust and scalable CHO cell lines for cGMP manufacturing
- Efficient cell culture and purification processes
- Well-established analytical methods

cGMP biomanufacturing

- Multiple stainless steel bioreactor lines, including a twin system with 2x 3,000 L
- Flexible single-use bioreactor lines up to 2,000 L
- State-of-the-art purification processes
- Guaranteed product quality and purity in accordance with cGMP guidelines

Rentschler Development Services

The company provides tailored service offerings for best-fit solutions for client projects. “Velocity” offers fast-track development for Phase I/II, “Flexibility” is for fully customized projects, “Liberty” offers standalone activities and work packages.

Our state-of-the-art Milford, MA site primarily focuses on the production of highly complex molecules for international clients. Thanks to a 22,000 square feet of manufacturing cleanroom space and four 2,000 L single-use bioreactors, we meet our clients’ changing needs by building design to accommodate future adaptions for scale and capacity.

As a world-class solution provider, we ensure optimum time-to-clinic and time-to-market by accelerating timelines to create competitive advantage for our clients. For seamless market approval, we consult and assist clients with regulatory queries, develop optimised strategies, and generate complete documentation for approval of clinical studies and market launch.

RICHTER BIOLOGICS

Name ›	Richter BioLogics
Address/P.O. Box ›	Suhrenkamp 59
Postal Code/City ›	22335 Hamburg
State ›	Hamburg
Contact Person ›	Dr. Thilo Kamphausen
Telephone ›	+49-40-55290-451
Fax ›	+49-40-55290-888
Email ›	BusinessDevelopment@richterbiologics.eu
Social Media ›	in
Number of Employees ›	> 400
Founded (year) ›	1987
Areas of Activity ›	Contract development and manufacturing organisation (CDMO)
Biological Patents ›	Several patents on manufacture of proteins and pDNA (pART process)
External Collaborations ›	Biotech and Pharma companies worldwide
Request for Further Collaborations ›	Richter BioLogics offers CDMO services from gene to finished product. Our teams provide top level solutions to bring your product to market. Contact us for more details.

Member of

BIO DEUTSCHLAND

Best-in-class CDMO for GMP-compliant microbial production of biopharmaceuticals

Richter BioLogics is a leading and expanding Germany-based contract development and manufacturing organisation (CDMO) specialised in a broad range of products derived from bacteria and yeasts. With a 35-year track record in cGMP manufacturing, Richter BioLogics provides its clients with a unique knowledge base in process and analytical validation, process performance qualification (PPQ) procedures, commercial production of therapeutic proteins, antibodies (e.g., VHH/ Nanobodies, Fab-fragments), bacterial vaccines, and plasmid DNA (pDNA) products.

Your product – our competence and dedication

Our focus is on our customers, their needs, timelines and quality requirements. Our seasoned, highly educated, and motivated teams support the global pharmaceutical and biotechnological industries with one-stop-shop services ranging from strain/process development to analytical development, manufacturing, QC testing and filling of finished product. In addition to our headquarters, we operate two GMP-compliant production facilities with total bioreactor capacities of 2x 1,500L and 1x 300L to provide manufacturing solutions for large and commercial scales. Further space and connections exist to install more capacity as needed by the customer.

Quality is our DNA

Richter BioLogics consistently works to the highest standards of pharmaceutical quality as verified by major regulatory bodies including but not limited to EMA, FDA, PMDA, ANVISA, MFDS, and more, as well as by numerous customer audits. Throughout the company teams have excellent expertise in the development and cGMP-compliant production of biopharmaceuticals. To ensure efficient, timely and transparent work, we apply professional project management methods and an integrated Quality Management System. The quality system

at Richter BioLogics meets the strictest standards of quality in biopharmaceutical production.

Our services

Our process development team possesses extensive experience in developing and optimising fermentation and purification processes. For initial strain development, a variety of proprietary *E. coli* expression systems are available to support strain selection. Small-scale models of existing processes provide helpful tools for trouble shooting, process characterisation, and validation and ensure a smooth scale-up to large-scale cGMP-compliant manufacture.

Additionally, our in-house QC testing covers development and validation of a variety of analytical methods (incl. biological assays), performance of stability studies, and characterisation of reference standards.

Richter BioLogics offers a full range of biopharmaceutical manufacturing services:

- Establishment of cell banks (MCB/WCB)
- In-house QC testing and release
- Stability studies according to ICH guidelines
- Strain and process development
- pART proprietary process– pDNA for different purposes at scales needed
- cGMP manufacturing for clinical phases I to III
- Commercial cGMP manufacturing
- Process validation and PPQ procedures

Thanks to the broad knowledge of Richter BioLogics's experts and many decades of experience gained from different kinds of projects, Richter BioLogics works out tailor-made solutions for its customers worldwide, which include large pharmaceutical companies as well as advanced biotech companies.

We manage each of our customer projects individually and with the utmost dedication and flexibility - a guarantee for a successful and ongoing partnership.

SciRhom

Name ›	SciRhom GmbH
Address/P.O. Box ›	Am Klopferspitz 19 (IZB)
Postal Code/City ›	82152 Martinsried
State ›	Bavaria
Contact Person ›	Dr. Jan Poth
Telephone ›	+49-89-614241230
Email ›	info@scirhom.com
Website ›	www.scirhom.com
Social Media ›	in
Number of Employees ›	9
Founded (year) ›	2016
Areas of Activity ›	Preclinical and early clinical development of therapeutics with novel mode of action, treatment of autoimmune and inflammatory diseases, key inflammation pathways, iRhom2/TACE signal transduction biology
Biological patent ›	Comprehensive international patent portfolio
External collaborations ›	Hospital for Special Surgery, New York, expert academic collaborators, highly reputable Contract Research Organisations

SciRhom and its Vision

SciRhom is a pioneering biotech enterprise with the vision to translate advanced scientific findings into game-changing therapies for the treatment of autoimmune and inflammatory diseases.

Based on a decade of ground-breaking research by Prof. Carl Blobel, M.D., Ph.D., co-founder of SciRhom and Director of the Arthritis and Tissue Degeneration Program at Hospital for Special Surgery, New York, SciRhom is developing first-in-class antibodies against the cellular target protein iRhom2 for the selective inhibition of the inflammatory master switch TACE.

SciRhom's Approach

TACE (TNFα converting enzyme or ADAM17) controls several major signalling pathways in health and disease, including TNFα, IL-6R, and EGFR signalling, and has therefore been considered a highly attractive target to block pro-inflammatory pathways. However, direct inhibition of TACE causes severe side effects, such as skin and intestinal lesions, since it leads to the blockade also of physiologically important and protective pathways. Very recently, iRhom2 (inactive Rhomboid 2, RHBDF2) was discovered as the exclusive key regulator of TACE for the disease-associated release of TNFα, IL-6R, and HB-EGF from immune cells. In contrast, the activation of TGFα as a crucial mediator of skin and intestinal barrier function is supported by both iRhom2 and its closely related family member iRhom1. SciRhom's highly specific antibodies against only iRhom2 open the exciting opportunity to selectively and simultaneously target the iRhom2-mediated pro-inflammatory activities of TACE, while preserving its iRhom1-supported protective functions important for normal physiology. This new mode of action allows for a highly efficacious but safe treatment of various disorders, including major debilitating autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and lupus glomerulonephritis.

The Innovation & Gründerzentrum Biotechnologie (IZB) in Martinsried near Munich, home of a number of biotech companies (© IZB)



Illustration of iRhom1/TACE and iRhom2/TACE complexes and their role in driving inflammatory processes (iRhom2/TACE) as well as protecting the skin & intestinal barrier (iRhom1/TACE and iRhom2/TACE)



Inhibiting iRhom2/TACE complexes by binding our antibody to iRhom2 simultaneously blocks a number of pathways driving inflammation, while the physiological effects, such as skin & intestinal barrier protection, are preserved through the activity of unaffected iRhom1/TACE complexes

SciRhom's Asset

SciRhom's key asset is a series of first-in-class humanised monoclonal antibodies (mAbs) against iRhom2 with excellent physicochemical, pharmacokinetic, and pharmacological properties. Reflecting the simultaneous blockade of several disease-driving pathways and the restoration of immune-balancing mechanisms, our antibodies have proven superior efficacy over the current standard of care single pathway inhibitors Humira, Remicade, RoActemra, and Skyrizi in various disease mouse models. Further to the unique mode of action, our anti-iRhom2 antibodies promise a better tolerability and a real disease-modifying effect. The CMC development of the clinical candidate SR-878 and its toxicological assessment were successfully completed. Based on the previous series A financing round, SciRhom has entered SR-878 into clinical development with the goal to ultimately demonstrate clinical proof-of-concept in two indications. SciRhom's antibodies are protected by four strong patent families that cover the antibodies themselves, their iRhom2 target epitopes, as well as their therapeutic use until 2039.

SciRhom's Management

Our management team unites several decades of biotech and big pharma experience in advancing therapeutics into early clinical development and beyond, and consists of

- Jan Poth, Ph.D., Managing Director & CEO
- Jens Ruhe, Ph.D., Co-Founder, Managing Director & COO
- Matthias Schneider, Ph.D., Co-Founder & CSO
- Jürgen Reeß, M.D., Ph.D., CMO

serumwerk bernburg

Name › Serumwerk Bernburg AG

Address/P.O. Box › Hallesche Landstrasse 105 b
Postal Code/City › 06406 Bernburg
State › Saxony-Anhalt
Contact Person › Armin Kleinschroth
Telephone › +49-3471-860-103
Email › info@serumwerk.de
Website › www.serumwerk.com
Social Media › in
Number of Employees › 300
Founded (year) › 1954

Areas of Activity › | Human medicine
| Veterinary medicine
| Active ingredient production
| Medical devices

Member of

BPI Bundesverband der Pharmazeutischen Industrie e.V.

Serumwerk Bernburg AG – your partner for Human and Veterinary Pharmaceuticals

Founded in 1954, Serumwerk Bernburg combines seven decades of pharmaceutical experience with state-of-the-art manufacturing technologies – Made in Germany.

Human or veterinary pharmaceuticals products or medical devices?

Serumwerk Bernburg is one of the few CMOs worldwide that serve both highly regulated markets with identical quality and process standards – from colloidal volume replacement solutions for hospitals to anti-infectives for animal husbandry. This dual expertise makes us a flexible partner for international pharmaceutical companies in over 90 countries.

Over the past decades, we have established ourselves as a globally recognized manufacturer and supplier for human and veterinary medicine. With our various production facilities, we cover a broad portfolio of pharmaceutical products in a variety of dosage forms. Modern synthesis and manufacturing facilities ensure absolute reliability. The combination of pharmaceutical expertise with decades of experience and comprehensive quality control guarantees reliable results. We remain committed to the high quality of our products and services – coupled with our commitment to adapting them flexibly at all times to the needs and preferences of our customers.

Contract Manufacturing

Our CMO portfolio includes ointments, infusion and injection solutions, colloidal plasma expanders, iron complex preparations and specialty polymeric active ingredients. All products can be developed in close coordination with your regulatory and commercial requirements. Please contact us with your specific inquiry – we see ourselves as your development partner, not just a manufacturer.

Technological Highlights

Our expertise in the modification of natural polysaccharides makes us the preferred partner for complex colloidal solutions.

In our GMP-compliant synthesis facilities, we produce active pharmaceutical ingredients, starting materials and excipients according to customer specifications – from route screening and process optimization through to commercial routine manufacturing. The close integration of synthesis and (sterile) final manufacturing on-site enables seamless quality control and shorter lead times.

From polymeric carriers to high-purity active ingredients – we synthesize active pharmaceutical ingredients for human and veterinary medicine according to your specifications:

- Dextrans (various molecular weights)
- DEAE-Dextrans (various molecular weights)
- Gleptoferron (iron dextran complex)
- Hydroxyethyl starch (various molecular weights)
- Ferric bepectate
- Amilomer (various sizes)
- Polysucrose (various molecular weights)
- Clenbuterol HCl

Other Specialities

- Degradable Starch Microspheres (DSM)
- Gelatin-Containing Solutions (Polygeline)
- Density Gradient Media

Ready for your next project – in the service for health.

sirius fine chemicals
SiChem

Name › **Sirius Fine Chemicals SiChem GmbH**

Address/P.O. Box › **Fahrenheitstr.1**
Postal Code/City › **28359 Bremen**
State › **Bremen**
Contact Person › **Dr. Miriam Rittner**
Telephone › **+49-421-2208-228**
Fax › **+49-421-2208-226**
Email Address › **mrittner@sichem.de**
Internet Website › **www.sichem.de**
Number of Employees › **17**
Founded (year) › **2001**

Areas of Activity ›
- **Tools for Life Sciences**
- **CRO / CDMO services (non-GMP / GMP)**
- **Purification / (Enantio)separation**

Sirius Fine Chemicals SiChem GmbH (SiChem) is a privately held company founded in 2001 in Bremen.

SiChem's unique expertise is based on the synthesis of masked derivatives of compounds with biologically and pharmacologically increased bioavailability (prodrugs) that are usually not suitable for drug development. The masked drug candidates are successfully tested against several pathological conditions, for instance cystic fibrosis (CF), diarrhoea, and inflammation. Some products have tested positively in animal and ex-vivo patient experiments.

Custom synthesis / CRO & CDMO services

SiChem provides flexible CRO and CDMO services for clients in the biochemical, biomedical, and pharmaceutical sectors, covering projects from early research through pharmaceutical development.

A particular strength is the production of small batches under both non-GMP and GMP conditions, supporting customers from early-stage R&D and preclinical development to early clinical phases.

SiChem's extensive experience in custom synthesis and contract research helps clients find optimum solutions for new and complex tasks – always in close dialogue and with professional documentation as standard. The team's chemical and technical know-how, continuously growing through numerous projects for the pharmaceutical and biotech industry, is available for new synthetic challenges and innovative research:

- Custom synthesis of building blocks & target structures (mg to kg scale)
- API metabolites & stable labelled isotopes
- FTE-based R & D
- Small-batch non-GMP & GMP manufacturing for early clinical development



Custom purification / isolation / enantioseparation (www.prep4U.de)

SiChem offers comprehensive services around preparative HPLC:

- Purification and isolation of compounds (e.g. purification of APIs and intermediates, pesticides, natural products / isolation of API impurities and metabolites)
- Enantioseparation of racemic mixtures

SiChem has profound and longstanding experience in the area of preparative HPLC – regardless of whether it is 100mg or 100kg that needs to be separated and regardless of whether this is reversed phase (RP) or normal phase (NP). Columns of (almost) every size and various stationary phases from polar to nonpolar and chiral are available. For sensitive compounds, supercritical fluid chromatography (SFC) with CO_2 as solvent is used. This technology makes a valuable contribution to the environment (Green Chemistry).

Tools for life sciences

SiChem synthesises fine chemicals and diagnostic tools for biochemical, biomedical, and pharmaceutical research. The core expertise is in the field of intracellular signalling, e.g. on derivatives of inositol phosphates. SiChem constantly develops new tools for R&D, especially photoactivatable and fluorescent compounds for which there is a fast-growing demand.

The portfolio is complemented by innovative tools for click chemistry (Si-CLICK®):

- clickable unnatural amino acids
- clickable dyes (Si-DYEs®)
- bi- and trifunctional clickable lipids
- clickable (PEGylated) tools

TRIGA-S
Studies. Services. Solutions.

Name ›	TRIGA-S GmbH
Address/P.O. Box ›	Mühltal 5
Postal Code/City ›	82392 Habach
State ›	Bavaria
Contact Person ›	Sabine Radiske (Founder & Managing Director) Dr. Norman Kairies (Business Development Manager) Eugen Brenninger (Client Solutions Manager)
Telephone ›	+49-8847-695-78-0
Email ›	sales@triga-s.de
Website ›	www.triga-s.de
Social Media ›	in
Number of Employees ›	100+
Founded (year) ›	1998
Type of Laboratory ›	Contract laboratory (BSL-2)
Areas of Activity ›	Services for analytical and clinical performance studies of in-vitro diagnostics (IVD), companion diagnostics (CDx) as well as individual services for IVD manufacturers and pharma R&D: I Study management & monitoring I Biostatistics & evidence I Sample management I Contract analytical testing & applications I Clinical study supply management
External Collaborations ›	Research institutes, clinics, contract development and manufacturing organisations, and regulatory consultants
Request for Further Collaborations ›	TRIGA-S seeks synergistic collaborations in the field of IVD development and pharmaceutical research
Member of	BIO DEUTSCHLAND

TRIGA-S GmbH
Studies. Services. Solutions.

TRIGA-S GmbH is a specialised Contract Research Organisation (CRO) for analytical and clinical performance studies in *in-vitro* diagnostics (IVDs) and companion diagnostics (CDx). We support IVD manufacturers with IVDR conformity assessment and pharmaceutical companies from exploratory R&D analytics to CDx validation. With ISO 13485 certification and an in-house BSL-2 laboratory, we provide individual services, complete solutions or support as Functional Service Provider (FSP).

For IVD Manufacturers: Performance Studies for Your Conformity Assessment

We run performance studies from concept to submission-ready report.

- Analytical and clinical performance studies under IVDR, ISO 20916 and, where applicable, CFR
- Verification and validation with defined endpoints and acceptance criteria
- Feasibility and proof-of-concept studies ahead of formal validation
- Studies for post-market performance follow-up (PMPF)

For Pharma: CDx and Early R&D Support

Combining IVD expertise with an understanding of pharmaceutical requirements, we focus on the diagnostic side of your programme.

- Exploratory R&D analytics and early biomarker hypothesis testing
- Feasibility analyses and method comparisons for platform selection
- Analytical and clinical validation of companion diagnostics
- Characterised sample material and customised collection kits

Our Modular Services

Study Management & Monitoring

- Study preparation, site management and monitoring
- Validated EDC/eCRF solutions with audit trails and query management

- Real-time dashboards on recruitment progress and data quality

Biostatistics & Evidence

- Study design, endpoints, acceptance criteria and sample size planning
- Guideline-compliant SAPs and SARs

Sample Management

- Sample collection studies and full chain-of-custody traceability
- Temperature-controlled storage with redundant systems
- Aliquoting, processing and customized panels

Contract Analytical Testing & Applications

- Clinical chemistry, immunoassays, ELISA and real-time PCR
- Exploratory testing and reliable results, even from small sample volumes

Clinical Study Supply Management

- Validated collection kits with pre-shipment quality checks
- Secure cold chains and global, customs-compliant logistics

Assay Development, Verification & Validation

- Precision, sensitivity and specificity assessments
- Method comparisons for platform selection
- Reports ready for inclusion in your technical documentation

What Sets Us Apart

- Regulatory confidence: complete, traceable, audit-ready study documentation
- Flexibility: no minimum quantities, responsive to short-notice changes
- Continuity: one point of contact across all services
- Depth: 25+ years of IVD expertise
- Knowledge transfer: hands-on workshops on IVD studies, regulatory affairs and biostatistics

Name › **Vetter Pharma International GmbH**

Address/P.O. Box › **Eywiesenstrasse 5**
Postal Code/City › **88212 Ravensburg**
State › **Baden-Wuerttemberg**
Contact Person › **Lars Hahn**
Telephone › **+49-751-3700-0**
Email › **EU and other international inquiries:**
info@vetter-pharma.com
US inquiries:
infoUS@vetter-pharma.com
Asia Pacific inquiries:
info@vetter-pharma.com
Website › **www.vetter-pharma.com**
Number of Employees › **7,400**
Founded (year) › **1950**

Areas of Activity › **Drug product development, aseptic clinical and commercial fill and finish, device assembly and packaging, analytical services, regulatory support, logistic services**

We place heightened focus on your success as your strategic partner

We produce aseptically prefilled syringes, cartridges, vials and dual-chamber systems as a globally operating CDMO partner. We are a family-owned, independent company rooted in 75+ years of history. We do not manufacture our own drugs – we focus on providing highly skilled support and state-of-the-art manufacturing resources. We support our customers from the initial phases of clinical drug product development and filling to commercial manufacturing, device assembly and packaging, and lifecycle management. Over 80% of our active projects are biologics.

We are a reliable, responsive, and progressive partner

Our portfolio of services includes dedicated resources for clinical development and commercial manufacturing as well as assembly and packaging, and more. We provide tailored solutions to meet your product's specific market needs.

Services

- Drug Product Development
  Support in navigating key early decisions in your product's evolution with scalability, quality and efficiency in mind.
- Aseptic Filling & Visual Inspection
  Comprehensive expertise in manufacturing injectable drug products and related visual inspection systems.
- Device Assembly & Packaging
  Strategic, technical and packaging support for patient-friendly combination products.
- Analytical Services
  Robust, customizable testing methods for drug products including evaluation and quality verification.
- Regulatory Support
  Support to achieve milestones related to compliance during clinical development, market authorization and beyond.
- Logistic Services
  Cutting-edge solutions that maximize efficiency, transparency and precision of a vital supply chain.

Fast facts: Vetter-at-a-glance

- Headquartered in Ravensburg, Germany
- Commercial production sites in Ravensburg and Langenargen, Germany
- Dedicated clinical production facilities in Rankweil, Austria, and Chicago, USA
- Branch offices for Asia Pacific in Singapore, Japan, South Korea, and China
- More than 7,400 employees worldwide
- A leading specialist in the development, aseptic production, assembly and secondary packaging of prefilled drug delivery systems
- International expertise with regulatory authorities including FDA, EMA, PMDA (Japan), and RP (Germany)
- Service offerings for pharma and biotech firms of all sizes and locations
- Numerous patents including technologies for protection against tampering and counterfeiting
- Lyophilization (freeze-drying) and siliconization specialist

For more information, please scan the QR code.

WACKER

Name ›	Wacker Biotech
Address/P.O. Box ›	Hans-Knöll-Strasse 3
Postal Code/City ›	07745 Jena
State ›	Thuringia
Contact Person ›	Dr. Ilona Koebsch
Telephone ›	+49-3641-5348-0
Email ›	info.biologics@wacker.com
Website ›	www.wacker.com/biologics
Social Media ›	in
Number of Employees ›	~ 600
Founded (year) ›	2005 (Wacker Biotech); 1914 (parent company Wacker Chemie AG)
Areas of Activity ›	I CDMO I Biologics I cGMP-Compliant Manufacturing I Process Development I R&D and Preclinical to Clinical and Commercial Drug Supply I Contract Research Services

Member of

BPI Bundesverband der Pharmazeutischen Industrie e.V.

BIO DEUTSCHLAND

Who We Are

Wacker Biotech is the expert CDMO partner for process development and manufacturing of advanced therapies and vaccines, as well as live microbial products (LMPs) and recombinant proteins based on microbial systems. Our advanced therapies capabilities span the full manufacturing value chain, from the production of plasmid and template DNA as a starting material for mRNA to the IVT of RNA to lipid nanoparticle (LNP) formulation.

Wacker Biotech is wholly owned by Munich, Germany-based Wacker Chemie AG, a publicly traded company founded in 1914 that has pioneered some of the modern era's leading chemical and biochemical manufacturing advances.

Our Global Sites & Capacities

A pioneer in microbial production with decades of experience, Wacker Biotech consists of four complementary, state-of-the-art sites: Amsterdam (Netherlands), Halle and Jena (Germany) and San Diego (USA). Our sites have received approvals from all the major regulatory agencies, including EMA and the FDA. Serving clients across the lifecycle from pre-clinical to commercial, we can produce at diverse scales, offering 16 GMP reactors and capacities ranging from 1.5 L for research-grade material up to 1500 L for high-quality and commercial GMP supply.

Scientific Research Expertise

Complementing our bioprocess development and manufacturing experts at our four global sites is a team of more than 180 dedicated research scientists at our parent company's R&D hub in Munich, including a Contract Research Services group for nucleic acids. These R&D experts continually lead new technological innovations and manage more than 200 active and pending patents and 35 active academic and industry collaborations.

Our Track Record

We have led multiple programmes throughout the entire product lifecycle from feasibility runs to commercial manufacturing. Some of the six released commercial products manufactured at our sites include Vaxchora®,

an attenuated oral cholera vaccine, and Spectrila®, an injectable for treating acute lymphoblastic leukaemia via the protein enzyme asparaginase. We have managed more than 200 projects for our clients.

In Wacker Biotech, you have a flexible partner offering science-driven solutions and guidance from concept to commercialisation.

Products at a Glance

- pDNA -> RNA -> LNP
- Recombinant proteins (based on microbial systems)
- Conjugates
- Live microbial products
- Vaccines (mRNA, protein, polysaccharide, live attenuated, inactivated)

Services at a Glance

- Contract Research Services
- Strain Development & Cell Banking
- Process Characterisation
- Process Development
- Process Validation
- GMP Manufacturing
- Analytical Development & Testing
- Technology Transfer
- Regulatory Filing Guidance

Capacities

- 100 L, 350 L, 650 L and 1500 L stainless steel
- 7.5 L glass; 43 L and 250 L single use

Proprietary Platforms

- ESETEC® – secretion platform utilising proprietary *E. coli* strain for expression of soluble proteins that has demonstrated a 3x COGS reduction
- FOLDTEC® – refolding platform utilising proprietary *E. coli* strain for expression of insoluble proteins that has demonstrated a 20x increase in productivity
- LIBATEC® – platform for producing live microbial products including live bacterial therapeutics in a monoseptic environment
- PLASMITEC® – platform for producing supercoiled/ linearised plasmid DNA (pDNA)

WuXi Biologics
Global Solution Provider

Name ›	WuXi Biologics Germany GmbH
Address/P.O. Box ›	Friedrich-Ebert-Straße 475
Postal Code/City ›	42117 Wuppertal
State ›	North Rhine-Westphalia
Email ›	Info.germany@wuxibiologics.com
Website ›	www.wuxibiologics.com
Social Media ›	in
Number of Employees ›	Approx. 150 in Germany
Founded (year) ›	2020
Type of Laboratory ›	GMP-certified quality-control laboratories and analytical support operations
Areas of Activity ›	Biologics CRDMO, drug-substance manufacturing, mammalian cell culture, technology transfer, MSAT, process validation, quality control, release and stability testing, warehousing and supply-chain coordination
External Collaborations ›	Collaborations with biotechnology and biopharmaceutical companies worldwide across biologics discovery, development and manufacturing
Request for Further Collaborations ›	Seeking collaborations with biotechnology and biopharmaceutical companies that require clinical-to-commercial biologics development, technology transfer, flexible drug-substance manufacturing and European supply options.

WuXi Biologics Germany: Manufacturing Agility in Europe

Global expertise, closer to European innovators

WuXi Biologics is a leading global contract research, development and manufacturing organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics. As of June 30, 2026, the company supported 1,064 integrated client projects, including 78 in Phase III and 28 in commercial manufacturing. Complex modalities represented more than half of the portfolio.

Flexible drug-substance manufacturing in Wuppertal

WuXi Biologics Germany brings this global expertise closer to European innovators. At the center of its German footprint is MFG19 in Wuppertal, a 30,000 m² cGMP drug-substance facility designed to support clinical, late-stage and commercial programs. The site currently provides 12,000 L of capacity through 6 × 2,000 L single-use bioreactors and is expansion-ready to 12 × 2,000 L bioreactors, bringing planned capacity to 24,000 L. Flexible batch manufacturing from 200 L to 6,000 L supports fed-batch, N-1 and N-stage perfusion processes.

An integrated German operating platform

The Wuppertal site is part of an integrated regional platform connecting drug-substance manufacturing and MSAT support in Wuppertal, GMP-certified quality-control capabilities in Wuppertal-Aprath, warehousing and logistics resources in Wuppertal and Düsseldorf and administrative functions in Leverkusen. Across this platform, dedicated teams support technology transfer, process validation, manufacturing, lifecycle management, testing and supply coordination, helping reduce handover risk as programs move from development toward commercial readiness.

European proximity with global supply options

Within Europe, Wuppertal and WuXi Biologics' established commercial manufacturing hub in Dundalk, Ireland, provide complementary options for clients planning clinical, late-stage and commercial supply. The Dundalk site offers 54,000 L of drug-substance capacity, operates under an HPRA GMP manufacturing license and supports EMA-approved commercial products.

Both operations connect regional execution with globally aligned technology, quality and project-governance systems. Through the company's Global Dual Sourcing strategy, clients can evaluate manufacturing pathways based on program stage, scale, market needs and supply strategy.

Quality confidence across a connected network

WuXi Biologics supports reliable execution across its connected network with an established regulatory and client-audit track record. As of June 2026, WuXi Biologics had passed 49 regulatory inspections, including 23 conducted by the FDA and EMA, secured 166 facility license approvals and passed more than 2,000 GMP quality audits by global clients, including over 280 audits by EU Qualified Persons. This track record is supported by integrated manufacturing, MSAT, quality and project teams working to manage technology transfer, PPQ and ongoing production with consistent technical standards.

Supporting the next stage of biologics innovation

Located in North Rhine-Westphalia, Wuppertal combines access to one of Europe's established life-sciences regions with the breadth of a global CRDMO network. WuXi Biologics Germany is building an agile clinical-to-commercial manufacturing hub designed to help biotechnology companies advance next-generation biologics with local access, flexible scale, quality confidence and more resilient supply options.

Name › **YMC Europe GmbH**

Address/P.O. Box › **Schöttmannshof 19**
Postal Code/City › **46539 Dinslaken**
State › **North Rhine-Westphalia**
Contact Person › **Dr. Friederike Becker**
Telephone › **+49-2064-427-0**
Fax › **+49-2064-427-222**
Email › **info@ymc.eu**
Website › **www.ymc.eu**
Social Media ›
Number of Employees › **50 (Europe), 485 (worldwide)**
Founded (year) › **1993**

Areas of Activity ›
- **Glass columns for lab and pilot scale**
- **Prepacked glass columns**
- **Laboratory services**
- **Preparative liquid chromatography**
- **Analytical liquid chromatography**

Your resource for chromatography

As a research-driven chromatography specialist, YMC provides chromatographic solutions for compounds such as peptides and proteins, mAbs and ADCs, as well as oligonucleotides from R&D scale through scale-up to production and final quality control in your lab. We supply innovative bio-chromatography resins and columns for preparative processes, as well as highly reproducible BioLC-(U)HPLC-columns for SEC, IEX, RP and HIC.

Furthermore, YMC glass columns in laboratory as well as pilot scale are designed to meet bio-chromatographers' demands. You can choose them empty as well as prepacked according to your requirements by YMC's in-house packing service. In addition, you can make use of on-demand services for application support, screening, analytical, or preparative method development. Trainings on different chromatographic topics complement the products and services.

Innovations

The most recent and interesting developments include:

- The new standard for columns for bio purification suitable for self-packing: YMC Pilot^{PLUS}
- Macro-porous AEX resin for the purification of large biomolecules: MacroSep IEX Q
- Innovative solutions for BioLC: YMC-Triart Bio(U)HPLC columns, also available in bioinert hardware

The broad and continuously growing portfolio of stationary phases especially designed for the separation of biomolecules provides high flexibility for the chromatographer and ensures successful lab results, day after day. Additionally, the availability of particle sizes from analytical to preparative scale guarantees smooth and easy scale-up processes.



Worldwide availability and support

YMC products are available worldwide through a dedicated support network that guarantees qualified and meaningful practical assistance with regard to method development, method transfer, method validation, purification services and custom column packing – locally, personally and efficiently. It is not only product specifications that represent YMC quality, but also the positive energy and dynamics of our employees, who provide competent and consistent performance together with pronounced reliability even for the most difficult and demanding separations. The YMC network consists of highly focused product specialist teams to provide active support for chromatographers.

Regulatory Support

Since all YMC processes and working procedures are thoroughly monitored and documented, YMC resins and glass columns are fully compliant with requirements. Full technical documentation is available to show compliance with all applicable regulations.

YUMAB

Name › **YUMAB GmbH**
Science Campus Braunschweig-Süd

Address/P.O. Box › **Inhoffenstr. 7**
Postal Code/City › **38124 Braunschweig**
State › **Lower Saxony**
Contact Person › **Dr. Inga Hochnadel**
Telephone › **+49-531-481170-0**
Email › **info@yumab.com**
Website › **www.yumab.com**
Social Media › in
Number of Employees › **30**
Founded (year) › **2012**
Type of Laboratory › **S1, S2**

Areas of Activity ›
- **Fully human antibody discovery & lead development**
- **Antibody Libraries**
- **Engineering & Humanization**
- **R&D services (CRO)**
- **Partnered innovation**

Request for Further Collaborations › **YUMAB seeks clients & partners for human antibody development in the biopharma, biotech, & diagnostic industries.**

Member of

BIO DEUTSCHLAND

Accelerating Biotherapeutic Innovation

YUMAB is a German biotech company offering contract and partnered research for the development of therapeutic antibodies from target to optimised lead candidates. The company was founded in 2012 with the aim of providing state-of-the-art and next-generation recombinant antibody technologies to researchers from early start-ups to biotech and biopharma industry, helping them to bridge the gap between research innovation and therapeutic application. Since then, the company has evolved into a global player advancing biomedicine by accelerating the development of next-generation biotherapeutics.

Translating Innovation by Technologies

The YUMAB® antibody platform provides access to challenging targets, supports all antibody drug modalities and accelerates the development of biotherapeutics by addressing the needs of manufacturing and clinical development through advanced protein engineering and lead optimisation technologies. The company delivers fully human and humanised therapeutic antibody candidates that are the closest to the natural human antibody repertoire.

Our highly diverse, fully human antibody libraries contain >10^{11} natural antibody sequences and specificities to all types of antigens. In addition, YUMAB can also access very broad immune repertoires from different immunised animal species (mouse, rat, rabbit, chicken, llama …), maximising epitope and functional diversity to identify the optimal drug candidate for each target and any modality. Our powerful *in-vitro* discovery technologies are efficient for rare and difficult target antigens and allow for the pre-design of functional and biophysical properties. Antibody candidates are identified rapidly within weeks. They are highly developable into all antibody drug formats including full-length IgG, Fab, scFv, bi- and multispecific, CAR, fusion proteins, and ADCs. Our advanced protein engineering technologies include in silico and experimental platforms that deliver lead candidates with desirable biophysical properties and lowest immunogenicity optimal for manufacturing and clinical development.

Therapeutic antibody
discovery & development

From Target to Lead

Proven Success

Our antibody platform has been proven in over 400 projects with more than 140 customers and partners worldwide, and by several drug candidates in clinical development. In 2020, YUMAB spun out CORAT Therapeutics to bring its proprietary COVID-19 antibody drug into the clinic in just 11 months. The virus-neutralising antibody COR-101 is uniquely designed to treat patients with high viral loads by not inducing unwanted immune responses. In addition, YUMAB is involved in numerous collaborations to develop novel technologies such as AI-assisted discovery and development, target discovery on tumour samples, mammalian display or TCR-like antibodies (TCRm).

Trusted and Collaborative Partner

YUMAB offers customised service and partnering concepts to accelerate the translation of your research innovation into drug development, with affordable entry costs, flexible licensing options, and no additional third-party obligations. Our team of experts is committed to close communication with clients and partners, providing advice and guidance throughout the antibody discovery and early development process.

YUMAB at a Glance

Therapeutic antibody platform

- Fully human libraries for low immunogenicity
- Broad immune repertoires of different species including close to human germline humanisation
- Canine & feline antibody libraries for animal health
- Optimised in vitro selection for difficult targets
- Rapid discovery within weeks

Direct link to lead development

- Advanced antibody lead development & optimisation
- All antibody modalities, all disease areas
- Robust, adjustable process, high success rates

YUMAB® platform

- Fully integrated discovery & development platform from target to optimised lead
- Modular projects with flexible entry & exit points

Flexible services, collaborations & partnering

- Fee-for-service & flexible licensing options
- No technology access fee
- Collaborative development

PRAIMERA BIOTECH

Name › **Praimera Biotech AG**

Address/P.O. Box › **Zeppelinstrasse 3**
Postal Code/City › **85399 Hallbergmoos**
State › **Bavaria**
Contact Person › **Daniel Marquard**
Telephone › **+49-811-1244-9240**
Email › **info@praimera.com**
Website › **www.praimera.com**
Number of Employees › **16**
Founded (year) › **2024**
Type of Laboratory › **S1**

Areas of Activity › **Fc engineering for next generation therapeutic antibodies, combining AI-driven computational predictions and in-house wet-lab validation**

AI-guided Fc engineering for next-generation therapeutic antibodies

Monoclonal antibodies are the dominant class of biopharmaceuticals, with a global market projected to reach US$ 680 billion by 2033. Their success in treating severe diseases such as cancers and autoimmune disorders stems from their ability to address pharmacological targets with high precision.

Most therapeutic antibodies are IgG molecules, composed of two antigen-binding fragments (Fabs) and one crystallizable fragment (Fc), which mediates immune effector functions and governs pharmacokinetics. Antibody development has focused largely on discovering new targets and Fab binders, while Fc engineering has been limited to a small set of well-characterized modifications, leaving immense therapeutic potential untapped.

Praimera Biotech AG harnesses this potential by combining proprietary AI workflows, deep expert knowledge and cutting-edge wet-lab technologies. This enables the evaluation of Fc sequence space and function at an unprecedented scale, leading to the discovery of a molecule library that opens new therapeutic opportunities.

By designing, validating, and developing innovative therapeutic antibodies, the company aims to disrupt current standards and push the boundaries of what is possible in antibody therapy, enabling breakthroughs in the treatment of severe diseases.



Profiles of Service Providers

Name › **ALTRO Innovativ-Versicherungsmakler GmbH**

Address/P.O. Box › **Landsberger Straße 402**
Postal Code/City › **81241 Munich**
State › **Bavaria**
Contact Person › **Christopher Kellner, Max-Emanuel Hudecek**
Telephone › **+49-89-863-89-09 0**
Email › **info@altroinnovativ.de**
Website › **altroinnovativ.de**
Social Media › **in**
Number of Employees › **20**
Founded (year) › **2004**

Areas of Activity › **Startups, life sciences, pharma, biotechnology, Venture Capital**

Protecting innovation – understanding risks, enabling growth

Insurance solutions for life sciences, pharmaceuticals, biotechnology and venture capital

Developing new therapies. Conducting clinical trials. Tapping into international markets. Financing and scaling up startups.

Companies in the life sciences, pharmaceuticals and biotechnology sectors are carrying out pioneering work every day. But as innovation grows, so do the risks: regulatory requirements, product liability issues, cyber-attacks, international liability risks and the protection of management and investors.

This is where ALTRO Innovativ comes in.

For more than 20 years, ALTRO Innovativ has been supporting companies in the biotechnology, pharmaceutical, medical technology and venture capital sectors in identifying, assessing and mitigating their individual risks. The focus is not on standard solutions, but on bespoke insurance concepts tailored to the respective development phases and business models.

Specialist in a demanding sector

The challenges faced by research-based companies differ significantly from those of traditional industrial firms. Clinical trials, international collaborations, intellectual property, regulatory requirements and investor interests call for specialized insurance solutions and a deep understanding of the sector.

ALTRO Innovativ supports companies in areas including:

- Public liability and product liability solutions
- D&O and E&O insurance
- Cyber insurance
- Cover for clinical trials and trial participants
- Property and all-risk insurance solutions
- Business interruption insurance
- Marine cargo and international insurance cover
- International insurance programs
- Insurance solutions for venture capital-backed companies

From startup to global expansion

Whether an innovative startup, a high-growth scale-up or an internationally active pharmaceutical company – every business is at a different stage of development and requires insurance solutions tailored to its specific needs.

Drawing on many years of market knowledge and an international network of partners, ALTRO Innovativ develops bespoke solutions that take both national and global risks into account. Clients benefit particularly from the experience of our specialist team when it comes to international operations and clinical trials.

Insurance cover does not end with the issue of a policy. ALTRO Innovativ sees itself as a long-term partner to its clients – from the initial risk analysis through to the implementation of bespoke insurance solutions and support in the event of a claim.

The focus is on personalized support, swift decision-making and a deep understanding of the challenges faced by innovative companies.

About ALTRO Innovativ

As part of the LEUE & NILL Group, an owner-managed family business, ALTRO Innovativ embodies family values such as reliability and trust. These values shape the way we think and act. As an independent insurance broker, we develop bespoke solutions for our clients.

- Over 20 years industry experience
- Specializing in innovative technology and research companies
- International insurance solutions
- Personalized support from industry experts

ambidex ip
experts in life sciences

Name › ambidexIP – Patent Attorneys

Address/P.O. Box › Jägerhofstr. 31
Postal Code/City › 45478 Mülheim an der Ruhr
Address/P.O. Box › Widdersdorfer Str. 236-240
Postal Code/City › 50825 Köln (Cologne)
State › North Rhine-Westphalia
Contact Person › Dr. Anna Katharina Heide, LL.M.
Dr. Sabrina Witthoff
Dr. Robert S. Jaekel
Dr. Peter Steinecke
Telephone › +49-208-599-638-0
Email › office@ambidexip.eu
Website › www.ambidexIP.eu
Social Media › in
Number of Employees › 14

Areas of Activity › Intellectual Property, IP consulting, IP strategy, prosecution, licensing, enforcement

Biological patent › We create IP protection for your product and technology

External Collaborations › International network of IP experts, patent attorneys and attorneys at law

Awards ›
- ambidexIP is ranked as one of Europe's Leading Patent Law Firms 2026
- recommended Patent Law Firm Biotechnology, Food & Healthcare by FINANCIAL TIMES

Member of

DECHEMA
Gesellschaft für Chemische Technik und Biotechnologie e.V.

You Innovate – We Empower

Innovative Ambidexterity – Exploring while simultaneously exploiting success is particularly challenging for resource-limited technology companies in the life sciences sector.

Our life science experts understand the balancing act between research and commercialization. Therefore, ambidexIP offers a service portfolio that is specifically tailored to the needs of technology companies.

We provide you with the tools for optimal exploitation of your innovations! We equip you with the relevant IP tools and support you operationally according to your needs.

With us by your side, you are supported by a team of patent attorneys and patent engineers with life science expertise and decades of experience.

AI in Life Sciences

A particular strength of ambidexIP is the protection of AI-assisted biotechnological, medical and diagnostic inventions. Drawing on our expertise at the interface of life sciences and artificial intelligence, we help clients identify protectable innovations and develop tailored IP strategies that translate advances in AI-assisted research and development into commercially relevant protection.

Protecting YOUR Values

The ambidexIP team is a unique ensemble of personalities and expertise: Combining scientific insight with IP expertise, we do more than assess inventions once they have been made. We engage proactively with our clients' ongoing research and development, identify potentially protectable aspects and suggest further developments, applications or targeted experiments that may strengthen their IP position. In this way, IP strategy becomes an integral part of the innovation process, aligned with both scientific and commercial objectives.

IAM 300

Anna Katharina Dr. Heide, LL.M.
Recommended Individual 2026

IAM says: Working at the convergence of life sciences, biotechnology and AI, Anna-Katharina Heide tackles some of the most technically demanding patent challenges. Her interdisciplinary expertise enables clients to develop commercially resilient IP strategies for next-generation therapeutic, diagnostics and platform technologies.



Creative SOLUTIONS for Hard Problems

Naturally, there are always new challenges we approach with due respect, curiosity and creativity. With determination, we develop ambitiously tailored solutions, allowing your ideas to thrive in a competitive environment.

Our expertise extends beyond patents to the complementary legal means of protecting biological materials and their derivatives. With experience spanning both strategic advice and contentious matters, we help clients find the right combination of know-how and trade secret protection, ownership rights under German civil law, contractual safeguards, and patents and other industrial property rights. This integrated approach helps clarify rights, prevent and resolve disputes and safeguard the commercial value of biological assets. By this approach we address and attract a diverse range of clients across the life sciences sector and offer our tailored IP patchwork approach® Service to:

INDUSTRIES

- Biopharma & Therapeutics
- Diagnostics & Medical Devices
- Cosmetics
- Supplements, Nutrient & Food
- Bioeconomy & Industrial Biotech
- Manufacturing & Process Engineering
- Biochips & Sensors
- Bioinformatics & AI in Biotech

OUR IP SERVICES

- Holistic Consulting
- Tailored IP Strategy
- Relief in IP Management
- International Prosecution
- Defense & Enforcement

BAVARIAN BIOTECH CLUSTER DEVELOPMENT

Bio[M]

Name › Bio[M] Biotech Cluster Development GmbH

Address/P.O. Box › Am Klopferspitz 19a
Postal Code/City › 82152 Martinsried, Munich
State › Bavaria
Contact Person › Prof. Dr. Ralf Huss
Telephone › +49-89-899679-0
Email › info@bio-m.org
Website › www.bio-m.org
Social Media ›
Number of Employees › 31
Founded (year) › 1997

Areas of Activity ›
- Supporting start-ups regarding foundation and financing with specialised coaching, training, and mentoring programmes
- Start-up Incubator MAxL (Munich Accelerator Life Sciences & Medicine)
- Initiatives: AI4Biotech - Accubator - DigiMed Bayern - PAM - NanoBiotechnology
- Supporting biotech and pharmaceutical companies with an extensive network
- Connecting Bavarian life sciences companies with national and international companies, investors, and relevant stakeholders
- National and international trade fairs, conferences and exhibitions
- Seminars and workshops
- Company database
- Online job market
- News, press releases, annual report „Biotech in Bavaria“

Bio[M] – Biotechnology Cluster Management for Munich and Bavaria

Since 1997, Bio[M] has been the central network organisation for the biotechnology sector in Munich and Bavaria, commissioned by the Bavarian Ministry of Economic Affairs. As a non-profit organisation, Bio[M] supports the biotech community in a variety of ways with its extensive network. The cluster management connects Bavarian life science companies with relevant national and international partners.

Bio[M] – central point of contact

- non-profit organisation funded by the Free State of Bavaria
- supporting start-ups and SMEs through specialised and customised business support services since 1997
- bringing together the key life sciences actors in Bavaria
- attracting international investors and industrial partners
- coaching founders and founders-to-be
- preparing the ground for a thriving and sustainable biotech economy in Bavaria
- connecting Bavarian biotechnology world-wide

Bavaria: the place for the medicine of the future

Bio[M] recognises the challenges of the medicine of the future and promotes the innovation process by identifying and connecting matching partners from science, industry, medicine, and finance. By organising individual partnerings with global and local companies as well as scientific institutions, we help companies to find the right contacts and to cooperate with leading organisations. In addition, Bio[M] offers a variety of workshops and training courses on industry-specific topics and advice on funding opportunities for small and medium-sized enterprises.

Member of

BIO DEUTSCHLAND

BioM for founders

BioM supports Bavarian biotech companies at every stage of setting up their business. Therefore, BioM has developed a unique support programme tailor-made for aspiring start-ups and entrepreneurs in the life sciences sector. In total, BioM has supported more than 300 start-up companies in almost 30 years.

From idea to success:

- Start-up Coaching – hands-on support
- Mentor Circle – get inspired by experts
- Pitch Days – raise money for your project
- BioEntrepreneur Bootcamp – validate your business idea
- BioAngels Investors Network – find the right investor
- m⁴ Award – for academic teams to spin-off
- MAxL – BioM pre-seed and early start-up incubator

MAxL – Munich Accelerator Life Sciences & Medicine

MAxL is BioM's unique start-up incubator and supports selected Bavarian pre-seed and early-stage start-up teams from the life sciences and healthtech sectors with well-targeted funding. On 900m² MAxL offers exclusive high-end infrastructure and access to a vibrant start-up community and BioM's extensive network.

News - Events - Jobs - Companies - Report

In addition, BioM offers comprehensive information on its website www.bio-m.org: current news, a company database, event information, a job exchange, and much more. Every year BioM publishes the report "Biotech in Bavaria", a compilation of current business figures and success stories of the Bavarian biotechnology and pharmaceutical industry with a comprehensive company list and detailed company profiles.

biomindz

Life Science Hub Mainz

Name › biomindz Standortentwicklungsgesellschaft Mainz mbH

Address/P.O. Box › Taunusstr. 59-61
Postal Code/City › 55118 Mainz
State › Rhineland-Palatinate
Contact Person › Felix Wälder
Telephone › +49-6131-126280
Email › info@biomindz.com
Website › biomindz.com
Social Media ›
Number of Employees › 7
Founded (year) › 2023

Areas of Activity ›

Integrated local economic development:
- promote growth, start-up and settlement conditions

Campus development:
- support for life science and biotechnology companies interested in setting up or growing at the Life Science Campus Mainz

Network development and management:
- enabling access to the biotech-ecosystem in Mainz
- connecting startups and companies with international companies and startups, investors and other relevant stakeholders
- organization of regular networking events

International PR and marketing:
- advertising and communication activities
- presence at national and international fairs, exhibitions and conferences

Member of

BIO DEUTSCHLAND

The Life Science Hub Mainz – for people's benefit

Over the years, Mainz has developed a global reputation as a successful life sciences and biotechnology hub and today provides an ideal environment for both fundamental and application-based research as well as businesses.

The hub's primary emphasis lies on immunology and individualized medicine, with a strong focus on oncology and the use of mRNA technologies. In addition, it boasts particularly strong expertise in diagnostics and analytics as well as other life sciences and technologies of the future.

Who we are

biomindz is the municipally owned life science development company of the City of Mainz.

We develop, connect and promote one of Europe's fastest-growing life science ecosystems by bringing together academia, industry, government and investors. Our mission is to create the conditions where scientific discoveries become medical breakthroughs, entrepreneurial success and better health for people around the world.

The aim is to support the state capital Mainz in maintaining its dynamic development and sustainably developing the location as a hotspot for biotechnology and life sciences in Europe.

Our services

The company's activities are divided into four key areas:

- Integrated local economic development to promote growth, start-up and settlement conditions.
- Development of the life science campus to attract companies to settle in the vicinity of the university, university medical center and university of applied sciences.
- Network development, to connect the various players and strengthen the existing ecosystem at the location.
- PR and marketing to raise the profile and market the location internationally.

Why entrepreneurs and scientists choose Mainz

Mainz is the place to biotech.
Home to BioNTech, TRON, Johannes Gutenberg University and the University Medical Center Mainz, Mainz combines world-class science, entrepreneurial ambition and global industry leadership.

Whether you are expanding into Europe, establishing a new R&D location or looking for strategic research partners, Mainz offers an ideal environment to research, innovate and grow.

How biomindz supports growth

From site selection and laboratory space to strategic partnerships, funding opportunities, talent access and international visibility, biomindz supports companies throughout every stage of their growth journey.

From the first conversation to long-term growth, we remain your trusted partner in Mainz.

Our promise

In Mainz you can successfully research, found and grow sustainably – for people's benefit!

More information

On our website (biomindz.com), you will find information on the prospects, strengths and potential for life science and biotechnology in Mainz. In addition, the website provides an overview of all life science and biotechnology companies as well as R&D organizations and science institutions. It offers direct contact to various persons who may help you if you have any interest in the life science hub Mainz.

BIO.NRW
The Home of Biotech

Name ›	BIO.NRW The Home of Biotech
Address/P.O. Box ›	c/o Juelich Research Center, D-L Wilhem-Johnen-Str
Postal Code/City ›	52428 Juelich
State ›	North Rhine-Westphalia
Contact Person ›	Dr. Nils Schrader
Telephone ›	+49-211-385-469-9200
Fax ›	+49-211-385-469-9220
Email ›	bio.nrw@bio.nrw.de
Website ›	www.bio.nrw.de
Social Media ›	
Number of Employees ›	4
Founded (year) ›	2008
Areas of Activity ›	| Technology transfer | Effective Network for Scientists, Founders and Entrepreneurs | Assisting Start-Ups and SMEs in Terms of Financing and Internationalisation | National and international fairs, exhibitions and conferences | Analysis of biotechnology in North Rhine-Westphalia for location data | Central Platform for Life Science Topics | Supporting Students and Young Talents
External Collaborations ›	| Local to international companies, research institutions, financiers, and further biotech stakeholders

Member of

BIO DEUTSCHLAND

BIO.NRW – Business for biotech

Since 2008, BIO.NRW is the official biotechnology network of the German federal state North Rhine-Westphalia (NRW). We catalyse the sustainable development of the state's biotech sector by building on NRW's strengths especially in pharmaceutical biotechnology, biomedicine and enabling technologies. BIO.NRW is actively supporting the implementation of life science technologies, which are key to answering the most challenging tasks of our society.

Our services include:

Central Platform for Life Science Topics

We organise congresses, workshops, expert panels and roundtable discussions to promote the dialogue between business, research, investors and policymakers to activate cooperation. Through annual international business delegations we support international market access to the global key markets in close co-operation with NRW.Global Business.

Effective Network for Scientists, Founders and Entrepreneurs

BIO.NRW offers valuable support of founders, entrepreneurs and start-ups by promoting access to private, public and venture capital through a unique network of investors: since 2009 the BIO.NRW Business Angel Circle brings together start-ups and founding projects from across Europe with experienced life science investors. The Business Angel network is part of BIO.NRWs community building activities to foster direct contacts and exchange among the stakeholders in NRW and beyond.

Assisting Start-Ups and SMEs in Terms of Financing and Internationalisation

Companies and academic institutions can generate awareness of their activities locally, nationally and internationally by being a part of the BIO.NRW shared booths at fairs, exhibitions and conferences.

Supporting Students and Young Talents

Tech transfer support is a key contribution from BIO.NRW. The network takes special interest in assisting young professionals in biotechnology. We offer activities and events that are of specific interest for founders and start-ups. The BIO.NRW Business Angel Network for example helps financing and funding biotech startups.

A snapshot of NRW's biotech sector

North Rhine-Westphalia is situated at Europe's geographic and economic centre. NRW is the state with Germany's highest gross domestic product (GDP), corresponding to 4.8% of the European GDP (EU-27). If classified as an independent nation, NRW would rank 20th in the world. In this vibrant industrial location the chemical and pharmaceutical industry traditionally plays an essential role. New companies and start-ups founded by young academics have been stimulating the corporate landscape in the life sciences sector for years.

NRW offers the most extensive network of academic institutions in Germany. Five of the ten largest universities (by number of students) in Germany are located in NRW. More than 20 Max Planck Institutes, Fraunhofer Institutes, Leibnitz Association facilities and Helmholtz research centers complement the academic research in the field of life sciences in NRW. This variety of academic institutions is a good basis for an agile start-up scene. Young, innovative companies such as Detechgene, BioThrust and PROSION, together with international global players such as Bayer, Qiagen, Miltenyi and a strong network of SMEs form the economic backbone of NRW.

Most of NRW's biotech companies have traditionally been active in the pharmaceutical sector, including diagnostics and platform technologies. The region offers a broad range of expertise and competencies across global enterprises, SMEs, academic institutions, university hospitals, biomedical centers, and technology centers. Companies such as Bayer, Miltenyi Biotec, QIAGEN, Lonza, Grünenthal, Johnson & Johnson, UCB, Takeda, MEDICE, Baxter, Octapharma, and others are located in Germany's economically leading federal state.

DC advisory
a Daiwa company

Name › **DC Advisory**

Address/P.O. Box › **Neue Mainzer Strasse 1**
Postal Code/City › **60311 Frankfurt am Main**
State › **Hesse**
Telephone › **+49-69-9720-040**
Email › **enquiries@dcadvisory.com**
Website › **www.dcadvisory.com**
Social Media › in 𝕏
Number of Employees › **750+**
Founded (year) › **1902**

Areas of Activity › **DC Advisory's global Healthcare team has extensive experience across a broad range of healthcare sub-sectors, with a track record in delivering results for clients, anywhere in the world.**

Sub-sectors include:
- **Care & Services**
- **Healthcare IT & Supply Chain**
- **Medtech & Life Sciences**
- **Pharma**

DC Advisory is an international investment bank committed to making a difference. Part of Daiwa Securities Group Inc., we offer access to over 750 professionals in 24 locations throughout Asia, Europe, and the US. Across 11 industry-focused teams, we offer tailored, independent advice on M&A, debt raisings and restructurings, private capital markets, secondary advisory, and access to unrivaled Asia investment knowledge.

Globally, DC Advisory has completed 80 Healthcare transactions since 2020. Selected notable transactions include:

- Isto Biologics, a portfolio company of Thompson Street Capital Partners, on its majority stake sale to Keensight Capital
- Savanne Life Sciences on its majority investment in Franklin Biolabs
- Halma on its sale of NovaBone Products to Isto Biologics
- Blackstone on its acquisition of I`rom Group Co. Ltd
- Näder Holding on its €1.1bn debt financing to support buyback of shares from EQT
- Eurazeo on the sale of Peters Surgical to Advanced Medical Solutions Group plc
- Altor Equity Partners on the acquisition of VTU Group
- c-Lecta on the sale of a majority stake to Kerry Group

Key contacts

Martin Moser
Managing Director
Frankfurt am Main | Germany
Martin.Moser@dcadvisory.com

Dr. Wolfgang Kazmierowski
Managing Director
Frankfurt am Main | Germany
Wolfgang.Kazmierowski@dcadvisory.com

Andrew Murray-Lyon
Managing Director
London | United Kingdom
Andrew.Murray-Lyon@dcadvisory.com

David Lyons
Managing Director
Dublin | Ireland
David.Lyons@dcadvisory.com

Marzia Cormun
Director
Milan | Italy
Marzia.Cormun@dcadvisory.com

Manish Gupta
Managing Director
Chicago | United States
Manish.Gupta@dcadvisory.com

Rich Blann
Managing Director
New York | United States
Richard.Blann@dcadvisory.com

Justin Balciunas
Managing Director
Washington, D.C. | United States
Justin.Balciunas@dcadvisory.com

Koki Kaita
Senior Managing Director
Tokyo | Japan
Koki.Kaita@daiwa.co.jp

Shinta Niwa
Managing Director
Tokyo | Japan
Shinta.Niwa@daiwa.co.jp

GTAI GERMANY TRADE & INVEST

MITTELSTAND GLOBAL HEALTH MADE IN GERMANY

Name › **Exportinitiative Gesundheitswirtschaft** *(Health Made in Germany)*, **Germany Trade & Invest**

Address/P.O. Box › **Friedrichstrasse 60**
Postal Code/City › **10117 Berlin**
State › **Berlin**
Contact Person › **Agnieszka Rzepka**
Email › **Agnieszka.Rzepka@gtai.de**
Website › **www.gtai.de/exgw**
Social Media › **in**
Number of Employees › **200-500**

Building Global Partnerships: How Germany Supports International Healthcare Business

The healthcare industry remains one of Germany's most innovative and export-oriented sectors. Companies across the industry face intensifying competition, regulatory challenges, evolving supply chains and growing demand for innovation.

To support German healthcare companies in international markets, the Export Initiative for the Healthcare Industry *(Exportinitiative Gesundheitswirtschaft, EXGW)* offers targeted services for business development and market expansion.

A Government Platform for International Growth

The Export Initiative is funded by the German Federal Ministry for Economic Affairs and Energy (BMWE) and implemented by Germany Trade & Invest (GTAI), Germany's international business promotion agency. Through its global network and market expertise, GTAI supports companies in identifying international opportunities, understanding market developments and building valuable business relationships.

Connecting German Healthcare Companies with Global Partners

One of the initiative's key services is HEALTH MADE IN GERMANY – Finding Partners, the official international company directory for the German healthcare industry. The platform enables international stakeholders to identify German companies with expertise in biotechnology, medical technology, pharmaceuticals, digital health and related fields. At the same time, it offers German companies a free opportunity to increase their international visibility and connect with potential business, research and distribution partners worldwide.

This is particularly relevant for the biotechnology sector, where innovation frequently depends on cross-border collaboration. Company profiles are published in English and can be searched using industry-specific filters and keywords, making it easier to identify suitable cooperation partners.

Supporting International Market Entry

Beyond digital visibility, the Export Initiative supports companies through trade fair participation, delegation visits, webinars, matchmaking activities and market information services. These activities help businesses identify opportunities, establish contacts and understand international healthcare markets.

New Consulting Vouchers for Selected Asian Markets

To strengthen the international competitiveness of German healthcare companies, the Export Initiative has introduced Consulting Vouchers *(Beratungsgutscheine)* for selected growth markets in Asia.

The program currently focuses on India, Indonesia and Vietnam and supports companies with expert consulting on:

- market potential assessments,
- market entry strategies,
- regulatory requirements,
- internationalization planning,
- business model development,
- partner identification and matchmaking.

The vouchers are particularly valuable for SMEs and startups seeking specialized expertise while reducing the financial barriers associated with international expansion.

Strengthening Germany's Healthcare Presence Worldwide

International success increasingly depends on visibility, market knowledge and reliable partnerships. By combining market intelligence, networking opportunities, the Finding Partners directory and the new Consulting Voucher program, the Export Initiative provides practical support for companies seeking to expand internationally.

The Export Initiative thus serves as a comprehensive platform that helps German healthcare companies connect with international partners, explore new markets and expand their global footprint.

HealthCapital
BERLIN BRANDENBURG

Name › HealthCapital Berlin Brandenburg

Address/P.O. Box › Fasanenstr. 85
Postal Code/City › 10623 Berlin
State › Berlin
Contact Person › Antonia Jung
Telephone › +49-30-46302-463
Email › healthcapital@berlin-partner.de
Website › www.healthcapital.de
Social Media › in #HealthCapitalBB

Areas of Activity ›
- Technology transfer between science and industry
- Initiation and support of networks
- Support for technology-oriented start-ups
- Funding support for innovative project concepts
- Providing and presenting regional life sciences information
- Building and coordinating of scientific and interdisciplinary networks
- Establishing contacts between experts from all disciplines
- Organisation of events and seminars, Public Relations work for the life sciences region

External Collaborations ›
- Member of the Council of European Bioregions (CEBR)
- Member and contact point in Berlin for Enterprise Europe Network (EEN)
- Collaborations with European Life Science clusters and SMEs in several European projects and other activities
- Bio Deutschland
- Global Health Hub

The German capital BioRegion …
… a Leading Hub for Life Sciences

The Berlin Brandenburg region is one of the leading, international locations for life sciences. The area concentrates on clinical research via a dense and compact healthcare network, and boasts a state-of-the-art IT infrastructure. It is no coincidence that the region is Germany's 'health capital' as it is home to both the German government, as well as the centre for healthcare industries.

The region's distinction is anchored in its unique research and clinical landscape, as well as its ability to closely link the key players in the life sciences and healthcare. Biotechnology, in particular, is a strong driving force within the Berlin Brandenburg healthcare industries ecosystem generating innovation and growth there and beyond. Through networking the pharmaceutical, diagnostics and medical technology sectors completely new fields of business are created. More than 300 biotechnology and 35 pharmaceutical companies are located in the German capital region. They include market leaders like Bayer, BERLIN-CHEMIE (Menarini), Daiichi Sankyo, Pfizer, Bausch + Lomb, Sanofi, and Takeda. Along with the sectors many small and mid-sized companies, they benefit from close cooperation, both with science and with more than 150 hospitals – above all, one of Europe´s largest university hospitals: Charité – Universitätsmedizin Berlin. Customers from research and industry have access to patient cohorts of urban and rural populations of about 180 ethnicities, covering all medical indications. The many technology parks and networks in the various branches of modern biotechnology create the excellent infrastructure and technological support that characterize the Berlin Brandenburg life sciences area. Focus of biotech activity within the region are biomedicine and diagnostics, therapeutics and regenerative medicine as well as industrial biotechnology.

Member of

BIO DEUTSCHLAND

… connected to the European Hotspots

Active cooperation in the networks of Europe's Bio-Regions has played a central role in the internationalisation efforts in the region. The region is a member of the Council of European Bioregions (CEBR).

… offering Service and Support for Life Sciences in the Capital Region

The central contact and coordination office for all issues concerning life sciences in the German capital region is HealthCapital. At the interface of business, science and clinics, HealthCapital drives networking and the technology transfer and supports companies interested in relocating to the region. Berlin Partner for Business and Technology and the Economic Development Agency Brandenburg (WFBB) work together to support the life sciences ecosystem in the German capital region.

Meet us 2027 at

- REGMED FORUM | February 11-12, Berlin, Germany
- BIO EUROPE SPRING | April 5-7, Lyon, France
- BIO:CAP | June 29-30, Berlin, Germany
- BIO INTERNATIONAL CONVENTION | June 7-10, Philadelphia, USA

HOX LIFE SCIENCE GmbH

Name ›	HOX Life Science GmbH
Address/P.O. Box ›	Wilhelm-Leuschner-Straße 68
Postal Code/City ›	60329 / Frankfurt a. M.
State ›	Hesse
Contact Person ›	Dr. Michael Merli
Telephone ›	+49-698700664-19
Email ›	michael.merli@hox.de
Website ›	www.hox.de
Social Media ›	in
Number of Employees ›	70+
Founded (year) ›	2019
Areas of Activity ›	Human Relations & Business Consulting, Marketing Solutions, Life Science Career Companions & Academy
External Collaborations ›	| btS – Life Sciences Studierendeninitiative e.V. | DKFZ Heidelberg

Just as HOX genes play a crucial role in embryonic development, at HOX Life Science we aim to make a vital contribution to the life science community. Since we ourselves are scientists with first-hand experience in the life sciences industry, we understand the language, needs, and requirements of our business partners and clients. Our motto is: “Scientists Supporting Scientists”.

HOX for Companies

Staffing, Recruiting & Employer Branding

Our holistic Human Relations Services Programme is tailored to the life science industry. To support and lighten the workload of internal HR, recruitment and staffing can be outsourced in full or in part, depending on actual needs. We will support you with customised solutions so that you can focus on your day-to-day operations even during peak times or staff shortages and still get in contact with many highly educated and experienced life science experts and specialists.

Candidates go through multiple steps in the candidate journey before they decide to apply to your company. We support you to improve the candidate experience along all touchpoints with your company as one part of our individually tailored employer branding strategy to position your company as an outstanding employer. With customised job ads and recruiting videos for social media and your webpage, we attract and retain suitable new employees for the long term.

Support in Marketing and Sales

We at HOX Life Science firmly believe that companies in the life science industry in particular need content-driven marketing concepts. This means that even when implementing the marketing mix, the focus should always be on the scientific content. After all, these are products that require clear explanations. Very often, advertising and selling life science products and pharmaceuticals involves observing special compliance rules.

According to our motto, “Scientists Supporting Scientists”, we offer marketing concepts tailored to the life science industry along with the corresponding op-

erational tools and measures. In joint sessions, we will develop the marketing strategy that meets the technical and scientific specifics of your product, and from there develop target-oriented marketing measures. We use intelligence to attract clients, not showmanship.

HOX for Experts

Job offers

At HOX, you can be sure that your expertise will be understood. We treat you as an individual and discuss your goals and wishes on a professional level. With our combined life science background and HR know-how, we support you honestly and competently in achieving your career goals. We maintain a strong partner network across:

- Pharma to biotech
- Food to chemistry
- Laboratory equipment & research products
- Diagnostics & medical technology

HOX Academy

Our online courses prepare scientists for careers in the life science industry:

- Business Administration: Understand the value chain of drug development, the role of marketing and sales, and career paths for scientists in pharma and biotech.
- Project Management: Learn Microsoft Project and apply real-world examples from the pharma and biotech industry to plan and manage projects effectively.
- Leadership: Many scientists aspire to leadership roles but are unsure about the required skills. Our course closes this gap by providing essential skills to guide your career towards management responsibilities.

iQ spaces

Name ›	iQ spaces Management GmbH
Address/P.O. Box ›	Neuer Wall 30
Postal Code/City ›	20354 Hamburg
State ›	Hamburg
Contact Person ›	Dr. Sonja Naber
Telephone ›	+49-40-33468-3120
Email ›	contact@iq-spaces.com
Website ›	www.iq-spaces.com
Social Media ›	in
Number of Employees ›	8
Founded (year) ›	2019
Areas of Activity ›	iQ spaces specializes in developing and renting high-tech laboratory, office, and research spaces tailored for the life sciences sector.
External Collaborations ›	Charité – Universitätsmedizin Berlin, Bayer AG

Member of

BIO DEUTSCHLAND

iQ spaces – Driving Innovation with Flexible Spaces

At iQ spaces, we understand the specialized needs of biotech and life science companies. We develop and let flexible laboratory, research, and office spaces that form the foundation for scientific discovery and breakthrough innovations.

Our facilities combine state-of-the-art infrastructure with modular layouts, providing the ideal environment for both established industry leaders and growing biotech firms.

Laboratory Solutions – Tailored to Your Growing Demands

We take pride in offering more than just spaces – we deliver highly specialized environments that cater to the technical and regulatory requirements of life sciences firms. From GMP-compliant labs to modular research and production facilities, we offer solutions that enable your teams to work efficiently and scale rapidly.

Each space is equipped with modular wet and dry labs, modern office setups, and scalable production zones. Whether you are in pharmaceutical R&D, medical diagnostics, or biomanufacturing, our laboratory solutions are fully customizable to your specifications.

Riverside Labs Berlin Mitte – A New Benchmark for Biotech

Riverside Labs Berlin Mitte, our new center for advanced gene and cell therapies, is a flagship 19,800 m² project developed with Charité and Bayer AG and supported by the Federal Government and the State of Berlin. Riverside Labs is part of the Health Innovation Quarter Berlin Mitte, directly adjacent to Bayer's Nordhafen campus, and will offer GMP-ready labs, cleanrooms, and office spaces for start-ups and academic teams.

The center is designed to accelerate clinical translation by supporting early-stage ventures through access to production facilities, regulatory expertise, and translational know-how. Its goal: to strengthen Berlin as a leading biotech location.

Our Other Spaces:

- iQ space Potsdam, located in the heart of the Potsdam Science Park, offers research and office spaces tailored for high-demand users. Flexible layouts support lab, office, and documentation areas, while advanced building systems enhance energy efficiency.
- iQ space Munich North, in the Munich Airport Business Park, features customizable spaces for production, logistics, research, and offices. It combines modern infrastructure, efficient warehousing, and sustainable energy solutions.

Strategic Locations in Leading Science and Biotech Hubs

iQ spaces operates in life science clusters across Germany, offering facilities in proximity to academic institutions, industry peers, and innovation ecosystems. Our locations are chosen to promote synergies between research, commercialization, and talent acquisition. We eliminate the need for significant upfront capital investments by offering flexible leasing options, allowing companies to focus on what matters most: advancing science.

iQ spaces – Empowering Science

- Life science-focused: Tailored to meet GMP, GLP, and other regulatory standards.
- Flexible leasing: Expandable spaces that grow with your company's needs.
- State-of-the-art infrastructure: Equipped with modular lab setups, advanced HVAC, and energy-efficient systems.
- Strategic locations: Proximity to top biotech clusters, academic institutions, and talent pools.
- Sustainability: Facilities designed to meet the highest environmental standards, crucial for future-proofing innovation.

More about our lab and research spaces:

IZB
Innovation and Start-up Center Biotechnology

Name ›	Fördergesellschaft IZB – Innovations- und Gründerzentrum Biotechnologie mbH
Address/P.O. Box ›	Am Klopferspitz 19
Postal Code/City ›	82152 Planegg/Martinsried
State ›	Bavaria
Contact Person ›	Christian Gnam
Telephone ›	+49-89-5527948-0
Fax ›	+49-89-5527948-29
Email ›	info@izb-online.de
Website ›	www.izb-online.de
Number of Employees ›	36
Founded (year) ›	1995
Type of Laboratory ›	S1
Areas of Activity ›	I Biotechnology I Life sciences
Number of Firms ›	over 40 startups
External Collaborations ›	I Collaborations with the scientific faculties on the Campus Martinsried I Munich Life Science Pitch Day with the High-Tech Gründerfonds Management GmbH I IZBrunch – Science meets Science I Law Lab – law for biotech businesses

ARRIVE.
A home for biotech founders

The Innovation and Start-up Center for Biotechnology (IZB) is where life science ideas are given the space to become companies. Founded in 1995, it is one of the leading biotechnology centers in Europe, with two sites near Munich: Planegg-Martinsried and Freising-Weihenstephan. Today, the IZB hosts over 40 biotech companies with more than 700 employees across 26,000 m². At the main site in Planegg-Martinsried, spanning 23,000 m², resident startups primarily focus on medical biotechnology. The IZB in Freising provides ideal conditions for founders in the life sciences sector.

EVOLVE.
Infrastructure for every stage

Founders should focus on their science, not their square meters. At the IZB, S1 laboratories and office spaces adapt flexibly to each company's needs, from the first lab bench to a growing team. In-house estate management and business development support keep daily operations running smoothly. The Martinsried site adds everything a working day demands: modern conference rooms, the design hotel CAMPUS AT HOME, two restaurants and the Bio Kids day-care centers.

THRIVE.
An ecosystem built for growth

No startup grows alone. What sets the IZB apart is its vibrant ecosystem: both sites sit at the heart of cutting-edge research. On the Weihenstephan campus, founders work next door to the TUM School of Life Sciences of the Technical University of Munich and the University of Applied Sciences Weihenstephan-Triesdorf. On the Martinsried/Großhadern campus, the IZB's neighbors include two Max Planck Institutes, faculties and facilities of LMU and the University Hospital of Munich-Großhadern.

The IZB actively cultivates this network. The Faculty Club G2B brings founders and scientists together to exchange ideas and know-how. Networking events, pitch events, and other industry-focused gatherings have made the IZB a key meeting point for the sector far beyond Munich. Arrive with an idea, evolve it in the lab, and thrive as a company.

IZB at a glance

- 26,000 m² of space across two locations
- Home to more than 40 biotech and life science companies
- Flexible laboratory and office structures
- On-site facility and estate management
- Access to leading research institutions and talent
- Strong links to investors and industry partners
- Networking and pitch formats
- Modern conference facilities
- CAMPUS AT HOME hotel
- Faculty Club G2B
- Restaurant and food lounge
- Bio Kids day-care facilities

Name › Life Science Nord Management GmbH

Address/P.O. Box › Steinhöft 5
Postal Code/City › 20459 Hamburg
State › Hamburg
Contact Person › Jan Phillip Denkers
(Manager PR & Communications)
Telephone › +49-176-84221286
Email › denkers@lifesciencenord.de
Website › www.lifesciencenord.de
Social Media › in
Number of Employees › 22
Founded (year) › 2004

Areas of Activity › Cluster Management

External Collaborations
- BIO Deutschland e. V.
- Council of BioRegions in Germany (AK-BioRegio)
- Council of European Bioregions (CEBR)
- Nordic Mentor Network for Entrepreneurship (NOME)
- MedTech Cluster Alliance D-A-CH

Together for Innovative Medicine

The Life Science Nord cluster in the federal states of Hamburg and Schleswig-Holstein embraces over 600 biotechnology, pharmaceutical, medical technology and digital health companies, clinics, and research institutes. More than 55,000 employees work in the industrial health economy.

Particular features of the cluster are the broad business base and the complete value chains from basic and applied research to clinical studies and the marketable end product. The outstanding, close cooperation between researchers, clinicians, and industrial partners in many fields is reflected in innovative products, projects, and technologies.

More than 330 Members, One Common Goal

The cluster management organisation Life Science Nord was set up by the Northern German federal states of Schleswig-Holstein and Hamburg to develop the cluster into a leading international life science network. The cluster agency Life Science Nord Management GmbH and the association Life Science Nord e.V. work as one together to achieve that goal.

More than 330 regional companies and institutions from the healthcare sector are active members of Life Science Nord. All members benefit from numerous competitive services and activities to promote regional networking, exchange experience and know-how, and jointly represent the life science sector of the two northernmost German federal states on a national and international level.

2024 Life Science Nord was awarded the GOLD label “Excel in Cluster Excellence” by the European Secretariat for Cluster Analysis (ESCA) for the fourth time in a row.

Member of

What Life Science Nord Offers

- Comprehensive support in initiating innovative projects, arranging contacts to experts, and providing know-how
- Fast and facilitated access to regional, national and EU funding programmes
- Welcome new members to the network and help them establish themselves within the Life Science Nord cluster
- Extensive opportunities for collaboration within an international industry network
- Participation in leading international and national industry trade shows
- Providing data on business and technological capabilities in medical technology, biotechnology, digital health, and pharma in Northern Germany
- Comprehensive support and guidance for startups and investors
- Providing the latest information on developments in business and science
- Organizing and hosting working groups, collaborative events, and networking activities
- Access to platforms where cluster stakeholders can share information to promote the dissemination of new developments within the cluster. These include the digital newsletter and a content hub – which can be accessed for free via the LSN website – as well as the communication of news related to the cluster through social media.

SWITZERLAND INNOVATION
PARK BASEL AREA | MAIN CAMPUS

S E
N N

Name › **Switzerland Innovation Park Basel Area Main Campus (developed by SENN)**

Address/P.O. Box › **Hegenheimermattweg 167A**
Postal Code/City › **4123 Allschwil**
State › **Basel-Land**
Contact Person › **Simon Koch**
Telephone › **+41-71-510-94-54**
Email › **sko@senn.com**
Website › **www.maincampus.ch**
Founded (year) › **2022**

Switzerland Innovation Park Basel Area Main Campus: A new home for life sciences

At the city boundary of Basel, the Switzerland Innovation Park Basel Area Main Campus is taking shape as Europe's largest life-sciences campus. Developed by Swiss real estate developer SENN, the campus brings together research, development and production in one highly connected ecosystem.

Flexible space for every stage

The defining feature of SIP Main Campus is its extensive hybrid space. Ranging from 250 to 28,000 m², the flexible floor plans can accommodate offices, laboratories, production facilities – or a combination of all three. Spaces can be scaled and adapted as companies evolve, giving them room to grow.

But SIP Main Campus is more than a collection of buildings. Architecture by Herzog & de Meuron and a continuous park running through the campus create a distinctive environment for work, exchange and collaboration. Restaurants, cafés, childcare, fitness facilities, an outdoor swimming pool and shops turn the site into a vibrant neighborhood.

Five buildings. One ecosystem.

Main Campus HQ – Collaboration by design

At the heart of Main Campus is a 50,000 m² office and laboratory hybrid for research, development and production. The building is organized around a park the size of a football field. Circulation balconies and iconic double-helix staircases encourage people to meet naturally – making chance encounters part of the concept. Together with the community management of Switzerland Innovation Park Basel Area, HQ creates an ecosystem designed to connect companies, researchers and partners.

HORTUS – Energy-positive by design

Timber, clay and no fossil-fuel technology: HORTUS demonstrates what radically sustainable construction

SIP MAIN CAMPUS

HORTUS

ALL

HOPE

SCALE

can look like. The building produces more energy than it consumes while offering an exceptional environment for the people who work there. Its design follows the principle of "Healing Architecture", developed by Herzog & de Meuron, and sets a new benchmark for sustainable office development.

ALL – Built for every future

ALL offers 20,000 m² of highly flexible space for laboratories, offices and production, with an uncompromising focus on sustainability. Designed by Herzog & de Meuron, the building accommodates flexible laboratory and office environments, from individual lab workstations to customized spaces. The Botnar Institute of Immune Engineering will move in as an anchor tenant by the end of 2026. LEED Platinum.

HOPE – Turnkey, elegant, sustainable

The House of Partnership and Engagement (HOPE) is located between Swiss TPH and MAIN CAMPUS HQ. Developed by SENN together with the R. Geigy Foundation and architects Felippi Wyssen, HOPE will offer around 8,000 m² of turnkey office and commercial space from 2028. Swiss TPH is the anchor tenant, with a guest house on the top floor. LEED Platinum.

SCALE – Built around your needs

SCALE offers up to 28,000 m² of build-to-suit space, developed together with Herzog & de Meuron and tailored precisely to the future tenant's requirements. Whether office, laboratory or GMP/small-scale production, the building provides the freedom to create a bespoke environment at realistic costs and with a guaranteed move-in date. Completion is planned for 2030. LEED Platinum.

A place to grow

With its combination of flexible space, outstanding architecture, infrastructure and community, SIP Main Campus is creating a new destination for the life-sciences industry in the Basel Area – a place where companies can establish themselves, collaborate and grow.

For current availability and leasing opportunities, please visit www.maincampus.ch.

WEINBERG CAMPUS TECHNOLOGIEPARK

STARTUP ELEVATOR

de:hub Life Science & Bioeconomy Halle (Saale)

Name › **Technologiepark Weinberg Campus**

Address/P.O. Box › **Weinbergweg 23**
Postal Code/City › **06120 Halle (Saale)**
State › **Saxony-Anhalt**
Contact Person › **Dr. Ulf-Marten Schmieder**
Telephone › **+49 (0) 345 13 14 15-00**
Email › **service@weinberg-campus.de**
Website › **weinberg-campus.de**
Social Media › in
Number of Employees › **30**
Founded (year) › **1993**
Type of Laboratory › **S1**

Areas of Activity › **Life Sciences, Bioeconomy, Biotechnology, Pharma, Materials Science, Biomedicine, Medical Technology, Digital Innovation**

Request for Further Collaborations › **Startups, companies and strategic partners**

The Weinberg Campus Technology Park in Halle (Saale) is one of Germany's leading hubs for life sciences, biotechnology and technology-driven innovation. Covering 134 hectares, it is the largest technology park in Central Germany and home to more than 100 technology companies and research institutes with around 6,000 employees. Since 1993, more than 300 startups have been supported here.

The Weinberg Campus brings together expertise in life sciences, bioeconomy, biotechnology, pharmaceuticals, materials science, biomedicine, medical technology and digital innovation. Companies benefit from modern office and laboratory facilities, high-tech infrastructure and proximity to renowned research institutions and Martin Luther University Halle-Wittenberg.

The Weinberg Campus supports companies from research and technology transfer to financing, market entry and scaling. Access to scientific expertise, talent, investors and industry partners helps turn research into market-ready innovations.

Startup Elevator

Startup Elevator is Central Germany's leading accelerator for life sciences, bioeconomy and digital innovation, helping startups turn innovation into sustainable growth. Startups benefit from expert coaching, access to infrastructure and co-working spaces, as well as connections to investors, industry partners and international networks.

The Startup Elevator offers three dedicated programs: a nine-month Business Accelerator focused on business model development, product-market fit and scaling; a three-month Investment Bootcamp covering finance strategy, pitching and investor readiness; and a six-month Digital Innovation Accelerator for startups in HealthTech, AI, SaaS and other digital solutions.

Member of

BIO DEUTSCHLAND

Image credits: © TGZ Halle / Marco Warmuth

de:hub Halle – Life Science & Bioeconomy

Since 2024, the Weinberg Campus has been part of Germany's Digital Hub Initiative, establishing Halle (Saale) as the first de:hub location in Saxony-Anhalt. With a focus on Life Science & Bioeconomy, de:hub Halle connects startups with SMEs, established companies, research institutions and investors, fostering collaboration, knowledge transfer and digital innovation.

As one of 25 de:hubs, de:hub Halle provides access to a nationwide ecosystem of more than 6,000 startups and 2,400 partners, creating opportunities for cooperation, visibility and growth.

Weinberg Campus Innovation Hub: Space for New Possibilities

Opening in 2027, the new Weinberg Campus Innovation Hub will provide additional space for innovative and growth-oriented companies. With 4,900 m² of gross floor area, it combines modern offices and coworking spaces with 15 flexible workshops and production laboratories, enabling companies to grow and scale at the Weinberg Campus.

Companies also benefit from direct access to the campus ecosystem, including research institutions, talent, investors, industry partners, mentoring and business development support.

Selection of Resident Biotech Companies

- BioSolutions Halle GmbH
- Heppe Medical Chitosan GmbH
- Icon Genetics GmbH
- IdentMe GmbH
- matrihealth GmbH
- Navigo Proteins GmbH
- NH DyeAGNOSTICS GmbH
- Nomad Bioscience GmbH
- Novartis Pharma GmbH
- PerioTrap Pharmaceuticals GmbH
- RGCC Central Europe GmbH
- Simris Biologics GmbH
- VEROVACCiNES GmbH
- Wacker Biotech GmbH

Technical University of Munich

Name ›	**Technical University of Munich (TUM), Campus Straubing for Biotechnology and Sustainability**
Address/P.O. Box ›	**Petersgasse 5**
Postal Code/City ›	**94315 Straubing**
State ›	**Bavaria**
Contact Person ›	**Prof. Dr. Volker Sieber, Rector of TUM Campus Straubing**
Telephone ›	**+49-9421-187-0**
Email ›	**info@cs.tum.de**
Website ›	**https://www.cs.tum.de/en/**
Social Media ›	in
Number of Employees ›	**400**
Founded (year) ›	**2017**
Areas of Activity ›	**Biogenic Materials, Chemical Biotechnology, Data Science and Optimization, Economics and Sustainable Policy, Management and Sustainability, Renewable Energies, Sustainable Chemicals and Processes**
Member of ›	**Professors of TUMCS are members in several research or industrial associations and editorial boards. Some of the most relevant are e.g. the Royal Society of Chemistry, DECHEMA, the American Economic Association, the European Society of Operational Research and the Sachverständigenrat Bioökonomie Bayern.**

The TUM Campus Straubing for Biotechnology and Sustainability (TUMCS) is an Integrative Research Institute of the Technical University of Munich (TUM). The mission of TUMCS is to enable the transformation of the economy and society towards sustainability. This mission is pursued by a profound interdisciplinary research and training in sustainable bio- and circular economy. Research and development of new technologies and concepts will only be successful when done interdisciplinary and combining different disciplines of natural sciences, engineering, and social sciences. Likewise, the transformation requires new professional profiles with the ability to think and act across the boundaries of disciplines. The special situation and unique selling point of TUMCS is that it bundles and connects the cross-cutting expertise and experts in the relevant fields of biotechnology, chemistry, economics, management, material science, process engineering and social sciences and places them under one roof.

Develop sustainable production processes

A strong research focus at TUMCS is on development and utilization of biotechnology for the conversion of renewable resources and renewable energy. The researchers work on fundamental concepts towards enhanced enzymatic and microbial systems (biochemistry, biocatalysis, bioinformatics, synthetic biology, etc.) to develop sustainable production processes for a wide range of basic and fine chemicals, fuels, materials, and pharmaceutical precursors.

To provide a platform to cooperate with external partners and industry, a Biofoundry was started as a virtual central unit at TUMCS. The SynBiofoundry@TUM offers a high-throughput technology platform to develop and optimize biotechnological production processes for academia and industry, integrating bioinformatics and machine learning approaches.

A Bio Scale-up Center Straubing is being established

TUMCS is embedded in a region dedicated to the use of biogenic raw materials and renewable energy. In the port of Straubing industrial area, a special zone has been reserved for the settlement of bioeconomy related companies.

The new Bio Scale-up Center Straubing, which is in the Technology and Start-up Center at the port, is intended to close the gap between laboratory and demonstration scale. The latest research results can be tested in the technical center and then transferred to demonstration scale. Placing the BioScale-up Center at this innovation hub was a strategic decision to further strengthen Straubing's bioeconomy ecosystem. Creating synergies with TUMCS, the port is building its activities around driving innovation in the bioeconomy. Important facilities here are the Technology and Start-up Center, offering laboratory and office space, as well as developed building plots at an area reserved for bioeconomy companies.

Resident companies include CASCAT GmbH, MicroPyros GmbH, Microbify GmbH, Bayernhof BioTec, ADM and Fraunhofer IGB BioCat. The site is supported by BioCampus Straubing GmbH, a service provider, which fosters networking, start-up support and infrastructure development. A first-of-its-kind infrastructure project currently under construction is the BioCampus MultiPilot, a publicly accessible demonstration facility for scaling industrial biotech processes up to 25 m^3.

German Biotech Companies

2cureX GmbH, Hamburg
2NA FISH GmbH, München
300MICRONS GmbH, Karlsruhe
3B Pharmaceuticals GmbH, Berlin
4 Animals AlsterScience GmbH, Hamburg
4HF Biotec GmbH, Freiburg
4SC AG, Martinsried
4TEEN4 Pharmaceuticals GmbH, Hennigsdorf
4ward-NA Biotech GmbH, Altomünster

A

Aachen Proteineers GmbH, Baesweiler
Aamuthera Biotech GmbH, Würzburg
AATec Medical GmbH, Planegg-Martinsried
AaviGen GmbH, Heidelberg
AB Enzymes GmbH, Darmstadt
Abalos Therapeutics GmbH, Düsseldorf
Abbott GmbH & Co. KG, Ludwigshafen; Wiesbaden
Abbott Rapid Diagnostics Jena GmbH, Jena
AbbVie Deutschland GmbH & Co. KG, Ludwigshafen; Wiesbaden
Abcalis GmbH, Braunschweig
ABclonal Germany GmbH, Düsseldorf
ABiTEP GmbH, Berlin
ACA CELL BIOTECH GmbH, Heidelberg
Acaryon GmbH, Berlin
acCELLerate GmbH, Hamburg
Ackermann Saatzucht GmbH & Co. KG, Irlbach bei Straubing
Acousia Therapeutics GmbH, Tübingen
acphis GmbH & Co. KG, Halstenbek
ActiTrexx GmbH, Mainz
Acus Laboratories GmbH, Düren
AdrenoMed AG, Hennigsdorf
AdVita Lifescience GmbH, Gundelfingen
AESKU.DIAGNOSTICS, Wendelsheim
Affimed GmbH, Mannheim
AGC Biologics GmbH, Heidelberg
Agrobiogen GmbH, Hilgertshausen-Tandern
AgroProtect GmbH, Geilenkirchen
Agrostim Biotechnologieprodukte GmbH, Großolbersdorf
AI-Driven Therapeutics GmbH, Leipzig
AiCuris Anti-infective Cures AG, Wuppertal
AID Diagnostika GmbH, Strassberg
aidCURE AG, Frankfurt
Aignostics GmbH, Berlin
aimed analytics, Bonn
Akribion Genomics AG, Zwingenberg
Alacris Theranostics GmbH, Berlin
Albutec GmbH, Rostock
Algenfarm Klötze GmbH & Co. KG, Klötze
Algenium GmbH, Bielefeld
Algiax Pharmaceuticals GmbH, Erkrath
Alithea Biotechnology GmbH, Freiburg
ALLERGOPHARMA GmbH & Co. KG, Reinbek
Allogenetics GmbH, Hannover
Almirall Hermal GmbH, Reinbek
Alpspitz Bioscience GmbH, Gattendorf
altona Diagnostics GmbH, Hamburg
Alvotech Germany GmbH, Jülich
alytas therapeutics GmbH, Jena
Ambiatec Biosolutions GmbH, Hamm
AMGEN GmbH, München
Amgen Research (Munich) GmbH, München
AMINO GmbH, Frellstedt
AMODIA Bioservice GmbH, Braunschweig
AmplexDiagnostics GmbH, Gars Bahnhof
AmpliVak Immunotherapy GmbH, Berlin
Amptec GmbH, Hamburg
AMSilk GmbH, Neuried
Analyticon Biotechnologies GmbH, Lichtenfels
AnalytiCon Discovery - Zweigniederlassung der BRAIN Biotech AG, Potsdam
Analytik Jena, Jena
Anavo Therapeutics, Heidelberg
Anchor Diagnostics GmbH, Hamburg
ANiMOX GmbH, Berlin
Aokin AG, Berlin
Aptamimetics GmbH, Stegen
Aptarion biotech AG, Berlin
Aptila Biotech GmbH, Berlin
Arcensus GmbH, Berlin
Ariceum Therapeutics GmbH, Berlin
ARTCLINE GmbH, Rostock
Artemiflow GmbH, Potsdam
ARTES Biotechnology GmbH, Langenfeld
ASA Spezialenzyme GmbH, Wolfenbüttel
Asbach Medical Products GmbH, Obrigheim
Ascend Advanced Therapies GmbH, Planegg-Martinsried
Ascendis Pharma GmbH, Heidelberg
ASKA Biotech GmbH, Hennigsdorf
Assay.Works GmbH, Regensburg
Astaxa GmbH, Ritschenhausen
Astra Biotech GmbH, Berlin
AstraZeneca GmbH, Hamburg
ATG:biosynthetics GmbH, Merzhausen
Athenata GmbH, Wuppertal
ATLAS Biolabs GmbH, Berlin
Attomol GmbH, Bronkow, OT Lipten
attyloid GmbH, Düsseldorf
AudioCure Pharma GmbH, Berlin
Auto Tissue Berlin GmbH, Berlin
Ava Lifescience GmbH, Denzlingen
AvenCell Europe GmbH, Dresden
AVENTRA Gesellschaft für biologische Diagnostik mbH, Osnabrück
Avocet Bio GmbH, Göttingen
Axara Bio GmbH, Hamburg
Axolabs GmbH, Kulmbach
axxelera UG, Karlsruhe

B

b.fab GmbH, Köln
B4 PharmaTech GmbH, Berlin
Badische Peptide & Proteine GmbH, Mannheim
baseclick GmbH, Neuried
BASF Metabolome Solutions GmbH, Berlin
BASF Personal Care and Nutrition GmbH, Monheim
BASF SE, Ludwigshafen
Baumschulen Oberdorla GmbH, Vogtei OT Oberdorla
Bavarian Nordic GmbH, Munich
Bayer AG, Wuppertal
BAYER CropScience AG, Monheim
Bayer Pharma AG, Berlin
BBT Biotech GmbH, Baesweiler
Beckman Coulter Biomedical GmbH, München
Beckman Coulter GmbH, München
Beiersdorf AG, Hamburg
Belyntic GmbH, Berlin
beniag GmbH, Jülich
betaSENSE GmbH, Münster
Bex-Biotec GmbH & Co. KG, Bönen
Biaffin GmbH & Co KG, Kassel
BianoGMP GmbH, 07546
BIBITEC GmbH & Co. KG, Bielefeld
Bicoll GmbH, Planegg/Martinsried
bifa Umweltinstitut GmbH, Augsburg
BIMOVIS GmbH, Heidelberg
Bind-X GmbH, Martinsried
BINOMED GmbH, Ulm
Bio-Protect GmbH, Konstanz
bio.logis digital health GmbH, Frankfurt
BioAgilytix Europe GmbH, Hamburg
Bioanalytics Gatersleben UG, Gatersleben
BioCheck GmbH, Münster
BioControl Jena GmbH, Jena
BioCopy Analytix GmbH, Frankfurt am Main
BioCopy GmbH, Emmendingen
BioEcho Life Sciences GmbH, Köln
Biofidus AG, Bielefeld
Biofrontera AG, Leverkusen
BioGenes GmbH, Berlin
BioKryo GmbH, Saarbrücken
Biolog Life Science Institute GmbH & Co. KG, Bremen
BioMed X GmbH, Heidelberg
Biomedro – Biomedizinische Forschung & Entwicklung Rostock GmbH, Bad Doberan
BioNTech Cell & Gene Therapies GmbH, Mainz
BioNTech Delivery Technologies GmbH, Mainz
BioNTech Diagnostics GmbH, Mainz
BioNTech GmbH, Mainz
BioNTech Idar-Oberstein Services GmbH, Idar-Oberstein
BioNTech Manufacturing GmbH, Mainz
BioNTech Manufacturing Marburg GmbH, Marburg
Biontex Laboratories GmbH, München
BioNukleo GmbH, Berlin
BIOPHARM GmbH, Eppelheim
Biophelion, Jena
Biophotonics Diagnostics GmbH, Jena
BioPlanta GmbH, Grimma
BIOPRACT GmbH, Berlin
BioSolveIT GmbH, Sankt Augustin
BioSpring - Gesellschaft für Biotechnologie mbH, Frankfurt a. Main
biosyn Arzneimittel GmbH, Fellbach
Biosynth GmbH, Berlin
biotechrabbit GmbH, Berlin
Biotest GmbH & Co. KGaA, Dreieich
BioTeSys GmbH, Esslingen
BioTeZ GmbH Biochemisch-Technologisches Zentrum, Berlin
BioThrust GmbH, Aachen
biotx.ai GmbH, Potsdam
Biotype GmbH, Dresden
BioVariance GmbH, Tirschenreuth
BioVersal Deutschland GmbH, Delitzsch
BIOVOX, Darmstadt
Bioweg UG, Quakenbrück
Bioworx, Berlin
bitop AG, Dortmund
Black Drop Biodrucker GmbH, Aachen
BlueBioTech GmbH, Büsum
BlueLab Wasseranalysesysteme GmbH, Tübingen
Bluu Seafood GmbH, Hamburg
Bock Bio Science GmbH, Bremen
Boehringer Ingelheim Biopharmaceuticals GmbH, Biberach an der Riss; Ingelheim
Boehringer Ingelheim RCV GmbH & Co KG, Ingelheim
Boehringer Ingelheim Therapeutics GmbH, Ochsenhausen
Booster Therapeutics GmbH, Berlin
botiss biomaterials GmbH, Zossen
BRAIN Biotech AG, Zwingenberg
BrainRepair UG, Bochum
Brandenburg Antiinfektiva GmbH, Borstel
Breakpoint Therapeutics GmbH, Hamburg
BromMarin GmbH, Freiberg
BSL BIOSERVICE Scientific Laboratories Munich GmbH, Planegg
BSV Bioscience GmbH, Baesweiler
Burgwedel Biotech GmbH, Burgwedel
Byonoy GmbH, Hamburg

C

c-LEcta GmbH, Leipzig
C1 Green Chemicals AG, Berlin
Cabaletta Bio (Germany) GmbH, München
CalTIC GmbH, Dortmund
Cambrex IEP GmbH, Wiesbaden
Cambrium GmbH, Berlin
Camm Solutions GmbH, Überlingen
CanChip GmbH, Potsdam
candidum GmbH, Stuttgart
Captain T Cell GmbH, Schönefeld
CarboCode Germany GmbH, Konstanz
CARDIOGEN GmbH, München
CARTemis Therapeutics GmbH, Berlin
CASCAT GmbH, Straubing
Catalent Düsseldorf GmbH, Langenfeld
CatalYm GmbH, Martinsried
CCRP Therapeutics GmbH, Berlin

CD4 Therapeutics GmbH, Starnberg
CE-Immundiagnostika GmbH, Neckargemünd
CeCaVa GmbH, Tübingen
CeGaT GmbH, Tübingen
Cell.Copedia GmbH, Leipzig
cellasys know-how GmbH, Kronburg
Cellbricks GmbH, Berlin
CellDEG GmbH, Berlin
Cellendes GmbH, Reutlingen
Cellerna Bioscience GmbH, Baesweiler
Cellex Cell Professionals GmbH, Cologne
CellServe GmbH, Berlin
Cellsystems GmbH, Troisdorf
Celltec Systems GmbH, Lübeck
CellTrend GmbH, Luckenwalde
Cellzome GmbH, Heidelberg
Celonic Deutschland GmbH & Co. KG, Heidelberg
Cenata GmbH, Tübingen
Centogene AG, Rostock
Cepheid GmbH, Frankfurt
Cevec Pharmaceuticals GmbH, Köln
Charles River Laboratories Germany GmbH, Erkrath; Freiburg
CheckImmune GmbH, Berlin
Cheplapharm Arzneimittel GmbH, Mesekenhagen
Cherry Biolabs GmbH, Winterhausen
chevita Tierarzneimittel GmbH, Pfaffenhofen
Chimera Biotec GmbH, Bremen; Bremen
Chr. Hansen GmbH, Nienburg/Weser
Chr. Hansen HMO GmbH, Rheinbreitbach
Chromatec GmbH, Greifswald
ChromoTek GmbH, Martinsried
Chugai Pharma Marketing Ltd., Frankfurt am Main
Clariant Produkte (Deutschland) GmbH, Planegg
CMR CureDiab Metabolic Research GmbH, Düsseldorf
CO.DON GmbH, Leipzig
CO2BioClean GmbH, Kronberg
Colipi Biotech, Hamburg
Complement Therapeutics GmbH, Munich
Computomics GmbH, Tübingen
Conaris Research Institute AG, Kiel
CONGEN Biotechnologie GmbH, Berlin
CORAT Therapeutics GmbH, Braunschweig
Corden BioChem GmbH, Frankfurt a. Main
Corden Pharma GmbH, Plankstadt
corlife oHG, Hannover
CPTx GmbH, Martinsried
Creative Therapeutics GmbH, Wuppertal
Crelux GmbH, Gräfelfing
CropEnergies AG, Mannheim
Crown Bioscience Germany GmbH, Hamburg
CrystalsFirst GmbH, Marburg
CSL Behring GmbH, Marburg
CureVac AG, Tübingen
Curexsys GmbH, Göttingen
Cygenia GmbH, Aachen
Cysal GmbH, Münster
Cytecs GmbH, Lippstadt
cytena GmbH, Freiburg
Cytion GmbH, Eppelheim
Cytolytics GbR, Tübingen
Cytophorics GbR, München

D

Danisco Deutschland GmbH, Niebüll
Data Powered Therapeutics GmbH, Göttingen
Davids Biotechnologie GmbH, Regensburg
DenovAI Biotech Germany GmbH, Heidelberg
Deoxy GmbH, München
Dermagnostix GmbH, Freiburg
Dermapharm AG, Grünwald
Detechgene GmbH, Köln
Dewpoint Therapeutics GmbH, Dresden
DexLeChem GmbH, Berlin
DiaPat GmbH, Hannover
Diarect GmbH, Freiburg
Differential Bio GmbH, Feldkirchen
DISCO Pharmaceuticals GmbH, Köln
Discovery Life Sciences Biomarker GmbH, Kassel
Dispendix GmbH, Stuttgart
DMG Deutsche Malaria GmbH, Hamburg
DNTOX GmbH, Düsseldorf
Doderm GmbH, Koblenz
Dr. Rölleke – Labor für Genetische Analytik GmbH, Potsdam
DRG Instruments GmbH, Marburg
DSM Nutritional Products GmbH, Estonia
Dynamic Biosensors GmbH, München
Dynamic42 GmbH, Jena
Dynavax GmbH, Düsseldorf

E

e~nema GmbH, Schwentinental
EastCyte Biosciences GmbH, Halle
EBViously, München
ecolocked GmbH, Berlin
ecSeq Bioinformatics GmbH, Leipzig
Eisbach Bio GmbH, Martinsried
Electrochaea GmbH, Planegg
eleva GmbH, Freiburg
Ella Biotech – Gesellschaft für angewandte Biotechnologie mbH, Fürstenfeldbruck
ellennbe GmbH, Bad Heilbrunn
EMP Genetech, Ingolstadt
Emsland-Stärke GmbH, Emlichheim
EnFin GmbH, Heidelberg
Enza Zaden Deutschland GmbH & Co. KG, Dannstadt-Schauernheim
Enzymaster Deutschland GmbH, Düsseldorf
Enzymicals AG, Greifswald
Epiblok Therapeutics GmbH, Berlin
Epigenomics AG, Heidelberg
EpiLogic GmbH, Agrarbiologische Forschung und Beratung, Freising
Epimune GmbH, Berlin
epiQ.bio UG, Regensburg
EPITOPIC GmbH, Leipzig
Epitype GmbH, Dresden
Eppendorf SE, Jülich
Erbslöh Geisenheim AG, Geisenheim

Ernst Benary Samenzucht GmbH, Hannover-Münden
ESTER Biotech GmbH, Leipzig
Esteve Pharmaceuticals GmbH, Berlin
ethris GmbH, Planegg
Eupheria Biotech GmbH, Dresden
Eurofins BioPharma Product Testing Munich GmbH, Planegg
Eurofins GeneScan GmbH, Freiburg
Eurofins Genomics Europe Pharma and Diagnostics Products & Services Sanger/PCR GmbH, Konstanz
Eurofins Genomics Germany GmbH, Ebersberg
Eurofins LifeCodexx GmbH, Planegg
EUROIMMUN Medizinische Labordiagnostika AG, Lübeck
EVANIUM Healthcare GmbH, Regensburg
eversyn, Magdeburg
EvlaBio, Düsseldorf
Evonik Industries AG, Essen; Hanau
Evonik Operations GmbH, Halle/Westfalen; Hanau
Evotec International GmbH, Hamburg
Evotec SE, Hamburg; Köln
evoxx technologies GmbH, Monheim am Rhein
EW Biotech GmbH, Leuna
Exact Sciences Proteomics GmbH, Planegg
Exazyme GmbH, Berlin
Exciva GmbH, Heidelberg
Eximmium Biotechnologies GmbH, München
Experimentelle Pharmakologie & Onkologie Berlin-Buch GmbH, Berlin
Exyte, Stuttgart

F

FamiCord AG, Leipzig
Feral GmbH, Berlin
FERRING Arzneimittel GmbH, Kiel
Formo Bio GmbH, Frankfurt am Main
Formycon AG, Martinsried
Formycon Project 203 GmbH, Martinsried
FRIZ Biochem GmbH, Neuried
FundaMental Pharma GmbH, Heidelberg
Fusix Biotech GmbH, München
FyoniBio GmbH, Berlin

G

GA Generic Assays GmbH, Dahlewitz
GALAB Technologies GmbH, Hamburg
Gen-H Genetic Engineering Heidelberg GmbH, Heidelberg
GEN-IAL GmbH, Troisdorf
Genaxxon bioscience GmbH, Ulm
GenCC GmbH & Co. KG, Heidelberg
Genedata Bioinformatik GmbH, Munich
Generatio GmbH - Center for Animal Genetics, Heidelberg General
GeneSurge GmbH, München
Genetek Biopharma GmbH, Berlin
GeneTide NXT GmbH, Germering
Genevention GmbH, Göttingen
GENEWIZ Germany GmbH, Leipzig
geneXplain GmbH, Wolfenbüttel
Genome Biologics, Frankfurt
Genovac GmbH, Freiburg
GenXPro GmbH, Frankfurt am2016 Main
GFE Blut mbH, Frankfurt a. Main
GlaxoSmithKline Biologicals, Dresden
Global Sustainable Transformation GST GmbH, Dachau
GlycoThera Analytics GmbH, Hannover
GlycoUniverse GmbH & Co.KGaA, Potsdam
glyXera GmbH, Magdeburg
GOENOMICS GmbH, Göttingen
Gold Standard Diagnostics Kassel GmbH, Kassel
GoodMills Innovation GmbH, Hamburg
GQ Bio Therapeutics GmbH, Hamburg
Green Elephant Biotech GmbH, Gießen
Grifols Deutschland GmbH, Frankfurt
Grünenthal GmbH, Aachen
GSK Vaccines GmbH, Marburg/Lahn
GVG Diagnostics GmbH, Leipzig

H

Hain Lifescience GmbH, Nehren
HD Therapeutics GmbH, Ketsch
Heidelberg Biolabs GmbH, Heidelberg
Heidelberg Epignostix GmbH, Heidelberg CEO
Heidelberg ImmunoTherapeutics GmbH, Heidelberg
Heidelberg Pharma AG, Ladenburg
Heidelberg Pharma Research GmbH, Ladenburg
Henkel AG & Co. KGaA, Düsseldorf
HepaRegeniX GmbH, Tübingen
Heppe Medical Chitosan GmbH, Halle
Heraeus Precious Metals GmbH & Co. KG, Hanau
Herbrand PharmaChemicals GmbH, Gengenbach
HEXAL AG, Holzkirchen
Highfine Biotech GmbH, Friedberg
highQu GmbH, Kraichtal
HMNC Brain Health, München
Horizon Pharma GmbH, Mannheim
HP Health Solutions Germany GmbH, Martinsried
HS Diagnomics GmbH, Berlin
HTCycle AG, Murchin
Human Gesellschaft für Biochemica und Diagnostica mbH, Wiesbaden
Human Tissue and Cell Research-Services (HTCR) GmbH, Planegg/Martinsried
humatrix AG, Pfungstadt
Hummingbird Diagnostics GmbH, Heidelberg
Hybro Saatzucht GmbH & Co. KG, Schenkenberg
HYCOR Europe Bio Crest B.V., Göttingen
Hygiena Diagnostics GmbH, Potsdam
HYpharm GmbH, Bernried

I

IBA Lifesciences GmbH, Göttingen
ibidi GmbH, Gräfelfing
IBT GmbH, Ertingen
IcanoMAB GmbH, Polling
ICHORtec GmbH, Düren
iDEL Therapeutics GmbH, Dortmund
IdentXX GmbH, Stuttgart
Idorsia (Berlin) Pharmaceuticals GmbH, Berlin

IDT Biologika GmbH, Dessau-Roßlau
IFB Halle GmbH, Halle
IFM Therapeutics GmbH, Bonn
IGUANA BioTechnology GmbH, München
IGV Institut für Getreideverarbeitung GmbH, Nuthetal
IIT - Institut für Innovationstransfer, Bielefeld
IMD Natural Solutions GmbH, Dortmund
IMGM Laboratories GmbH, Martinsried
immatics NV, Tübingen
Immucor Medizinische Diagnostik GmbH, Dreieich
Immundiagnostik AG, Bensheim
immune Advice GmbH, Reutlingen
Immungenetics AG, Hamburg
Immunic AG, Gräfelfing
immunoGlobe Antikörpertechnik GmbH, Himmelstadt
Immunologik GmbH, Berlin
Immunservice GmbH, Hamburg
Immutep GmbH, Berlin
imusyn GmbH & Co. KG, Hannover
in.vent DIAGNOSTICA GmbH, Hennigsdorf
Independent Data Lab UG, München
Indical Bioscience GmbH, Leipzig
INDIVUMED GmbH, Hamburg
InfanDx AG, Köln
Infinite Roots, Hamburg
inflamed pharma GmbH, Jena
InflaRx N.V., Jena
ingineeon GmbH, Martinsried
iniuva GmbH, Hamburg
Innocent Meat GmbH, Papendorf
InnovaPlant GmbH & Co. KG, Gensingen
Innovative Molecules GmbH, München
innoVitro GmbH, Jülich
InSCREENeX GmbH, Braunschweig
Insempra GmbH, Martinsried
Institut Virion\Serion GmbH, Würzburg
Intana Bioscience GmbH, Martinsried
Intavis Peptide Services GmbH, Tübingen
INVICOL GmbH, Berlin
INVIGATE GmbH, Jena
Invitek Molecular GmbH, Berlin
Invitris GmbH, Planegg-Martinsried
InVivo BioTech Services GmbH, Hennigsdorf
iOmx Therapeutics AG, Martinsried
Ionera Technologies GmbH, Freiburg
ions.bio GmbH, Planegg
Ipsen Pharma GmbH, München
Iris Biotech GmbH, Marktredwitz
IRUBIS GmbH, München
ISAR Bioscience GmbH, Planegg
Isarna Therapeutics GmbH, Gräfelfing CEO
Isoloid GmbH, Düsseldorf
ITM Isotope Technologies Munich SE, Garching
IVD – Gesellschaft für Innovative Veterinärdiagnostik mbH, Seelze-Letter

J

Jena Bioscience GmbH, Jena
JPT Peptide Technologies GmbH, Berlin
JunctuCell Biomed Manufacturing GmbH, Hohenbrunn

K

Kaesler Nutrition GmbH, Cuxhaven
Katairo GmbH, Tübingen Commercial
KHR Biotech GmbH, Mainz
khumbu.ai Pharmaceuticals GmbH, München
Koralo GmbH, Baldham
KreLo GmbH, Ulm
KULT FARM, Berlin
Kupando GmbH, Schönefeld
KWS LOCHOW GmbH, Einbeck
KWS SAAT SE & Co. KGaA, Einbeck
KyDo Therapeutics, Dortmund
Kynda Biotech GmbH, Jelmstorf
Kyoobe Tech GmbH, Leinfelden-Echterdingen

L

Labor Dr. Merk & Kollegen, Ochsenhausen
LABOR FÜR DNA-ANALYTIK, Freiburg
Labvantage - Biomax GmbH, Martinsried
Lallemand Biologicals GmbH, Wismar
LAMPseq Diagnostics GmbH, Bonn
Larova GmbH, Jena
Laves-Arzneimittel GmbH, Ronnenberg
Lead Discovery Center GmbH, Dortmund
LenioBio GmbH, Düsseldorf
LEO Pharma GmbH, Neu-Isenburg
LEUKOCARE AG, Martinsried
LF-Biotech GmbH, Schornsheim
LGC Genomics GmbH, Berlin
Life & Brain GmbH, Bonn
LifeGlimmer GmbH, Berlin
lifespin GmbH, Regensburg
Ligandis UG, Gülzow-Prüzen
Lignilabs GmbH, Mainz
Lignopure GmbH, Hamburg
Lilly Deutschland GmbH, Bad Homburg
LIMAA Technologies GmbH, Berlin
Limagrain GmbH, Edemissen
LINDIS Biotech GmbH, Puchheim
Lindis Bloodcare GmbH, Hennigsdorf
Lionex GmbH, Braunschweig
LipiTune GmbH, Aachen
Lipocyte BioMed GmbH, Bremen
Lipotype GmbH, Dresden
Loewe Biochemica GmbH, Sauerlach
Lohmann Animal Health GmbH, Cuxhaven
Lohmann Breeders GmbH, Cuxhaven
Lonza Cologne GmbH, Köln
Lumatix Biotech GmbH, Garching
Lumobiotics GmbH, Karlsruhe
Lysando Innovations Lab GmbH, Regensburg
Lysatpharma GmbH, Jena

M

Mallia Therapeutics GmbH, Erlangen
MalVa GmbH, Heidelberg
Matricel GmbH, Herzogenrath
MBBL Dr. Bartling GmbH, Bielefeld
mbiomics GmbH, Neuried
MEATOSYS GmbH, Hamburg
medac, Wedel
Medea Biopharma, Ludwigshafen
Mediagnost GmbH, Reutlingen
Medical Biomaterial GmbH, Neustadt-Glewe
MEDICHEM Diagnostica GmbH & Co. KG, Steinenbronn
Medigene Immunotherapies GmbH, Planegg
MEDIPAN GMBH, Dahlewitz
MEDIWISS Analytik GmbH, Moers
Medprin Biotech, Frankfurt am Main
Meidrix Biomedicals GmbH, Esslingen
MELEMA Pharma GmbH, Hamburg
MERCK KGaA, Darmstadt
Merlion Pharmaceuticals GmbH, Berlin
Merz Pharma GmbH & Co. KGaA, Dessau-Roßlau; Frankfurt a. Main
metabion GmbH, Planegg
Metabolon GmbH, Hallbergmoos
MetaSysX GmbH, Potsdam
Micro Pro GmbH, Gommern Impressum
Microbify GmbH, Straubing
Microcoat Biotechnologie GmbH, Bernried
MicroHarvest GmbH, Hamburg
Micromun, Greifswald
Microsynth Seqlab GmbH, Göttingen
MiGenTra GmbH, Berlin
Mikrogen GmbH, Neuried
Milenia Biotec GmbH, Gießen
Miltenyi Biomedicine GmbH, Bergisch Gladbach
Miltenyi Biotec B.V. Co.KG, Bergisch Gladbach
Miltenyi Biotec GmbH, Teterow
Milupa GmbH, Frankfurt
Mimi-Q GmbH, Potsdam
Minaris Regenerative Medicine GmbH, Taufkirchen
Minerva Analytix GmbH, Rangsdorf
Minerva Biolabs GmbH, Berlin
MINITÜB GmbH, Tiefenbach
mir|detect GmbH, Bremerhaven
Mireca Medicines GmbH, Tübingen
MLM Medical Labs GmbH, Mönchengladbach
mo:re GmbH, Hamburg
MoBiTec GmbH, Hamburg
MODAG GmbH, Wendelsheim
Moderna Germany GmbH, München
Molecular Health GmbH, Heidelberg
MOLEQLAR Analytics GmbH, Berlin
moloX GmbH, Berlin
Molzym GmbH & Co.KG, Bremen
Mosaiques Diagnostics and Therapeutics AG, Hannover
MRM Proteomics Europe GmbH, Rüsselsheim am Main
MSAID GmbH, Garching
MSD SHARP & DOHME GmbH, München
MucosaTec GmbH, Schiffweiler
multiBIND biotec GmbH, Leverkusen
multimmune GmbH, München
Multiplexion GmbH, Friedrichshafen
Mundipharma GmbH, Frankfurt
MyBiotech GmbH, Überherrn
Mycolever GmbH, Rheinbach
MyoPax GmbH, Berlin
myotwin GmbH, Göttingen
Myriad GmbH, München
MyriaMeat GmbH, München
myriamed GmbH, Göttingen
Myxotech GmbH, Saarbrücken

N

nadicom Gesellschaft für angewandte Mikrobiologie mbH, Heilbronn
nandatec GmbH, Lübeck
Nanion Technologies GmbH, München
Nanogami GmbH, Leipzig
NanotecMARIN GmbH, Ingelheim
NanoTemper Technologies GmbH, München
nanoTOOLS Antikörpertechnik GmbH & Co. KG, Teningen
nanozoo GmbH, Jena
Navigo Proteins GmbH, Halle
NEC Bio Therapeutics GmbH, Mannheim
NEOsphere Biotechnologies GmbH, Martinsried
Neovii Biotech GmbH, Gräfelfing
Nephrolyx GmbH, Berlin
Neracare GmbH, Frankfurt
Neuron-D GmbH, Dresden
NeuroProfile GmbH, Regensburg
new/era/mabs GmbH, Potsdam
nextplant UG, Berlin
NExtTec GmbH, Hilgertshausen
NGP Polymers GmbH, Jena
NH DyeAGNOSTICS GmbH, Halle
Ningaloo Biosystems GmbH, Köln
Nomad Bioscience GmbH, Halle
Norbitec GmbH, Uetersen
Norddeutsche Pflanzenzucht Hans-Georg Lembke KG, Holtsee
Norden Vaccines GmbH, Braunschweig
Nordmark Pharma GmbH, Uetersen
Nordsaat Saatzucht GmbH, Langenstein
Norika, Groß-Lüsewitz
Noselab, München
Nosh.bio GmbH, Berlin
Nostos Genomics GmbH, Berlin
NOVA green GmbH, Vechta-Langförden
Novaliq GmbH, Heidelberg
Novis GmbH, Tübingen
Novo Nordisk Pharma GmbH, Mainz
Novozymes Berlin GmbH, Berlin
NPZ Innovation GmbH, Holtsee
NUMAFERM GmbH, Düsseldorf
numares AG, Regensburg
Numinous Microbials GmbH, Tübingen

O

Ocean Pharma GmbH, Reinbek
oceanBASIS GmbH, Kiel
Octapharma Biopharmaceuticals GmbH, Heidelberg
Octapharma GmbH, Langenfeld
Ohly GmbH, Hamburg
OligoScience Biotechnology GmbH, Bönen
OMEICOS Therapeutics GmbH, Berlin
OmicScouts, Freising
OmicsDiscoveries GmbH, Planegg
OmnilinX Therapeutics GmbH, Düsseldorf
Oncimmune Germany GmbH, Dortmund
OncoLead GmbH & Co. KG, Karlsfeld
Oncoscience GmbH, Schenefeld
OPSYON Therapeutics GmbH, München
optiferm GmbH, Oy-Mittelberg
ORGENTEC Diagnostika GmbH, Mainz
origenis GmbH, Martinsried
ORYX GmbH & Co. KG, Baldham
OxProtect GmbH, Münster

P

P. H. Petersen Saatzucht Lundsgaard GmbH & Co. KG, Grundhof
Pacifico Biolabs, Leipzig
Pacuna Biotech GmbH, Berlin
PAIA Biotech GmbH, Köln
PAM Theragnostics GmbH, Hennigsdorf
PAN-Biotech GmbH, Aidenbach
PAN-Seratech GmbH, Aidenbach
Panosome GmbH, Heidelberg
Pantherna Therapeutics GmbH, Hennigsdorf
PELOBIOTECH GmbH, Martinsried
Pentixapharm AG, Würzburg
PEPperPRINT GmbH, Heidelberg
Peptide Specialty Laboratories GmbH, Heidelberg
peptides&elephants GmbH, Hennigsdorf
PerioTrap Pharmaceuticals GmbH, Halle
perora GmbH, Heidelberg
Pfizer Deutschland GmbH, Berlin
Pfizer Manufacturing Deutschland GmbH, Freiburg
Phaeosynt GmbH, Hannover Beliebte
PharmaInformatic, Emden
PHARMAPLANT, Artern
PharmaZell GmbH, Raubling
Pharmbiotec GmbH, Schiffweiler
Phenos GmbH, Hannover
Phialogics GmbH, Frankfurt am Main
Phyton Biotech GmbH, Ahrensburg
Phytowelt GreenTechnologies GmbH, Nettetal
Picea Biosolutions GmbH, Offenburg
Pico Bioscience GmbH, Freiburg
Pieris Pharmaceuticals GmbH, Hallbergmoos
Pixelbiotech GmbH, Schriesheim
PL BioScience GmbH, Aachen
Planet A Foods GmbH, Plamegg
Planton GmbH, Kiel
PlasmidFactory GmbH, Bielefeld
Plasmidsaurus GmbH, Köln
Plectonic Biotech GmbH, Hallbergmoos Commercial
PLS-Design GmbH, Hamburg
pluriSelect Life Science UG, Leipzig
PolymerActive GmbH, Offenburg
Polypharm GmbH, Darmstadt
PolyQuant GmbH, Bad Abbach
PortaCellTec biosciences GmbH, Göttingen
Praimera Biotech AG, Hallbergmoos
PRAMOMOLECULAR GmbH, Berlin
Precision for Medicine GmbH, Berlin
PreOmics GmbH, Martinsried
Priavoid GmbH, Düsseldorf
PRIMACYT Cell Culture Technology GmbH, Schwerin
Prime Vector Technologies GmbH, Tübingen
Primogene GmbH, Leipzig
ProBioGen AG, Berlin
PROGEN Biotechnik GmbH, Heidelberg
Project Eaden GmbH, Berlin
ProJect Pharmaceutics GmbH, Martinsried
PromoCell GmbH, Heidelberg
ProtaGene CGT GmbH, Heidelberg
ProtaGene GmbH, Dortmund; Heilbronn
ProteinDistillery GmbH, Ostfildern
Proteome Factory AG, Berlin
Proteome Sciences R&D GmbH & Co. KG, Frankfurt a. Main
Proteros Biostructures GmbH, Martinsried
Protevo Bio UG, Planegg
PROVIREX Genome Editing Therapies GmbH, Hamburg
Provita Supplements GmbH, Pinneberg
provitro AG, Berlin
PUEVIT GmbH, Dresden
PXBioVisioN GmbH, Hannover

Q

Q-bios GmbH, Edingen-Neckarhausen
QIAGEN, Hilden
QLi5 Therapeutics AG, Dortmund
QTAS GmbH, München
Qualitype GmbH, Dresden
QUASAR Therapeutics GmbH, Planegg
qubeto GmbH, Münster
Quidel Germany GmbH, Kornwestheim

R

R-Biopharm AG, Darmstadt
ravo Diagnostika GmbH, Freiburg
Reaction Biology Europe GmbH, Freiburg
Recipharm Verwaltung GmbH, Wasserburg
ReliaTech GmbH, Wolfenbüttel
Rentschler Biopharma SE, Laupheim
Repairon GmbH, Göttingen
Resolve BioSciences GmbH, Monheim
REVIER Therapeutics GmbH, Heidelberg
Revvity chemagen Technologie GmbH, Baesweiler
Revvity Gene Delivery GmbH, Grafelfing
RHEACELL GmbH, Heidelberg
Ribocon GmbH, Bremen
Richter BioLogics GmbH, Hamburg

Ridom GmbH, Münster
RN.AI Therapeutics GmbH, Neuherberg
RNATICS GmbH, Martinsried
RNhale GmbH, Planegg Kontakt
Roboscreen GmbH, Leipzig
Roche Diagnostics GmbH, Penzberg
Roche mtm laboratories AG, Mannheim

S

Saaten-Union BIOTEC GmbH, Seeland
Saatzucht Josef Breun GdbR, Herzogenaurach
Saatzucht Steinach GmbH & Co KG, Steinach
Saatzucht Streng-Engelen GmbH & Co. KG, Uffenheim
Salata AG, Ritschenhausen
Sanofi-Aventis Deutschland GmbH, Frankfurt
Sartorius CellGenix GmbH, Freiburg
Sartorius Stedim Biotech, Göttingen
Sartorius Stedim Cellca GmbH, Göttingen
Sartorius Xell GmbH, Schloß Holte-Stukenbrock
SCG Cell Therapy GmbH, Martinsried
ScheBo® Biotech AG, Gießen
Scienion GmbH, Berlin
Scientific Research and Development GmbH, Oberursel
Sciomics GmbH, Neckargemünd
SciRhom GmbH, Martinsried
ScreenFect GmbH, Eggenstein-Leopoldshafen
ScreenSYS GmbH, Freburg
Seamless Therapeutics GmbH, Dresden
Secarna Pharmaceuticals GmbH & Co. KG^, Martinsried
seedalive GmbH, Osnabrück
SeedForward GmbH, Osnabrück
Selecta Klemm GmbH & Co. KG, Stuttgart
selectION Therapeutics GmbH, Martinsried
SELENIOS-BIOTECH GmbH, Berlin
Senara GmbH, Freiburg
Senova Gesellschaft für Biowissenschaft und Technik mbH, Weimar
SenseUp GmbH, Jülich
SensID GmbH, Rostock
Senzyme GmbH, Troisdorf
SEQ-IT GmbH & Co. KG, Kaiserslautern
Sequantrix GmbH, Aachen
SequentiX - Digital DNA Processing, Klein Raden
Seracell Pharma GmbH, Rostock
Seramun Diagnostica GmbH, Heidesee
Seratec Gesellschaft für Biotechnologie mbH, Göttingen
Serengen GmbH, Dortmund
SEROTUNE Biosciences GmbH, Gräfelfing
serYmun Yeast GmbH, Bernburg/Saale
Sidanis Pharma GmbH, Hamburg
Siemens Healthcare Diagnostics Products GmbH, Marburg
sifin diagnostics gmbh, Berlin
Sigma-Aldrich Biochemie GmbH, Hamburg
Signatope GmbH, Reutlingen
Signature Diagnostics GmbH, Potsdam
SILANTES GmbH, München
Silence Therapeutics GmbH, Berlin
Simris Biologics GmbH, Berlin
Singleron BioTechnologies GmbH, Köln
Sirana Pharma GmbH, Plannegg-Martinsried
Sirius Fine Chemicals SiChem GmbH, Bremen
siTOOLs Biotech GmbH, Martinsried
Smartbax GmbH, Oberschleißheim
Solana Research GmbH, Windeby
Soluventis GmbH, Dortmund
Sonnera Biotech GmbH, Erlangen
SP Sourcon Padena GmbH, Tübingen
SPARK Microgravity GmbH, München
SparkSeven Bio GmbH, Martinsried
Sphingotec GmbH, Hennigsdorf
Squarix GmbH, Marl
SRTD biotech GmbH, Jülich
Stabizym GmbH, Roßdorf
STADA Arzneimittel AG, Bad Vilbel
StarSEQ GmbH, Mainz
Steffens Biotechnische Analysen GmbH, Freiburg
StemVAC GmbH, Bernried
sterna biologicals GmbH, Marburg
SternEnzym GmbH & Co. KG, Ahrensburg
Subitec GmbH, Köngen
Südwestsaat GmbH, Aschersleben
Südzucker AG, Mannheim
Sumaya Biotech GmbH & Co. KG, Heidelberg
SURFACtoBioTech GmbH, Hamburg
Surflay Nanotec GmbH, Berlin
Sweethoven Biotech, Bonn
SymBiosis GmbH, Eppelheim
Symrise AG, Holzminden
Symvion Biotech GmbH, Laudenbach
Synaptic Systems, Göttingen
Syngenta Agro GmbH, Frankfurt am Main
Syngenta Seeds GmbH, Bad Salzuflen
Synovo GmbH, Tübingen
Syntab Therapeutics GmbH, Würselen
Sysmex Partec GmbH, Görlitz
Systasy Bioscience GmbH, München

T

T-CURX GmbH, Würzburg
T-knife GmbH, Berlin
Tacalyx GmbH, Berlin
Taconic Biosciences GmbH, Leverkusen
Takeda GmbH, Konstanz
targenomix GmbH, Potsdam
Taros Chemicals GmbH & Co. KG, Dortmund
Tcelltech GmbH, Mannheim
TECNARO GmbH, Ilsfeld Kontaktieren
Telexos GmbH, Weiden
Tentamus Pharma & Med Deutschland GmbH, Karlsruhe
TETEC – Tissue Engineering Technologies AG, Reutlingen
Teva GmbH, Ulm
tgcBIOMICS GmbH, Bingen
The Cultivated B GmbH, Heidelberg
TherapySelect Dr. Frank Kischkel, Heidelberg
Therawis Diagnostics GmbH, München
Therawis Pharma GmbH, München
Thermo Fisher Scientific - Phadia GmbH, Freiburg

Thermo Fisher Scientific – B.R.A.H.M.S GmbH, Hennigsdorf
Thermo Fisher Scientific GENEART GmbH, Regensburg
Thermosome GmbH, Martinsried
Therycell GmbH, Berlin
tiakis Biotech AG, Kiel
Tib Molbiol Syntheselabor GmbH, Berlin
tilibit nanosystems GmbH, München
Tinplant, Wanzleben
TissUse GmbH, Berlin
TME Pharma NV, Berlin
Toleris Biotherapeutics GmbH, Würzburg
TolerogenixX GmbH, Heidelberg
Topas Therapeutics GmbH, Hamburg
traceless materials GmbH, Hamburg
Tranquil Immune GmbH, Bonn
Transimmune AG, Düsseldorf
trenzyme GmbH, Konstanz
TriMedicales GmbH, Dietzenbach
TRION Research, Puchheim
Trypto Therapeutics GmbH, Berlin
Tuari Therapeutics GmbH, Wolfratshausen
Tubulis GmbH, Martinsried
TunaTech GmbH, Düsseldorf

U

Ucaneo Biotech GmbH, Berlin
UCB Pharma GmbH, Monheim
UGA Biopharma GmbH, Hennigsdorf
UGiSense AG, Dortmund
Ultrabright Biotech GmbH, Hallbergmoos
Umlaut.bio GmbH, Heidelberg
upcyte technologies GmbH, Hamburg
URSAPHARM Arzneimittel GmbH, Saarbrücken

V

Varicula Biotec GmbH, Wismar
VARUTA GmbH, Solingen
Vaximm GmbH, Mannheim
Vaxxinova Autogenous Vaccines GmbH, Cuxhaven
Vaxxinova Diagnostics GmbH, Leipzig
Velvio GmbH, Regensburg
Veraxa Biotech GmbH, Heidelberg
vermicon AG, Hallbergmoos
VEROVACCiNES GmbH, Halle
Viacure Therapeutics GmbH, Radeberg
Vibalogics GmbH, Cuxhaven
Vicinity Bio GmbH, Tübingen
ViferaXS GmbH, Tübingen
ViGeneron GmbH, Martinsried
Vincerx Pharma GmbH, Monheim
Viramed Biotech AG, Planegg
Viscofan DE GmbH, Weinheim
Vitrofluidix, Köln Handelsregisternummer
VivaCell Biotechnology GmbH, Denzlingen
vivo Science GmbH, Gronau
Vivoryon Therapeutics NV, Halle

W

W. von Borries-Eckendorf GmbH & Co. KG, Holtsee
Wacker Biotech GmbH, Halle; Jena
Wacker Chemie AG, München
WeissBioTech GmbH, Ascheberg
WMT AG, Heidelberg
WuXi Biologics Germany GmbH, Leverkusen

X

X-Zell Biotech GmbH, Lennestadt
XanTec bioanalytics GmbH, Düsseldorf
Xitra Therapeutics, Greifswald
XL-protein GmbH, Freising
XNApharma GmbH, Gera
Xvir Therapeutics GmbH, München

Y

Yokogawa Insilico Biotechnology GmbH, Stuttgart
YUMAB GmbH, Braunschweig

Z

Zedira GmbH, Darmstadt
zell-kontakt GmbH, Nörten-Hardenberg
Zellwerk GmbH, Oberkrämer OT Eichstädt
ZentriForce Pharma Research GmbH, Heidelberg
Zentrum für Humangenetik und Laboratoriumsdiagnostik, Martinsried
ZytoVision GmbH, Bremerhaven

(All data is provided without guarantee.)

Become a partner in the next edition of the guide!

Contact:

Andreas Macht
Sales & Marketing
Tel. +49-30-264921-54
andreas.macht@knowb.io

IDT BIOLOGIKA

Expertise, Capacity and Flexibility to Scale Your Product

IDT Biologika. More than 100 years in Biologics Manufacturing.
End-to-End Services. Clinical & Commercial.

Drug Substance

Cell-culture and microbial-based:
200 L - 800 L - 2,000 L

Drug Product

Vials and Prefilled Syringes

Ask About Our Latest High-Speed Filling Capabilities

Recombinant Proteins, Vaccines, Gene & Immune Therapeutics,
Oncolytic Viruses, Monoclonal Antibodies, Biosimilars

SK bioscience

Proud to be part of the
SK bioscience family.

IDT Biologika
Dessau-Rosslau, Germany

www.idt-biologika.com

Contact us